https://crcwarriors.org/ 2026-05-20 daily 1.0 https://crcwarriors.org/ensayos-clinicos 2026-05-20 daily 0.9 https://crcwarriors.org/medicamentos 2026-05-20 weekly 0.9 https://crcwarriors.org/noticias-cientificas 2026-05-20 daily 0.8 https://crcwarriors.org/noticias 2026-05-20 daily 0.8 https://crcwarriors.org/combinaciones 2026-05-01 weekly 0.8 https://crcwarriors.org/eficacia 2026-05-01 weekly 0.8 https://crcwarriors.org/eficacia/kras 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/braf 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/msi 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/biomarker-unselected 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/her2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/msi-h 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/mmr 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/mss 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ras 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/egfr 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/pik3ca 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/nras 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/tp53 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/all 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ras%2Fbraf 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/apc 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/met 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ddr 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/tmb 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/alk 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/atm 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/smad4 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/pten 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ret 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/vegf 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/arid1a 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/mlh1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/pd-l1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ccne1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/fbxw7 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ros1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/tie2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/blm 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ccnd1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/pole 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb3 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/prex2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/rb1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/brca1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/cdh17 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/mutyh 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/pms2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/brca2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/egfr+pathway 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk3 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ctnnb1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/msh2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/msi-h%2Fdmmr 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/nf1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/palb2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/cdkn2a 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/idh1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/keap1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/msh6 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/notch1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/pathogenic+variants 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/pik3r1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51d 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/tcf7l2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/wild-type 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/actl6b 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/bcl2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/chek2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb4 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr3 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/idh2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/smarca4 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/tgfbr2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/arid1b 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/cdk4 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/cna 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/igf1r 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/line-1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/myc 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/nthl1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/pi3k+pathway 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/pold1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/sox9 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/vegfa 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/arid2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/cdk6 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/hpv 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/jag1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/map2k1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51c 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ras%2Fbraf%2Fegfr%2Fpik3ca%2Fmap2k1%2Fmet%2Fret%2Falk%2Fros1%2Fntrk%2F 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/smad2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/stk11 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/vegfr 2026-05-01 monthly 0.7 https://crcwarriors.org/nuestra-historia 2026-05-01 monthly 0.7 https://crcwarriors.org/contacto 2026-05-01 monthly 0.6 https://crcwarriors.org/ayuda 2026-05-01 monthly 0.6 https://crcwarriors.org/colabora 2026-05-01 monthly 0.6 https://crcwarriors.org/ensayo/NCT07596290/yang-et-al-inmunoterapia-dual-anti-pd-1-ctla-4-para-el-cancer-colorrectal-localmente-avanzado-larc 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07596290/yang-et-al-anti-pd-1-ctla-4-dual-immunotherapy-for-larc 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07533227/trasplante-de-la-microbiota-intestinal-para-el-tratamiento-de-la-caquexia-tumoral-avanzada 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07533227/intestinal-microbiota-transplantation-for-treating-advanced-tumor-cachexia 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06106165/mejorando-la-participacion-de-las-mujeres-musulmanas-en-los-programas-de-deteccion-del-cancer-imcan 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06106165/improving-muslim-women-s-uptake-of-cancer-screening-imcan 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07595276/comparacion-de-la-eficacia-y-la-seguridad-de-enlituo-r-frente-a-erbitux-r-mas-folfox-en-el-cancer-colorrectal-localmente-avanzado-metastasico-con-estado-ras-braf-de-tipo-salvaje-y-mss-pmmr 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07595276/comparing-efficacy-and-safety-of-enlituo-r-versus-erbitux-r-plus-folfox-in-locally-advanced-metastatic-colorectal-cancer-with-ras-braf-wild-type-and-mss-pmmr-status 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07595874/botensilimab-y-balstilimab-como-tratamiento-neoadyuvante-para-el-cancer-colorrectal-avanzado-susceptible-de-reseccion 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07595874/neoadjuvant-botensilimab-and-balstilimab-for-the-treatment-of-advanced-resectable-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07595107/concordancia-entre-las-recomendaciones-de-un-modelo-de-lenguaje-extenso-y-las-de-un-equipo-multidisciplinario-en-el-cancer-de-recto 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07595107/concordance-between-large-language-model-and-multidisciplinary-team-recommendations-in-rectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07596732/red-unificada-estatal-para-la-intervencion-remota-del-fortalecimiento-y-el-ejercicio 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07596732/statewide-unified-network-for-remote-intervention-of-strength-and-exercise 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07594925/radioterapia-de-corta-duracion-seguida-de-inmunoterapia-combinada-con-quimioterapia-para-el-cancer-colorrectal-localmente-avanzado-con-estabilidad-de-microsatelites-un-ensayo-clinico-prospectivo 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07594925/short-course-radiotherapy-followed-by-immunotherapy-combined-with-chemotherapy-for-microsatellite-stable-locally-advanced-rectal-cancer-a-prospective-randomized-controlled-phase-ii-clinical-trial 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07594626/bms-986504-en-combinacion-con-pemetrexed-para-el-tratamiento-de-tumores-solidos-metastasicos-con-delecion-de-mtap 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07594626/bms-986504-in-combination-with-pemetrexed-for-the-treatment-of-metastatic-solid-tumors-with-mtap-deletion 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06124378/tislelizumab-neoadyuvante-en-combinacion-con-quimioterapia-para-el-tratamiento-del-cancer-colorrectal-mss 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06124378/neoadjuvant-tislelizumab-with-chemotherapy-for-the-treatment-of-mss-colon-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06293625/personalizacion-y-optimizacion-de-la-quimioterapia-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado-pero-resecable-en-pacientes-de-edad-avanzada-de-70-anos-o-mas 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06293625/personalising-and-refining-neo-adjuvant-chemotherapy-in-locally-advanced-but-resecable-colon-cancer-in-the-elderly-of-70-years-old-or-more 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06368141/quimioterapia-neoadyuvante-combinada-con-terapia-secuencial-con-inhibidores-de-puntos-de-control-inmunitario-ici-en-el-cancer-colorrectal-localmente-avanzado 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06368141/neoadjuvant-chemotherapy-plus-sequential-immune-checkpoint-inhibitor-ici-therapy-in-locally-advanced-colon-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07284992/scrt-frente-a-lcrt-seguido-de-un-inhibidor-de-pd-l1-mas-capeox-como-terapia-neoadyuvante-en-pacientes-con-cancer-colorrectal-localmente-avanzado-larc 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07284992/scrt-vs-lcrt-followed-by-pd-l1-inhibitor-plus-capeox-as-tnt-in-patients-with-larc 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06405139/irinotecano-nanoliposomal-oxaliplatino-mas-capecitabina-como-terapia-de-conversion-en-el-cancer-colorrectal-localmente-avanzado 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06405139/nanoliposomal-irinotecan-oxaliplatin-plus-capecitabine-as-conversion-therapy-of-locally-advanced-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07503639/ensayo-clinico-umbrella-de-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07503639/umbrella-trial-of-neoadjuvant-therapy-for-locally-advanced-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06301386/everolimus-en-combinacion-con-un-inhibidor-de-pd-1-en-pacientes-con-cancer-colorrectal-avanzado 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06301386/everolimus-combined-with-pd-1-in-advanced-colorectal-cancer-patients 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT04838496/quimioterapia-de-induccion-para-el-cancer-colorrectal-localmente-avanzado 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT04838496/induction-chemotherapy-for-locally-advanced-rectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06055439/un-estudio-de-fase-1-2-para-evaluar-chm-2101-una-terapia-celular-t-con-receptor-quimerico-de-antigeno-17-car-autologa 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06055439/a-phase-1-2-study-to-evaluate-chm-2101-an-autologous-cadherin-17-chimeric-antigen-receptor-car-t-cell-therapy 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06770270/pucotenlimab-mas-radioterapia-y-quimioterapia-para-el-tratamiento-neoadyuvante-del-cancer-de-recto-localmente-avanzado-pucrt 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06770270/pucotenlimab-plus-radiotherapy-and-chemotherapy-for-neoadjuvant-treatment-of-locally-advanced-rectal-cance-pucrt 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05856305/terapia-de-radiacion-estereotactica-en-tumores-del-tracto-nervioso-con-o-sin-clorofilina 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05856305/scrt-in-tnt-with-or-without-chlorophyllin 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07527520/radioterapia-neoadyuvante-con-hipofraccionamiento-moderado-combinada-con-quimioterapia-e-inmunoterapia-para-el-cancer-colorrectal-localmente-avanzado-de-alto-riesgo-con-pmmr-mss-un-ensayo-de-fase-ii 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07527520/neoadjuvant-moderately-hypofractionated-radiotherapy-combined-with-chemotherapy-and-immunotherapy-for-high-risk-pmmr-mss-locally-advanced-rectal-cancer-a-prospective-multi-center-randomized-control 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05571644/tratamiento-neoadyuvante-con-mfolfoxiri-mas-cadonilimab-ak104-frente-a-mfolfox6-en-cancer-colorrectal-localmente-avanzado 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05571644/neoadjuvant-treatment-with-mfolfoxiri-plus-cadonilimab-ak104-versus-mfolfox6-in-locally-advanced-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04833387/anticuerpo-anti-pd-1-tras-quimiorradioterapia-neoadyuvante-en-cancer-colorrectal-localmente-avanzado-pmmr-mss 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT04833387/pd-1-antibody-following-preoperative-chemoradiotherapy-for-locally-advanced-pmmr-mss-rectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05723562/un-estudio-de-dostarlimab-en-pacientes-con-cancer-colorrectal-localmente-avanzado-dmmr-msi-h-no-tratados-previamente 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05723562/a-study-of-dostarlimab-in-untreated-dmmr-msi-h-locally-advanced-rectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06647680/quimioterapia-neoadyuvante-e-inhibidor-de-pd-1-para-el-cancer-colorrectal-localmente-avanzado-control-01 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06647680/neoadjuvant-chemotherapy-and-pd-1-inhibitor-for-locally-advanced-rectal-cancer-control-01 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06014372/envafolimab-como-monoterapia-o-envafolimab-capeox-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06014372/envafolimab-monotherapy-or-envafolimab-capeox-as-neoadjuvant-therapy-for-locally-advanced-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06252142/estudio-que-evalua-si-la-estrategia-de-esperar-y-observar-es-adecuada-en-el-cancer-de-recto 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06252142/study-for-wait-and-watch-suitable-in-rectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07523763/inmunoterapia-neoadyuvante-a-dosis-bajas-en-el-cancer-colorrectal-localmente-avanzado-con-deficiencia-de-mmr 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07523763/neoadjuvant-low-dose-immunotherapy-in-locally-advanced-mmr-deficient-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05507112/time-en-inmunoterapia-combinada-con-quimiorradioterapia-neoadyuvante-en-el-cancer-de-recto 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05507112/time-in-immunotherapy-combined-with-ncrt-for-rectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07347951/un-estudio-de-fase-ii-realizado-en-un-unico-centro-sobre-la-eficacia-y-la-seguridad-de-la-combinacion-de-radioterapia-estereotactica-scrt-con-quimioterapia-capox-serplulimab-y-bevacizumab-en 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07347951/a-single-center-phase-ii-study-on-efficacy-safety-of-scrt-capox-serplulimab-bevacizumab-for-mss-rectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07359989/leucina-mas-quimiorradioterapia-para-el-tratamiento-neoadyuvante-del-cancer-colorrectal-localmente-avanzado 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07359989/leucine-plus-radiochemotherapy-for-neoadjuvant-treatment-of-locally-advanced-rectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05585814/capeox-en-combinacion-con-bevacizumab-mas-un-anticuerpo-anti-pd1-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-con-estabilidad-microsatelital 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05585814/capeox-combined-with-bevacizumab-plus-anti-pd1-antibody-as-neoadjuvant-therapy-for-microsatellite-stable-locally-advanced-rectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07154316/ensayo-clinico-fase-ii-aleatorizado-y-controlado-que-compara-la-quimiorradioterapia-neoadyuvante-lcrt-frente-a-la-radioterapia-neoadyuvante-de-corta-duracion-scrt-combinada-con-capox-un-inhibidor-de 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07154316/phase-ii-rct-of-lcrt-vs-scrt-capox-pd-1i-cox-2i-in-mss-locally-advanced-rectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06052332/eficacia-y-seguridad-de-la-terapia-neoadyuvante-convencional-frente-a-la-terapia-neoadyuvante-total-en-pacientes-de-edad-avanzada-con-cancer-colorrectal-localmente-avanzado 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06052332/efficacy-and-safety-of-conventional-neoadjuvant-therapy-versus-total-neoadjuvant-therapy-in-older-patients-with-locally-advanced-rectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07549906/iparomlimab-tuvonralimab-neoadyuvante-mas-capeox-frente-a-iparomlimab-tuvonralimab-mas-capeox-y-propranolol-para-el-cancer-colorrectal-localmente-avanzado-pmmr-un-estudio-prospectivo-unicentrico-y 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07549906/neoadjuvant-iparomlimab-tuvonralimab-plus-capeox-versus-iparomlimab-tuvonralimab-plus-capeox-and-propranolol-for-locally-advanced-pmmr-colon-cancer-a-prospective-single-center-multi-cohort-study 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05426005/cadonilimab-para-el-cancer-colorrectal-avanzado-msi-h-dmmr-que-no-responde-al-bloqueo-de-pd-1-pd-l1 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05426005/cadonilimab-for-pd-1-pd-l1-blockade-refractory-msi-h-dmmr-advanced-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT02572141/quimioterapia-perioperatoria-con-folfox-o-capox-frente-a-quimioterapia-postoperatoria-para-el-cancer-colorrectal-localmente-avanzado-optical 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT02572141/folfox-or-capox-perioperative-chemotherapy-versus-postoperative-chemotherapy-for-locally-advanced-colon-cancer-optical 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT03466424/radioterapia-de-corta-duracion-5-x-6-gy-7-gy-8-gy-seguida-de-quimioterapia-neoadyuvante-para-el-cancer-de-recto-localmente-avanzado 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT03466424/short-course-radiotherapy-5x6gy-7gy-8gy-followed-by-neo-adjuvant-chemotherapy-for-locally-advanced-rectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06884670/evaluacion-de-la-eficacia-y-la-seguridad-del-anticuerpo-monoclonal-anti-pd-1-en-combinacion-con-il-2-y-capeox-en-la-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-previo-a-la 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06884670/assessment-of-efficacy-and-safety-of-pd-1-monoclonal-antibody-combined-with-il-2-and-capeox-in-neoadjuvant-therapy-for-locally-advanced-rectal-cancer-prior-to-surgery-a-prospective-multi-center 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06369259/estudio-de-fase-2-abierto-con-avutometinib-inhibidor-de-raf-mek-en-combinacion-con-defactinib-inhibidor-de-fak-y-cetuximab-en-pacientes-con-cancer-colorrectal-avanzado-irresecable-y-resistente-a-los 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06369259/open-label-phase-2-study-of-avutometinib-raf-mek-clamp-in-combination-with-defactinib-fak-inhibitor-and-cetuximab-in-patients-with-unresectable-anti-egfr-refractory-advanced-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07579780/bloqueo-del-plexo-hipogastrico-superior-durante-la-cirugia-laparoscopica-del-cancer-colorrectal 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07579780/superior-hypogastric-plexus-block-during-laparoscopic-colorectal-cancer-surgery 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07403877/inmunoterapia-neoadyuvante-radioterapia-en-cancer-colorrectal-localmente-avanzado-msi-h-dmmr 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07403877/neoadjuvant-immunotherapy-radiotherapy-in-msi-h-dmmr-locally-advanced-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07404228/estudio-multidimensional-disenado-para-desarrollar-un-marco-metodologico-basado-en-datos-de-resonancia-magnetica-rm-con-el-fin-de-predecir-la-respuesta-patologica-completa-pcr-en-pacientes-con-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07404228/multidimensional-study-designed-to-develop-a-methodological-framework-based-on-mri-data-to-predict-pathological-complete-response-pcr-in-patients-with-locally-advanced-rectal-cancer-after-neoadjuvant 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07113275/un-ensayo-clinico-que-compara-la-radioterapia-de-ciclo-largo-frente-a-la-radioterapia-de-ciclo-corto-seguida-de-inmunoterapia-combinada-con-terapia-neoadyuvante-total-tnt-frente-a-la-radioterapia-de 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07113275/a-clinical-trial-comparing-long-course-versus-short-course-radiotherapy-followed-by-immunotherapy-combined-with-total-neoadjuvant-therapy-tnt-to-long-course-radiotherapy-followed-by-tnt-in-locally 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06229340/leflunomida-o-combinacion-de-un-inhibidor-de-mek-e-hidroxicloroquina-para-pacientes-con-mutaciones-en-ras-que-no-responden-al-tratamiento 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06229340/leflunomide-or-combination-of-mek-inhibitor-and-hydroxychloroquine-for-refractory-patients-with-ras-mutations 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05999812/ensayo-clinico-de-acido-al-trans-retinoico-bevacizumab-y-atezolizumab-en-cancer-colorrectal 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05999812/clinical-trial-of-all-trans-retinoic-acid-bevacizumab-and-atezolizumab-in-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07413146/quimioterapia-neoadyuvante-con-capeox-frente-a-cirugia-inicial-en-cancer-colorrectal-localmente-avanzado-con-niveles-elevados-de-cea-un-ensayo-clinico-aleatorizado-abierto-y-de-un-solo-centro 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07413146/neoadjuvant-capeox-versus-upfront-surgery-for-locally-advanced-colon-cancer-with-elevated-cea-a-single-center-open-label-randomized-controlled-trial 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06594692/radioterapia-de-curso-corto-con-preservacion-de-los-ganglios-junto-con-capox-y-sintilimab-para-el-cancer-colorrectal-localmente-avanzado-mss-un-estudio-aleatorizado-prospectivo-y-multicentrico 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06594692/node-sparing-short-course-radiation-with-capox-and-sintilimab-for-mss-locally-advanced-colon-cancer-a-randomized-prospective-multicenter-study 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06207981/estudio-de-fase-iii-que-evalua-la-quimioterapia-de-induccion-seguida-de-quimiorradioterapia-en-comparacion-con-la-quimiorradioterapia-estandar-para-el-carcinoma-de-celulas-escamosas-localmente 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06207981/phase-iii-study-evaluating-induction-chemotherapy-followed-by-chemoradiotherapy-compared-to-standard-chemoradiotherapy-for-locally-advanced-scca 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06853769/terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06853769/neoadjuvant-therapy-for-locally-advanced-rectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06035133/tratamiento-del-cancer-colorrectal-localmente-avanzado-con-radioterapia-eliminacion-de-la-terapia-tnt-y-terapia-neoadyuvante 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06035133/treatment-of-low-locally-advanced-rectal-cancer-with-radiotherapy-removal-tnt-plus-neoadjuvant-therapy 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT03997435/folfoxiri-con-o-sin-intensificacion-para-el-cancer-de-recto 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT03997435/folfoxiri-with-or-without-intensification-for-rectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07425054/quimiocirradiacion-adaptada-a-la-respuesta-del-adn-tumoral-circulante-de-vph-tratamiento-con-retifanlimab-en-cancer-anal-en-estadio-avanzado 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07425054/hpv-ctdna-response-adapted-chemoradiation-retifanlimab-treatment-in-advanced-stage-anal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06998758/megestrol-acetato-para-mejorar-la-perdida-de-peso-relacionada-con-la-quimioterapia-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06998758/megestrol-acetate-in-improving-neoadjuvant-chemotherapy-related-weight-loss-in-locally-advanced-crc 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07192627/reseccion-endoscopica-con-dispositivo-de-corte-esd-en-el-cancer-colorrectal-localmente-avanzado-tras-quimiorradioterapia-qrt 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07192627/esd-in-locally-advanced-rectal-cancer-following-crt 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07080411/la-eficacia-de-la-radioterapia-adaptativa-en-linea-guiada-por-resonancia-magnetica-para-el-cancer-de-recto-localmente-avanzado 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07080411/the-efficacy-of-mr-guided-online-adaptive-radiotherapy-for-locally-advanced-rectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06380101/evaluacion-de-un-alimento-medico-con-restriccion-de-aminoacidos-no-esenciales-neaar-en-combinacion-con-terapia-neoadyuvante-total-para-el-cancer-colorrectal-localmente-avanzado-larc 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06380101/evaluating-a-nonessential-amino-acid-restriction-neaar-medical-food-with-total-neoadjuvant-therapy-for-locally-advanced-rectal-cancer-larc 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06596343/evaluacion-de-los-beneficios-de-la-medicina-tradicional-china-personalizada-en-el-tratamiento-postoperatorio-del-cancer-colorrectal-localmente-avanzado 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06596343/evaluating-the-benefits-of-personalized-traditional-chinese-medicine-in-postoperative-treatment-for-locally-advanced-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05673772/radioterapia-secuencial-preoperatoria-de-corta-duracion-y-folfox-para-el-cancer-colorrectal-localmente-avanzado 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05673772/preoperative-sequential-short-course-radiation-therapy-and-folfox-for-locally-advanced-rectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06443671/fruquintinib-neoadyuvante-mas-tislelizumab-en-combinacion-con-mcapeox-frente-a-capeox-para-el-cancer-colorrectal-localmente-avanzado-de-pmmr-mss-intermedio-alto 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06443671/neoadjuvant-fruquintinib-plus-tislelizumab-combined-with-mcapeox-versus-capeox-for-mid-high-pmmr-mss-locally-advanced-rectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06542588/radioterapia-de-corta-duracion-seguida-de-quimioterapia-neoadyuvante-hlx07-y-serplulimab-en-el-cancer-colorrectal-localmente-avanzado-larc 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06542588/short-course-radiotherapy-followed-by-neoadjuvant-chemotherapy-hlx07and-serplulimab-in-larc 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07134101/terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-en-el-recto-inferior-smarti-rc01 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07134101/neoadjuvant-therapy-for-locally-advanced-low-rectal-cancer-smarti-rc01 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07433673/gemcitabina-cisplatino-nab-paclitaxel-gap-y-cemiplimab-para-el-cancer-de-las-vias-biliares-localmente-avanzado-btc 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07433673/gemcitabine-cisplatin-nab-paclitaxel-gap-and-cemiplimab-for-locally-advanced-biliary-tract-cancer-btc 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06441565/fruquintinib-solo-o-en-combinacion-con-hai-folfox-para-el-cancer-colorrectal-refractario 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06441565/fruquintinib-with-or-without-hai-folfox-for-refractory-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06516445/radioterapia-de-corta-duracion-seguida-de-camrelizumab-en-combinacion-con-fluzoparib-y-quimioterapia-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06516445/scrt-followed-by-camrelizumab-combined-with-fluzoparib-and-chemotherapy-as-neoadjuvant-therapy-for-larc 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06099951/tratamiento-neoadyuvante-total-para-cancer-colorrectal-localmente-avanzado-con-pmmr-anticuerpo-anti-pd-1-con-folfoxiri-y-radioterapia-preoperatoria 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06099951/total-neoadjuvant-treatment-for-pmmr-locally-advanced-low-rectal-cancer-anti-pd-1-antibody-with-folfoxiri-and-preoperative-radiation-therapy 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07166263/seguridad-y-eficacia-de-nk510-en-el-tratamiento-del-cancer-gastrico-y-del-cancer-colorrectal 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07166263/safety-and-efficacy-of-nk510-to-treat-gastric-cancer-and-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06307548/cirugia-guiada-por-imagen-de-fluorescencia-seguida-de-terapia-fotodinamica-intraoperatoria-para-mejorar-el-control-tumoral-local-en-pacientes-con-cancer-colorrectal-localmente-avanzado-o-recurrente 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06307548/fluorescence-image-guided-surgery-followed-by-intraoperative-photodynamic-therapy-for-improving-local-tumor-control-in-patients-with-locally-advanced-or-recurrent-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04677413/radioterapia-ultrafraccionada-para-el-cancer-de-recto 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04677413/ultra-fractionated-radiotherapy-for-rectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT02983578/danvatirsen-y-durvalumab-en-el-tratamiento-de-pacientes-con-cancer-de-pancreas-avanzado-y-refractario-cancer-de-pulmon-no-microcitico-y-cancer-colorrectal-con-deficiencia-en-la-reparacion-de-errores 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT02983578/danvatirsen-and-durvalumab-in-treating-patients-with-advanced-and-refractory-pancreatic-non-small-cell-lung-cancer-and-mismatch-repair-deficient-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06577194/un-estudio-de-un-solo-centro-de-un-solo-brazo-sobre-radioterapia-neoadyuvante-de-curso-corto-con-il-2-seguida-de-inmunoterapia-secuencial-con-capox-combinada-con-un-anticuerpo-anti-pd-1-e-il-2-para 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06577194/a-single-center-single-arm-study-of-neoadjuvant-short-course-radiotherapy-with-il-2-followed-by-sequential-immunotherapy-with-capox-combined-with-pd-1-antibody-and-il-2-for-locally-advanced-rectal 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06949111/radioterapia-terapia-sistemica-como-terapia-de-conversion-para-cancer-de-colon-pmmr-mss-t4m0-neo-color 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06949111/radiotherapy-systemic-therapy-as-conversion-therapy-for-pmmr-mss-t4m0-colon-cancer-neo-color 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07281157/irinotecano-liposomal-mas-capecitabina-y-enronsubemab-en-combinacion-con-radioterapia-de-corta-duracion-para-el-tratamiento-neoadyuvante-del-cancer-colorrectal-localmente-avanzado 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07281157/irinotecan-liposome-plus-capecitabine-and-enronsubemab-combined-with-short-course-radiotherapy-for-neoadjuvant-treatment-of-locally-advanced-rectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07467590/combinacion-de-radioterapia-en-dosis-altas-y-bajas-con-inmunoterapia-y-tki-en-cancer-colorrectal-avanzado-un-estudio-de-fase-ii 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07467590/combination-of-high-and-low-dose-radiotherapy-with-immune-therapy-and-tki-in-advanced-colorectal-cancer-a-phase-ii-study 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT03985891/la-eficacia-de-js001-en-combinacion-con-quimioterapia-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT03985891/the-efficacy-of-js001-combined-with-chemotherapy-in-patients-with-locally-advanced-colon-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04495088/quimioterapia-folfox-preoperatoria-frente-a-quimioterapia-postoperatoria-adaptada-al-riesgo-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04495088/preoperative-folfox-versus-postoperative-risk-adapted-chemotherapy-in-patients-with-locally-advanced-rectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT01918527/quimioterapia-neoadyuvante-frente-al-tratamiento-estandar-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT01918527/neoadjuvant-chemotherapy-versus-standard-treatment-in-patients-with-locally-advanced-colon-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT03840239/tnt-para-aumentar-la-tasa-de-respuesta-completa-clinica-en-el-cancer-colorrectal-localizado-en-la-parte-distal 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT03840239/tnt-to-increase-the-clinical-complete-response-rate-for-distal-larc 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06014944/radioterapia-de-corta-duracion-combinada-con-furoquintinib-y-anticuerpo-monoclonal-anti-pd-1 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06014944/short-course-radiotherapy-combined-with-furoquintinib-and-pd-1-monoclonal-antibody 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT04701476/tate-y-pembrolizumab-mk3475-en-el-tratamiento-del-mcrc-y-el-nsclc 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04701476/tate-and-pembrolizumab-mk3475-in-mcrc-and-nsclc 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07291414/una-plataforma-de-automonitoreo-para-el-seguimiento-de-la-seguridad-de-los-medicamentos-y-las-posibles-complicaciones-en-pacientes-con-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07291414/a-self-monitoring-platform-for-tracking-medication-safety-and-concerns-in-cancer-patients 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05806931/administracion-secuencial-de-tas-ox-en-combinacion-con-tas-iri-alternada-con-bevacizumab-para-el-tratamiento-de-pacientes-con-cancer-colorrectal-metastasico-en-lineas-de-tratamiento-avanzadas 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05806931/sequential-tas-ox-alternating-with-tas-iri-plus-bevacizumab-for-late-line-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05484024/radioterapia-de-corta-duracion-seguida-de-quimioterapia-e-inhibidor-de-pd-1-para-el-cancer-colorrectal-localmente-avanzado 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05484024/short-course-radiotherapy-followed-by-chemotherapy-and-pd-1-inhibitor-for-locally-advanced-rectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05608044/un-estudio-de-botensilimab-y-balstilimab-para-el-tratamiento-del-cancer-colorrectal 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05608044/a-study-of-botensilimab-and-balstilimab-for-the-treatment-of-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06435689/estudio-y-modulacion-de-las-respuestas-inmunitarias-en-los-canceres-colorrectales-primarios-y-metastasicos 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06435689/study-and-modulation-of-immune-responses-in-primary-and-metastatic-colon-cancers 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05959356/cetuximab-y-envafolimab-mas-mfolfoxiri-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-irresecable-del-lado-izquierdo-con-ras-braf-de-tipo-salvaje-y-mss 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05959356/cetuximab-and-envafolimab-plus-mfolfoxiri-as-first-line-treatment-for-ras-braf-wild-type-mss-unresectable-left-side-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06449989/comparacion-de-la-concordancia-molecular-genetica-del-tumor-primario-y-las-metastasis-cerebrales-del-cancer-colorrectal 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06449989/comparison-of-molecular-genetic-concordance-of-the-primary-tumor-and-brain-metastases-of-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06826092/metformina-para-el-tratamiento-de-pacientes-con-mcrc-que-reciben-folfiri-mas-terapia-dirigida 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06826092/metformin-for-the-treatment-of-mcrc-patients-undergoing-folfiri-plus-target-therapy 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07502014/un-estudio-clinico-de-iparomlimab-y-tuvonralimab-en-combinacion-con-fruquintinib-y-radioterapia-heterogenea-en-comparacion-con-fruquintinib-como-tratamiento-de-tercera-linea-y-en-lineas-posteriores 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07502014/a-clinical-study-of-iparomlimab-and-tuvonralimab-combined-with-fruquintinib-and-heterogeneous-radiotherapy-versus-fruquintinib-as-third-line-and-subsequent-line-treatment-for-metastatic-colorectal 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06555003/quimioterapia-con-debiri-mas-otros-farmacos-frente-a-quimioterapia-sola-en-metastasis-hepaticas-del-cancer-colorrectal 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06555003/debiri-plus-chemotherapy-vs-chemotherapy-alone-in-colorectal-cancer-liver-metastases 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06992648/trifluridina-tipiracil-mas-regorafenib-frente-a-trifluridina-tipiracil-mas-bevacizumab-para-el-cancer-colorrectal-metastasico-refractario 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06992648/trifluridine-tipiracil-plus-regorafenib-vs-trifluridine-tipiracil-plus-bevacizumab-for-refractory-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07030257/estudio-de-cp-383-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07030257/study-of-cp-383-in-patients-with-advanced-or-metastatic-solid-tumors 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07228832/estudio-de-fase-iii-con-ivonescimab-o-bevacizumab-en-combinacion-con-folfox-en-pacientes-con-cancer-colorrectal-metastasico 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07228832/phase-iii-study-of-ivonescimab-or-bevacizumab-combined-with-folfox-in-patients-with-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07307690/programas-de-ejercicio-fisico-de-8-semanas-frente-a-12-semanas-en-pacientes-con-cancer-colorrectal 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07307690/8-weeks-vs-12-weeks-physical-exercise-programmes-in-colorectal-cancer-patients 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07503756/js212-terapias-combinadas-en-el-cancer-colorrectal-metastasico 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07503756/js212-combination-therapies-in-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04967183/polyprev-estudio-para-comparar-la-prueba-inmunoquimica-fecal-con-la-vigilancia-endoscopica-tras-la-reseccion-de-adenomas-avanzados-en-los-programas-de-deteccion-del-cancer-colorrectal-mediante-la 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04967183/polyprev-study-to-compare-fecal-immunochemical-test-with-endoscopic-surveillance-after-advanced-adenoma-resection-in-fecal-immunochemical-test-colorectal-cancer-screening-programs 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06495853/estudio-prospectivo-de-fase-ii-sobre-el-refuerzo-circunferencial-continuo-de-la-anastomosis-rectal-laparoscopica-para-prevenir-complicaciones 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06495853/prospective-phase-ii-study-on-continuous-circumferential-reinforcement-of-laparoscopic-rectal-anastomosis-to-prevent-complications 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07108127/eficacia-y-seguridad-de-los-biosimilares-de-trastuzumab-y-los-biosimilares-de-pertuzumab-en-combinacion-con-quimioterapia-para-el-tratamiento-neoadyuvante-de-pacientes-con-cancer-colorrectal 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07108127/efficacy-and-safety-of-trastuzumab-biosimilars-and-pertuzumab-biosimilars-combined-with-chemotherapy-for-neoadjuvant-treatment-of-patients-with-locally-advanced-her2-positive-rectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06776757/sintilimab-en-combinacion-con-cetuximab-y-quimioterapia-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-avanzado-con-ras-braf-de-tipo-salvaje 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06776757/sintilimab-in-combination-with-cetuximab-and-chemotherapy-as-first-line-treatment-for-ras-braf-wild-type-advanced-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06790212/quimioterapia-neoadyuvante-con-capox-mas-ivonescimab-frente-a-capox-en-el-cancer-colorrectal-localmente-avanzado 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06790212/neoadjuvant-capox-plus-ivonescimab-versus-capox-for-locally-advanced-colon-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07226115/aprendizaje-predictivo-basado-en-el-empalme-para-la-evaluacion-individual-de-la-quimioterapia-en-el-cancer-colorrectal 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07226115/splicing-based-predictive-learning-for-individual-chemotherapy-evaluation-in-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04959604/mapeo-de-los-ganglios-linfaticos-mediante-un-tinte-fluorescente-en-el-cancer-de-colon 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04959604/lymph-node-mapping-via-flourescent-dye-in-colon-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04556253/ak104-en-el-carcinoma-gastrico-y-el-cancer-colorrectal-localmente-avanzado-msi-h-dmmr 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT04556253/ak104-in-locally-advanced-msi-h-dmmr-gastric-carcinoma-and-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07509424/radioterapia-neoadyuvante-de-corta-duracion-seguida-de-una-combinacion-de-disitamab-vedotina-sintilimab-y-capecitabina-en-el-cancer-colorrectal-localmente-avanzado-con-expresion-de-her2 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07509424/neoadjuvant-short-course-radiotherapy-followed-by-a-combination-of-disitamab-vedotin-sintilimab-and-capecitabine-in-locally-advanced-her2-expressing-rectal-cance 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06204094/radioterapia-que-preserva-los-ganglios-linfaticos-combinada-con-quimioterapia-neoadyuvante-total-con-capox-y-sintilimab-para-el-cancer-colorrectal-medio-y-bajo-con-mss 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06204094/node-sparing-radiotherapy-combined-with-total-neoadjuvant-capox-and-sintilimab-for-mss-middle-and-low-rectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07512674/radioterapia-de-curso-corto-modificada-combinada-con-inmunoterapia-quimioterapia-y-terapia-dirigida-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-mss 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07512674/modified-short-course-radiotherapy-combined-with-immunochemotherapy-and-targeted-therapy-as-first-line-treatment-for-mss-metastatic-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT02008656/ensayo-que-evalua-la-supervivencia-libre-de-enfermedad-a-3-anos-en-pacientes-con-cancer-colorrectal-localmente-avanzado-tratados-con-quimiorradiacion-mas-quimioterapia-de-induccion-o-consolidacion-y 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT02008656/trial-evaluating-3-year-disease-free-survival-in-patients-with-locally-advanced-rectal-cancer-treated-with-chemoradiation-plus-induction-or-consolidation-chemotherapy-and-total-mesorectal-excision-or 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06923345/radioterapia-de-larga-duracion-modificada-seguida-de-quimioterapia-e-inhibidor-de-pd-1-para-pacientes-con-cancer-colorrectal-localmente-avanzado-de-riesgo-alto-y-con-msi-pmmr-estudio-modifi-rc-i 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06923345/modified-long-course-radiotherapy-followed-by-chemotherapy-and-pd-1-inhibitor-for-mss-pmmr-high-risk-mid-low-larc-modifi-rc-i 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04046445/estudio-de-fase-1b-para-evaluar-atp128-vsv-gp128-y-bi-754091-en-pacientes-con-cancer-colorrectal-en-estadio-iv 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT04046445/phase-1b-study-to-evaluate-atp128-vsv-gp128-and-bi-754091-in-patients-with-stage-iv-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06882915/eficacia-y-seguridad-de-trifluridina-tipiracil-tas-102-en-combinacion-con-bevacizumab-y-putalimab-en-el-tratamiento-de-pacientes-con-cmmr-despues-de-una-cirugia-citoreductora-un-estudio-clinico-de-un 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06882915/efficacy-and-safety-of-trifluridine-tipiracil-tas-102-combined-with-bevacizumab-and-putalimab-in-the-treatment-of-patients-with-mcrc-after-cytoreductive-surgery-a-single-arm-single-center-clinical 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06992258/un-ensayo-aleatorizado-de-fase-ii-que-compara-fruquintinib-y-tas-102-con-fruquintinib-en-pacientes-con-cancer-colorrectal-avanzado-metastasico-refractario 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06992258/a-randomized-phase-2-trial-of-fruquintinib-and-tas-102-as-compared-to-fruquintinib-in-patients-with-refractory-advanced-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06787105/fruquintinib-en-pacientes-con-cancer-colorrectal-metastasico 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06787105/fruquintinib-in-patients-with-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05185947/estudio-de-paclitaxel-intravenoso-e-intraperitoneal-y-nilotinib-oral-para-la-carcinomatosis-peritoneal-procedente-de-cancer-primario-de-colon-apendice-intestino-delgado-estomago-colangiocarcinoma 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05185947/study-of-intravenous-and-intraperitoneal-paclitaxel-and-oral-nilotinib-for-peritoneal-carcinomatosis-from-colorectal-appendiceal-small-bowel-gastric-cholangiocarcinoma-breast-ovarian-or-other 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06522919/tratamiento-secuencial-con-inmunoterapia-y-quimioterapia-que-consiste-en-la-administracion-de-pembrolizumab-mas-vacuna-de-celulas-dendriticas-seguido-de-trifluridina-tipiracil-mas-bevacizumab-en 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06522919/sequential-immunochemotherapy-treatment-with-pembrolizumab-plus-dendritic-cell-dc-vaccine-followed-by-trifluridine-tipiracil-plus-bevacizumab-in-refractory-mismatch-repair-proficient-pmmr-or 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06663319/un-estudio-de-jnj-89402638-para-cancer-colorrectal-y-gastrico-metastasico 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06663319/a-study-of-jnj-89402638-for-metastatic-colorectal-and-gastric-cancers 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05093907/un-estudio-para-evaluar-la-seguridad-y-la-eficacia-de-bey1107-en-combinacion-con-capecitabina-en-pacientes-con-cancer-colorrectal-metastasico 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05093907/a-study-to-evaluate-safety-and-efficacy-of-bey1107-in-combination-with-capecitabine-in-patients-with-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06195111/un-estudio-en-el-mundo-real-de-un-regimen-que-contiene-trifluridina-tipiracil-para-el-tratamiento-de-pacientes-con-mcrc-estudio-reflect 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06195111/a-real-world-study-of-trifluridine-tipiracil-containing-regimen-for-the-treatment-of-patients-with-mcrc-reflect-study 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05710809/el-proyecto-save-sarcopenia-y-vertigo-en-pacientes-ancianos-con-cancer-colorrectal 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05710809/the-save-project-sarcopenia-and-vertigo-in-aging-patients-with-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07528209/quimioterapia-neoadyuvante-con-capox-con-o-sin-pucotenlimab-mas-radioterapia-selectiva-para-el-cancer-colorrectal-localmente-avanzado 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07528209/neoadjuvant-capox-with-or-without-pucotenlimab-plus-selective-radiotherapy-for-locally-advanced-rectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06678919/registro-agmt-de-cancer-colorrectal-metastasico-mcrc-en-tercera-linea-de-tratamiento-y-posteriores 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06678919/agmt-metastatic-colorectal-cancer-registry-mcrc-third-line-and-beyond 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04235114/evaluacion-de-89zr-dfo-nimotuzumab-para-la-obtencion-de-imagenes-no-invasivas-de-canceres-egfr-mediante-tomografia-por-emision-de-positrones-tep 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04235114/evaluation-of-89zr-dfo-nimotuzumab-for-non-invasive-imaging-of-egfr-cancers-by-positron-emission-tomography-pet 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07200141/aumento-simultaneo-de-la-dosis-en-la-radioterapia-neoadyuvante-para-el-cancer-de-recto 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07200141/simultaneous-boost-in-neoadjuvant-radiotherapy-for-rectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06098560/el-adn-tumoral-circulante-ctdna-como-biomarcador-predictivo-para-la-inmunoterapia-en-pacientes-con-cancer-colorrectal-avanzado-o-localmente-avanzado-con-dmmr-msi-h 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06098560/circulating-tumor-dna-ctdna-as-a-predictive-biomarker-for-immunotherapy-in-advanced-or-locally-advanced-dmmr-msi-h-colorectal-patients 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05462236/inhibidor-de-mnk-aum001-en-combinacion-con-pembrolizumab-o-irinotecan-para-el-tratamiento-del-cancer-colorrectal-metastasico 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05462236/mnk-inhibitor-aum001-in-combination-with-either-pembrolizumab-or-irinotecan-to-treat-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05645094/envafolimab-como-tratamiento-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado-y-resecable-con-msi-h-dmmr 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05645094/neoadjuvant-envafolimab-in-resectable-and-locally-advanced-msi-h-dmmr-rectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07116577/radioterapia-combinada-con-ql1706-tas-102-y-bevacizumab-en-mcrc 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07116577/radiotherapy-combined-ql1706-tas-102-and-bevacizumab-in-mcrc 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05803382/evaluacion-de-la-adicion-de-un-farmaco-antitumoral-zen003694-al-tratamiento-de-quimioterapia-habitual-capecitabina-para-canceres-metastasicos-o-irresecables 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05803382/testing-the-addition-of-an-anti-cancer-drug-zen003694-to-the-usual-chemotherapy-treatment-capecitabine-for-metastatic-or-unresectable-cancers 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06794931/estudio-sobre-el-impacto-de-una-dieta-mediterranea-modificada-en-pacientes-con-cancer-colorrectal-que-reciben-tratamiento-oncologico-activo 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06794931/study-on-the-impact-of-a-modified-mediterranean-diet-in-patients-with-colorectal-cancer-undergoing-active-medical-oncology-treatment 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05057052/crioablacion-combinada-con-sintilimab-mas-regorafenib-en-metastasis-hepaticas-de-cancer-colorrectal-previamente-tratadas 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05057052/cryoablation-combined-with-sintilimab-plus-regorafenib-in-previously-treated-colorectal-cancer-liver-metastasis 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04730544/dos-esquemas-de-tratamiento-combinados-con-nivolumab-e-ipilimumab-en-pacientes-con-mcrc-dmmr-y-o-msi 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT04730544/two-combination-treatment-regimens-of-nivolumab-and-ipilimumab-in-patients-with-dmmr-and-or-msi-mcrc 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05523245/prediccion-de-la-eficacia-de-la-terapia-neoadyuvante-en-pacientes-con-cancer-colorrectal-localmente-avanzado-mediante-una-plataforma-de-inteligencia-artificial-basada-en-la-resonancia-magnetica 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05523245/predicting-the-efficacy-of-neoadjuvant-therapy-in-patients-with-locally-advanced-rectal-cancer-using-an-ai-platform-based-on-multi-parametric-mri 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05808790/metastasis-pulmonares-de-cancer-colorrectal-metastasis-pulmonar-versus-radioterapia-ablativa-estereotactica 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05808790/colorectal-pulmonary-metastases-pulmonary-metastasectomy-versus-stereotactic-ablative-radiotherapy 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06843655/marcadores-radiologicos-en-el-cancer-de-recto-localmente-avanzado 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06843655/radiological-markers-in-locally-advanced-rectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT03657641/regorafenib-y-pembrolizumab-en-el-tratamiento-de-participantes-con-cancer-colorrectal-avanzado-o-metastasico 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT03657641/regorafenib-and-pembrolizumab-in-treating-participants-with-advanced-or-metastatic-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06276686/ejercicio-para-mejorar-la-eficacia-de-la-quimiorradioterapia-prolongada-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06276686/exercise-for-improving-long-course-chemoradiotherapy-efficacy-in-people-with-locally-advanced-rectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06867822/ensayo-clinico-de-proagio-en-cancer-colorrectal-avanzado-o-metastasico 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06867822/trial-of-proagio-in-advanced-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT02863172/base-molecular-de-las-variaciones-en-los-sindromes-hereditarios-de-cancer-colorrectal 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT02863172/molecular-basis-for-variations-in-hereditary-colorectal-cancer-syndromes 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04673955/investigacion-en-la-practica-clinica-del-inhibidor-de-braf-encorafenib-y-el-cetuximab-como-tratamiento-de-nueva-generacion-para-el-ccrc 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04673955/braf-inhibitor-encorafenib-and-cetuximab-real-life-investigation-of-next-generation-crc-treatment 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT03860272/anticuerpo-monoclonal-anti-ctla-4-modificado-mediante-ingenieria-de-la-region-fc-en-cancer-avanzado 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT03860272/fc-engineered-anti-ctla-4-monoclonal-antibody-in-advanced-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07543471/un-estudio-de-fase-i-multicentrico-aleatorizado-doble-ciego-y-controlado-en-paralelo-que-compara-hlx05-n-con-erbitux-r-en-el-cancer-colorrectal-metastasico 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07543471/a-phase-i-multicentre-randomized-double-blind-parallel-controlled-study-of-hlx05-n-vs-erbitux-r-in-metastatic-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05601505/estrategia-de-tratamiento-neoadyuvante-guiada-por-el-adn-tumoral-circulante-para-el-cancer-colorrectal-localmente-avanzado 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05601505/circulating-tumor-dna-guided-neoadjuvant-treatment-strategy-for-locally-advanced-rectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06353854/cohorte-nacional-prospectiva-para-evaluar-biomarcadores-predictivos-de-resistencia-a-la-inmunoterapia-en-pacientes-con-cancer-colorrectal-metastasico-msi-dmmr-coresim 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06353854/prospective-national-cohort-evaluating-predictive-biomarkers-of-resistance-to-immunotherapy-in-patients-with-msi-dmmr-metastatic-colorectal-cancer-coresim 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07268677/un-estudio-clinico-de-un-solo-brazo-que-evalua-la-combinacion-de-pirfenidona-y-sintilimab-con-la-quimioterapia-neoadyuvante-estandar-en-pacientes-con-cancer-colorrectal-y-metastasis-peritoneal 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07268677/a-single-arm-clinical-study-evaluating-pirfenidone-and-sintilimab-in-combination-with-standard-neoadjuvant-chemotherapy-for-colorectal-cancer-patients-with-peritoneal-metastasis 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06149481/estudio-de-fase-i-ii-del-regimen-de-inmunoterapia-combinada-sx-682-vacuna-triadeno-retifanlimab-y-agonista-de-il-15-n-803-star15-para-el-cancer-colorrectal-metastasico-mcrc 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06149481/phase-i-ii-study-of-the-combination-immunotherapy-regimen-sx-682-triadeno-vaccine-retifanlimab-and-il-15-agonist-n-803-star15-for-metastatic-colorectal-cancer-mcrc 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05663775/mesalazina-como-tratamiento-profilactico-para-prevenir-la-colitis-tras-el-tratamiento-con-ipilimumab-nivolumab-ipi-nivo 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05663775/prophylactic-mesalamine-to-prevent-colitis-following-treatment-with-ipilimumab-nivolumab-ipi-nivo 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07355764/ma-crc-ii-016-shr-1811 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT04874259/terapia-local-para-metastasis-hepaticas-irresecables-de-cancer-colorrectal 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04874259/lt-for-unresectable-colorectal-liver-metastasis 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06484153/fruquintinib-y-pirfenidona-en-combinacion-con-un-anticuerpo-anti-pd-1-en-el-tratamiento-del-carcinoma-colorrectal-avanzado-o-metastasico-pmmr-mss 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06484153/fruquintinib-and-pirfenidone-in-combination-with-anti-pd-1-antibody-in-advanced-or-metastatic-pmmr-mss-colorectal-carcinoma 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05772923/preservacion-de-organos-en-el-cancer-de-recto-braquiterapia-de-contacto-con-rayos-x-frente-a-la-prolongacion-del-intervalo-de-espera-y-la-escision-local 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05772923/organ-preservation-in-rectal-cancer-contact-x-ray-brachytherapy-vs-extending-the-waiting-interval-and-local-excision 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06662643/un-ensayo-clinico-que-compara-la-anastomosis-de-turnbull-cutait-escalonada-con-la-anastomosis-directa-mas-ileostomia-profilactica-en-el-tratamiento-del-cancer-rectal-bajo-despues-de-la-reseccion-del 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06662643/a-clinical-trial-comparing-staged-turnbull-cutait-pull-through-anastomosis-with-direct-anastomosis-plus-prophylactic-ileostomy-in-the-treatment-of-low-rectal-cancer-after-internal-sphincter-resection 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05366881/estudio-prospectivo-observacional-de-validacion-del-ensayo-de-cfdna-para-la-deteccion-temprana-del-cancer-y-la-enfermedad-residual-minima 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05366881/cfdna-assay-prospective-observational-validation-for-early-cancer-detection-and-minimal-residual-disease 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06829355/estudio-de-inmunoterapia-con-timalfasina-y-regimen-triple-en-cancer-colorrectal-avanzado-mss-pmmr 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06829355/thymalfasin-immunotherapy-study-with-triple-regimen-in-advanced-mss-pmmr-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06907095/evaluacion-de-una-cohorte-para-la-deteccion-temprana-del-cancer-en-individuos-de-alto-riesgo-mediante-el-analisis-de-fluidos-corporales 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06907095/cohort-evaluation-of-body-fluids-early-detection-of-cancer-in-high-risk-individuals 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05860322/el-efecto-de-la-suplementacion-con-inulina-en-los-resultados-de-la-cirugia-de-cancer-colorrectal 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05860322/the-effect-of-inulin-supplementation-on-colorectal-surgery-outcomes 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT04587128/terapia-anti-egfr-en-lineas-tempranas-para-facilitar-el-retratamiento-en-pacientes-seleccionados-con-mcrc 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT04587128/early-line-anti-egfr-therapy-to-facilitate-retreatment-for-select-patients-with-mcrc 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07363408/ivonescimab-y-adg126-solos-y-en-combinacion-con-leucovorina-y-fluorouracilo-o-el-regimen-folfiri-para-el-tratamiento-del-cancer-colorrectal-avanzado-metastasico-con-estabilidad-microsatelital 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07363408/ivonescimab-and-adg126-alone-and-in-combination-with-leucovorin-and-fluorouracil-or-folfiri-regimen-for-the-treatment-of-microsatellite-stable-advanced-metastatic-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06831669/metabolomica-para-predecir-la-respuesta-al-tratamiento-y-las-toxicidades-en-el-cancer-de-recto 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06831669/metabolomics-to-predict-treatment-response-and-toxicities-in-rectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07362823/un-estudio-sobre-la-eficacia-del-modelo-de-educacion-sobre-habitos-saludables-en-el-metaverso-basado-en-el-modelo-transteorico-para-mejorar-la-calidad-de-vida-y-modificar-el-estilo-de-vida-en 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07362823/a-study-on-the-efficacy-of-the-metaverse-lifestyle-health-education-model-based-on-the-transtheoretical-model-for-improving-quality-of-life-and-modifying-lifestyle-in-colorectal-cancer-survivors 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05914766/una-intervencion-informativa-y-de-apoyo-para-pacientes-con-cancer-de-recto-localmente-avanzado 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05914766/an-informational-and-supportive-care-intervention-for-patients-with-locally-advanced-rectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06846268/adg126-y-pembrolizumab-como-tratamiento-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06846268/neoadjuvant-adg126-and-pembrolizumab-in-locally-advanced-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06878131/precision-mrd-estudio-observacional-prospectivo-sobre-terapia-sistemica-dirigida-por-biomarcadores-en-pacientes-con-cancer-colorrectal-y-enfermedad-residual-minima 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06878131/precision-mrd-prospective-observational-study-of-biomarker-directed-systemic-therapy-for-colorectal-cancer-patients-with-minimal-residual-disease 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07012954/cetuximab-o-bevacizumab-guiados-por-ctdna-mas-trifluridina-tipiracil-en-pacientes-con-mcrc-con-ras-braf-de-tipo-salvaje 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07012954/ctdna-guided-cetuximab-or-bevacizumab-plus-trifluridine-tipiracil-in-ras-braf-wild-type-mcrc 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06698146/metastasis-colorrectal-en-el-higado-extraccion-con-trasplante-auxiliar-y-reseccion-tardia 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06698146/colorectal-metastasis-to-liver-extraction-with-auxiliary-transplant-and-delayed-resection 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06980454/comparacion-de-la-farmacocinetica-en-la-fase-i-de-hlx05-frente-a-erbitux-r-en-hombres-chinos-sanos-seguridad-inmunogenicidad-y-farmacocinetica 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06980454/phase-i-pk-comparison-of-hlx05-vs-erbitux-r-in-healthy-chinese-males-safety-immunogenicity-and-pharmacokinetics 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07088393/diagnostico-mediante-inteligencia-artificial-de-los-diferentes-patrones-de-crecimiento-histopatologico-de-las-metastasis-hepaticas-del-cancer-colorrectal 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07088393/artificial-intelligence-diagnosis-of-different-histopathological-growth-patterns-of-colorectal-cancer-liver-metastasis 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07363863/patron-de-tratamiento-y-resultados-en-el-carcinoma-rectal-localmente-avanzado 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07363863/pattern-of-treatment-and-outcomes-of-locally-advanced-rectal-carcinoma 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06778382/terapia-sistemica-diferida-tras-un-tratamiento-local-destructivo-de-las-oligometastasis-pulmonares-despues-de-haber-confirmado-la-ausencia-de-enfermedad-ned-en-el-cancer-colorrectal 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06778382/delayed-systemic-therapy-following-destructive-local-treatment-of-pulmonary-oligometastases-after-no-evidence-of-disease-ned-in-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05994482/colonoscopia-de-vigilancia-en-adultos-mayores-el-estudio-survolderadults 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05994482/surveillance-colonoscopy-in-older-adults-the-survolderadults-study 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07372300/electrohipertermia-modulada-en-combinacion-con-terapia-multimodal-para-el-cancer-de-recto-localmente-avanzado 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07372300/modulated-electro-hyperthermia-in-combination-with-multimodal-therapy-for-locally-advanced-rectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT03465982/momento-optimo-para-la-cirugia-minimamente-invasiva-tras-la-quimiorradioterapia-neoadyuvante-para-el-cancer-de-recto 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT03465982/timing-to-minimally-invasive-surgery-after-neoadjuvant-chemoradiotherapy-for-rectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06234007/radioterapia-de-corta-duracion-seguida-de-fruquintinib-mas-adebrelimab-y-capox-en-el-tratamiento-neoadyuvante-completo-del-cancer-colorrectal-localmente-avanzado-un-estudio-multicentrico-de-un-solo 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06234007/short-course-radiotherapy-followed-by-fruquintinib-plus-adebrelimab-and-capox-in-the-full-course-neoadjuvant-treatment-of-locally-advanced-rectal-cancer-a-multicenter-single-arm-open-label-study 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05776381/el-impacto-de-una-herramienta-de-apoyo-a-la-toma-de-decisiones-en-las-elecciones-de-tratamiento-para-pacientes-con-un-polipo-colorrectal-maligno-inesperado 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05776381/the-impact-of-a-patient-decision-aid-on-treatment-choices-for-patients-with-an-unexpected-malignant-colorectal-polyp 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07565831/estudio-sobre-la-prediccion-de-metastasis-en-los-ganglios-linfaticos-regionales-en-el-cancer-colorrectal-mediante-tomografia-computarizada-espectral-combinada-con-msi 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07565831/study-on-the-prediction-of-regional-lymph-node-metastasis-in-colorectal-cancer-by-spectral-ct-combined-with-msi 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07562711/estudio-aleatorizado-sobre-la-metilacion-del-ctdna-plasmatico-para-guiar-las-decisiones-sobre-la-quimioterapia-adyuvante-en-pacientes-con-cancer-colorrectal-t3n0-de-alto-riesgo 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07562711/randomized-study-of-plasma-ctdna-methylation-to-guide-adjuvant-chemotherapy-decisions-in-high-risk-t3n0-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07171554/evaluacion-de-una-prueba-diagnostica-para-identificar-los-mejores-farmacos-para-el-tratamiento-del-cancer-colorrectal-metastasico 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07171554/evaluation-of-a-diagnostic-test-to-identify-the-best-drugs-for-treatment-of-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06179602/estudio-de-cohorte-prospectivo-sobre-la-ablacion-termica-de-tumores-hepaticos-malignos 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06179602/prospective-cohort-study-on-thermal-ablation-of-malignant-liver-tumors 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07381309/virus-oncolitico-h101-radioterapia-estereotactica-ablativa-sbrt-quimioterapia-terapia-dirigida-inmunoterapia-para-metastasis-hepaticas-irresecables-de-cancer-colorrectal-crlm 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07381309/oncolytic-virus-h101-sbrt-chemotherapy-targeted-therapy-immunotherapy-for-unresectable-crlm 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT04304209/anticuerpo-anti-pd1-sintilimab-en-combinacion-con-quimiorradioterapia-para-el-cancer-colorrectal-localmente-avanzado 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT04304209/pd1-antibody-sintilimab-chemoradiotherapy-for-locally-advanced-rectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT03711110/estrategias-de-prevencion-cardiovascular-en-pacientes-oncologicos-de-edad-avanzada-ensayo-clinico-cartier 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT03711110/cardiovascular-prevention-strategies-in-elderly-patients-with-cancer-cartier-clinical-trial 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06043466/un-ensayo-clinico-dirigido-a-las-celulas-t-con-receptor-quimerico-de-antigeno-car-t-contra-el-antigeno-cea-para-el-tratamiento-de-tumores-solidos-malignos-avanzados-cea-positivos 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06043466/a-clinical-trial-targeting-cea-chimeric-antigen-receptor-t-car-t-for-cea-positive-advanced-malignant-solid-tumors 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06268015/optimizacion-de-botensilimab-y-balstilimab-en-el-cancer-colorrectal 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06268015/botensilimab-and-balstilimab-optimization-in-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06808685/estudio-nacional-multicentrico-en-el-mundo-real-para-evaluar-la-eficacia-y-la-seguridad-del-bevacizumab-biosimilar-elovie 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06808685/real-world-multicenter-national-study-to-evaluate-the-effectiveness-and-safety-of-biosimilar-bevacizumab-elovie 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06848465/terapia-de-radiacion-intrahepatica-guiada-por-imagenes-combinada-con-inmunoterapia-y-quimioterapia-para-el-cancer-colorrectal-con-metastasis-hepaticas 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06848465/ldrt-combined-with-immunochemotherapy-for-colorectal-cancer-with-liver-metastasis 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05674526/un-estudio-de-fase-1b-de-wu-nk-101-en-combinacion-con-cetuximab 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05674526/a-phase-1b-study-of-wu-nk-101-in-combination-with-cetuximab 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05970302/xelox-bevacizumab-tislelizumab-para-el-tratamiento-de-primera-linea-del-mcrc-con-mss-pmmr-y-mutacion-en-ras 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05970302/xelox-bev-tislelizumab-for-first-line-treatment-of-mss-pmmr-ras-mutated-mcrc 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05913674/viabilidad-tecnica-de-la-quimioterapia-intraperitoneal-modificada-en-las-primeras-etapas-del-periodo-postoperatorio-mepic 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05913674/technical-feasibility-of-modified-early-post-operative-intraperitoneal-chemotherapy-mepic 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07393048/aplicacion-y-exploracion-de-la-tecnologia-de-deteccion-personalizada-de-ctdna-mrd-para-predecir-la-eficacia-de-la-terapia-neoadyuvante-en-el-cancer-de-recto 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07393048/application-and-exploration-of-personalized-ctdna-mrd-detection-technology-in-predicting-the-efficacy-of-neoadjuvant-therapy-for-rectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06714357/acido-valproico-para-potenciar-la-eficacia-del-tratamiento-anti-egfr-y-prevenir-revertir-la-resistencia-en-el-cancer-colorrectal 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06714357/valproic-acid-to-potentiate-anti-egfr-treatment-efficacy-and-prevent-revert-resistance-in-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07581912/tratamiento-neoadyuvante-con-fulzerasib-mas-cetuximab-n01-en-cancer-colorrectal-localmente-avanzado-con-mutacion-kras-g12c-con-o-sin-metastasis-resecables 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07581912/neoadjuvant-treatment-of-fulzerasib-plus-cetuximab-n01-in-kras-g12c-mutated-locally-advanced-colorectal-cancer-with-or-without-resectable-metastases 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06762405/prodige-90-ffcd-2204-dostarlimab-neoadyuvante-con-radioterapia-de-corta-duracion-en-una-estrategia-de-observacion-y-espera-para-pacientes-con-cancer-colorrectal-localmente-avanzado-inestable-en 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06762405/prodige-90-ffcd-2204-neoadjuvant-dostarlimab-with-short-course-radiotherapy-in-a-watch-and-wait-strategy-for-microsatellite-unstable-or-mismatch-repair-deficient-locally-advanced-rectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06940388/tratamiento-neoadyuvante-total-con-o-sin-tislelizumab-para-el-cancer-colorrectal-localmente-avanzado 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06940388/total-neoadjuvant-treatment-with-or-without-tislelizumab-for-locally-advanced-rectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05220800/efectos-de-la-administracion-intravenosa-de-hierro-en-pacientes-con-deficiencia-de-hierro-y-cancer-colorrectal-que-no-presentan-anemia 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05220800/effects-of-intravenous-administered-iron-in-non-anemic-iron-deficient-patients-with-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06298916/64cu-lnth-1363s-en-pacientes-con-sarcoma-o-cancer-del-tracto-gastrointestinal 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06298916/64cu-lnth-1363s-in-patients-with-sarcoma-or-gastrointestinal-tract-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05731726/serplulimab-en-combinacion-con-capeox-y-celecoxib-como-tratamiento-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05731726/serplulimab-combined-with-capeox-celecoxib-as-neoadjuvant-treatment-for-locally-advanced-rectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07025850/estudio-de-eficacia-de-la-digoxina-en-combinacion-con-serplulimab-y-quimioterapia-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-avanzado-mss 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07025850/efficacy-study-of-digoxin-combined-with-serplulimab-and-chemotherapy-in-first-line-treatment-of-mss-advanced-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07580027/radioterapia-preoperatoria-adaptativa-concomitante-con-quimioterapia-para-el-adenocarcinoma-rectal-ensayo-adaptativo-de-cancer-rectal-02 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07580027/preoperative-adaptive-radiotherapy-concomitant-to-chemotherapy-for-rectal-adenocarcinoma-adaptive-rectal-cancer-trial-02 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05646511/tnt-de-quimiorradioterapia-qrt-capox-frente-a-qrt-capoxiri-para-el-cancer-colorrectal-localmente-avanzado 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05646511/tnt-of-scrt-capox-vs-scrt-capoxiri-for-locally-advanced-rectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06557668/resultados-clinicos-del-tratamiento-con-inmunomoduladores-y-terapias-contra-el-cancer-en-pacientes-con-cancer-colorrectal 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06557668/clinical-outcomes-of-treatment-with-immunomodulator-plus-cancer-therapies-for-patients-with-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06680739/analisis-del-perfil-de-celulas-individuales-para-predecir-la-persistencia-de-la-respuesta-a-la-inmunoterapia 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06680739/single-cell-profiling-persistance-to-immunotherapy 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07409805/vacuna-ymn-136-para-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal-que-presentan-progresion-tras-el-tratamiento-en-tercera-linea 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07409805/ymn-136-vaccine-for-patients-with-liver-metastasis-of-colorectal-cancer-progressing-after-third-line-treatment 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06130280/un-estudio-sobre-la-radioterapia-estereotactica-de-cuerpo-unico-sbrt-guiada-por-resonancia-magnetica-rm-en-pacientes-con-metastasis-hepaticas-procedentes-del-cancer-colorrectal 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06130280/a-study-of-single-fraction-stereotactic-body-radiation-therapy-sbrt-guided-by-magnetic-resonance-imaging-mri-in-people-with-liver-metastasis-from-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT03525262/terapia-oncologica-para-el-cancer-de-prostata-que-garantiza-la-preservacion-de-los-nervios-y-los-vasos-sanguineos-poten-c 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT03525262/prostate-oncologic-therapy-while-ensuring-neurovascular-conservation-poten-c 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06455254/cadonilimab-en-combinacion-con-regorafenib-como-tratamiento-de-tercera-linea-en-pacientes-con-crlm-mss 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06455254/cadonilimab-combined-with-regorafenib-as-a-third-line-treatment-in-patients-with-mss-crlm 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05844514/analisis-del-aliento-en-pacientes-con-cancer-colorrectal-cobra2 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05844514/colorectal-breath-analysis-cobra2 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05030493/un-analisis-adicional-de-los-datos-del-estudio-exploratorio-paradigm-nct02394834-en-pacientes-con-cancer-colorrectal-avanzado-o-recurrente 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05030493/an-additional-analysis-of-data-from-the-paradigm-exploratory-study-nct02394834-in-patients-with-advanced-recurrent-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07210502/efectos-secundarios-de-la-braquiterapia-de-baja-dosis-y-la-radioterapia-ultrafraccionada-en-el-cancer-de-prostata-de-riesgo-bajo-a-intermedio 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07210502/side-effects-of-low-dose-rate-brachytherapy-and-ultra-hypofractionated-radiotherapy-in-low-to-intermediate-risk-prostate-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06191120/imagenes-moleculares-con-fapi-para-el-diagnostico-del-subtipo-desfavorable-cms4-de-cancer-colorrectal 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06191120/fapi-molecular-imaging-for-diagnosis-of-the-cms4-unfavorable-colorectal-cancer-subtype 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT02521844/un-estudio-para-evaluar-la-seguridad-y-la-tolerabilidad-de-etc-1922159-como-agente-unico-y-en-combinacion-con-pembrolizumab-en-tumores-solidos-avanzados 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT02521844/a-study-to-evaluate-the-safety-and-tolerability-of-etc-1922159-as-a-single-agent-and-in-combination-with-pembrolizumab-in-advanced-solid-tumours 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT01174121/inmunoterapia-con-linfocitos-infiltrantes-tumorales-para-pacientes-con-cancer-metastasico 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT01174121/immunotherapy-using-tumor-infiltrating-lymphocytes-for-patients-with-metastatic-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06253871/un-estudio-de-fase-i-ib-de-iam1363-en-canceres-her2 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06253871/a-phase-1-1b-study-of-iam1363-in-her2-cancers 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06229041/tratamiento-neoadyuvante-total-inmunoterapia-para-cancer-colorrectal-localmente-avanzado-de-alto-riesgo-tnti 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06229041/total-neoadjuvant-treatment-immunotherapy-for-high-risk-locally-advanced-rectal-cancer-tnti 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04585035/estudio-para-evaluar-d-1553-en-sujetos-con-tumores-solidos 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT04585035/study-to-evaluate-d-1553-in-subjects-with-solid-tumors 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06560671/comparacion-de-la-satisfaccion-del-paciente-y-la-eficacia-tras-la-aplicacion-de-un-nuevo-metodo-o-de-un-metodo-convencional-de-educacion-sanitaria-para-la-preparacion-intestinal-antes-de-la 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06560671/compare-the-patient-satisfaction-and-effectiveness-after-novel-application-based-or-conventional-health-education-of-bowel-preparation-for-colonoscopy 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06078670/inhibidor-de-parp-cvl218-en-terapia-combinada-para-pacientes-con-tumores-solidos-avanzados 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06078670/parp-inhibitor-cvl218-in-combination-therapy-for-patients-with-advanced-solid-tumors 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07198958/registro-de-eventos-adversos-inmunologicos-en-pacientes-onco-hematologicos-tratados-con-inmunoterapia 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07198958/immune-adverse-events-registry-in-onco-hematologic-patients-treated-with-immunotherapy 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07407647/dhea-vaginal-para-mejorar-la-salud-vaginal-despues-de-la-radioterapia-en-mujeres-con-cancer-ginecologico-anal-o-de-recto 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07407647/vaginal-dhea-to-improve-vaginal-health-after-radiation-for-women-with-gynecologic-anal-or-rectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06979882/investigacion-de-la-dinamica-de-la-metilacion-multigenica-en-la-vigilancia-de-la-respuesta-al-tratamiento-en-el-carcinoma-intestinal 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06979882/investigating-multigene-methylation-dynamics-in-treatment-response-surveillance-for-intestinal-carcinoma 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06267378/evaluacion-de-la-fragilidad-y-sus-efectos-en-pacientes-que-se-someten-a-una-cirugia-mayor-del-tracto-gastrointestinal 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06267378/assessing-frailty-and-its-impacts-on-patients-facing-major-gi-surgery 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT03875781/estudio-de-no-inferioridad-de-la-quimioterapia-preoperatoria-sin-irradiacion-pelvica-para-el-cancer-de-recto 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT03875781/non-inferiority-study-of-preoperative-chemotherapy-without-pelvic-irradiation-for-rectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05726136/administracion-de-liquidos-y-volumen-plasmatico-durante-la-cirugia 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05726136/fluid-challenge-and-plasma-volume-during-surgery 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06746545/un-estudio-clinico-prospectivo-de-etiqueta-abierta-de-un-solo-brazo-de-fase-ii-para-evaluar-la-combinacion-de-fruquintinib-con-s-1-en-el-tratamiento-del-cancer-colorrectal-metastasico 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06746545/a-prospective-open-label-single-arm-phase-ii-clinical-study-of-fruquintinib-combined-with-s-1-for-the-treatment-of-metastatic-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06889610/un-estudio-clinico-de-fase-ii-sobre-la-ablacion-multimodal-combinada-con-terapia-sistemica-en-tumores-solidos-avanzados 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06889610/a-phase-ii-clinical-study-of-multimodal-ablation-combined-with-systemic-drug-therapy-for-advanced-solid-tumors 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06831981/hipertermia-con-quimiorradioterapia-en-el-cancer-de-recto 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06831981/hyperthermia-with-chemoradiotherapy-in-rectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05296681/producto-microbiano-para-promover-la-salud-del-microbioma-y-mejorar-la-administracion-de-la-quimioterapia 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05296681/microbiotic-product-to-promote-microbiome-health-and-improve-chemotherapy-delivery 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07277842/pd-1-folfoxiri-frente-a-capox-como-terapia-neoadyuvante-total-para-cancer-de-recto-pmmr 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07277842/pd-1-folfoxiri-vs-capox-as-total-neoadjuvant-therapy-for-pmmr-low-rectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06959550/estudio-de-fase-ii-del-anticuerpo-biespecifico-anti-pd-1-vegf-ivonescimab-en-pacientes-con-cancer-colorrectal-metastasico-previamente-tratado 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06959550/phase-ii-study-of-anti-pd-1-vegf-bispecific-antibody-ivonescimab-in-patients-with-previously-treated-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06424522/un-programa-de-manejo-intestinal-enema-rectal-retrogrado-para-el-tratamiento-del-sindrome-de-reseccion-anterior-baja-en-pacientes-con-cancer-de-recto 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06424522/a-bowel-management-program-retrograde-rectal-enema-for-the-treatment-of-low-anterior-resection-syndrome-in-rectal-cancer-patients 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05963490/regorafenib-solo-o-en-combinacion-con-radioterapia-hipofraccionada-de-baja-dosis-mas-toripalimab-para-el-cancer-colorrectal-metastasico 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05963490/regorafenib-alone-or-in-combination-with-hypofractionated-low-dose-radiotherapy-plus-toripalimab-for-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06642844/quimioterapia-basada-en-bevacizumab-adaptada-a-la-farmacocinetica-del-bevacizumab-en-el-tratamiento-de-primera-linea 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06642844/bevacizumab-based-chemotherapy-adapted-to-bevacizumab-pharmacokinetics-in-1st-line-treatment 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06843434/un-estudio-de-botensilimab-y-balstilimab-para-el-adenocarcinoma-rectal 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06843434/a-study-of-botensilimab-and-balstilimab-for-rectal-adenocarcinoma 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07066657/un-estudio-de-mrg007-arr-217-en-pacientes-con-tumores-solidos-avanzados 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07066657/a-study-of-mrg007-arr-217-in-patients-with-advanced-solid-tumors 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04938986/interes-del-immunoscore-r-como-herramienta-complementaria-postoperatoria-para-la-deteccion-del-riesgo-de-recurrencia-en-pacientes-con-cancer-colorrectal-no-metastasico 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04938986/interest-of-the-immunoscore-r-as-a-post-operative-complementary-tool-for-the-detection-of-the-risk-of-recurrence-in-patients-with-nonmetastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06722534/celecoxib-para-la-prevencion-de-la-progresion-en-el-sindrome-de-peutz-jeghers 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06722534/celecoxib-for-prevention-of-progression-in-peutz-jeghers-syndrome 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07135115/intervenciones-dirigidas-al-estilo-de-vida-para-mejorar-el-cribado-del-cancer-colorrectal 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07135115/targeting-lifestyle-to-improve-colorectal-cancer-screening 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05229003/irinotecan-mas-anlotinib-o-ademas-en-combinacion-con-penpulimab-para-el-tratamiento-de-segunda-linea-del-mcrc 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05229003/irinotecan-plus-anlotinib-or-further-in-combination-with-penpulimab-for-second-line-treatment-of-mcrc 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05022030/mcapox-cetuximab-frente-a-mfolfox6-cetuximab-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-del-lado-izquierdo-con-genes-ras-braf-de-tipo-salvaje 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05022030/first-line-mcapox-cetuximab-vs-mfolfox6-cetuximab-for-metastatic-left-sided-crc-with-wild-type-ras-braf-genes 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07272642/un-estudio-de-fase-i-multicentrico-y-basado-en-imagenes-de-lnth-2403-en-participantes-con-tumores-solidos-localmente-avanzados-o-metastasicos 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07272642/a-phase-1-multicenter-imaging-study-of-lnth-2403-in-participants-with-locally-advanced-or-metastatic-solid-tumors 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07067385/vacuna-de-arnm-personalizada-contra-el-cancer-para-el-tratamiento-de-tumores-solidos-gastrointestinales 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07067385/personalized-mrna-cancer-vaccine-for-gastrointestinal-solid-tumor-treatment 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05611034/perfusion-pulmonar-in-vivo-ivlp-para-el-cancer-colorrectal-metastasico-en-pulmon 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05611034/in-vivo-lung-perfusion-ivlp-for-colorectal-cancer-metastatic-to-lung 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07178613/evaluacion-de-la-seguridad-y-eficacia-de-la-administracion-de-serina-en-combinacion-con-farmacos-a-base-de-fluorouracilo 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07178613/assessment-of-the-dose-safety-and-efficacy-of-serine-combined-with-fluorouracil-drugs 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT02113384/cancer-colorrectal-localmente-avanzado-celulas-tumorales-exfoliadas-del-peritoneo 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT02113384/locally-advanced-rectal-cancer-exfoliated-peritoneal-tumor-cells 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07260617/asociacion-entre-la-composicion-de-la-microbiota-intestinal-y-el-estado-nutricional-en-pacientes-con-cancer-digestivo 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07260617/association-between-composition-of-the-gut-microbiota-and-nutritional-status-in-digestive-oncology 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05167071/estudio-de-hbm4003-en-combinacion-con-toripalimab-en-pacientes-con-tumores-neuroendocrinos-avanzados-y-otros-tumores-solidos 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05167071/hbm4003-combine-with-toripalimab-in-patients-with-advanced-nen-and-other-solid-tumors-study 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07068529/desarrollo-y-validacion-de-biomarcadores-metabolicos-para-el-diagnostico-precoz-el-pronostico-y-la-deteccion-de-la-recurrencia-del-cancer-colorrectal-metbio-crc 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07068529/development-and-validation-of-metabolic-biomarkers-for-early-diagnosis-prognosis-and-recurrence-of-colorectal-cancer-metbio-crc 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05954429/un-estudio-para-evaluar-el-tratamiento-de-tercera-linea-con-fruquintinib-en-combinacion-con-serplulimab-en-pacientes-con-cancer-colorrectal-metastasico-avanzado-no-limitado-al-higado-un-estudio-de 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05954429/a-study-to-explore-the-third-line-treatment-of-fruquintinib-combined-with-serplulimab-in-advanced-non-liver-limited-metastatic-colorectal-cancer-a-single-center-phase-2-study 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07446465/quimioterapia-folfox-combinada-con-fruquintinib-y-serplulimab-como-terapia-de-conversion-de-primera-linea-para-cancer-colorrectal-pmmr-mss-inicialmente-irresecable 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07446465/folfox-chemotherapy-combined-with-fruquintinib-and-serplulimab-as-first-line-conversion-therapy-for-initially-unresectable-pmmr-mss-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05025826/estudio-que-evalua-la-neurotoxicidad-en-pacientes-con-cancer-gastrointestinal-metastasico-que-reciben-phycocare-r-o-placebo-durante-la-quimioterapia-basada-en-oxaliplatino 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05025826/study-evaluating-neurotoxicity-in-patients-with-metastatic-gastro-intestinal-cancer-taking-phycocare-r-or-placebo-during-oxaliplatin-based-chemotherapy 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07239466/un-estudio-piloto-que-evalua-la-suplementacion-con-hidroxibutirato-en-combinacion-con-radioterapia-de-corta-duracion-seguida-de-inmunoterapia-combinada-con-terapia-neoadyuvante-con-capeox-en 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07239466/a-pilot-study-evaluating-hydroxybutyrate-supplementation-concomitant-to-short-course-radiotherapy-followed-by-immunotherapy-combined-with-capeox-neoadjuvant-therapy-in-patients-with-locally-advanced 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06300463/estudio-de-plataforma-sobre-combinaciones-de-inmunoterapia-en-metastasis-hepaticas-del-cancer-colorrectal 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06300463/platform-study-of-immunotherapy-combinations-in-colorectal-cancer-liver-metastases 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07279077/radioterapia-de-baja-dosis-con-conservacion-de-los-ganglios-linfaticos-administrada-de-forma-concurrente-con-quimioterapia-e-inhibidor-de-pd-1-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07279077/node-sparing-low-dose-radiotherapy-concurrent-with-chemotherapy-and-pd-1-inhibitor-in-pmmr-mss-high-risk-locally-advanced-colon-cancer-a-prospective-single-arm-phase-ii-trial 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05904665/estrategia-de-seguimiento-postoperatorio-guiada-por-la-metilacion-del-adn-tumoral-circulante-en-el-cancer-colorrectal-no-metastasico 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05904665/circulating-tumor-dna-methylation-guided-postoperative-follow-up-strategy-for-non-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05722288/alimentacion-con-horarios-restringidos-frente-a-asesoramiento-nutricional-para-la-reduccion-de-los-efectos-secundarios-del-tratamiento-con-radioterapia-o-quimiorradioterapia-en-pacientes-con-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05722288/time-restricted-eating-versus-nutritional-counseling-for-the-reduction-of-radiation-or-chemoradiation-tx-side-effects-in-patients-with-prostate-cervical-or-rectal-cancers 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04713618/cambios-en-la-salud-pelvica-la-funcion-sexual-y-la-calidad-de-vida-en-mujeres-con-cancer-pelvico-que-se-someten-a-radioterapia 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT04713618/changes-in-pelvic-health-sexual-function-and-quality-of-life-in-women-with-pelvic-cancer-undergoing-radiation-therapy 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT04008030/un-estudio-de-nivolumab-nivolumab-mas-ipilimumab-o-quimioterapia-a-eleccion-del-investigador-para-el-tratamiento-de-participantes-con-cancer-colorrectal-metastasico-mcrc-con-deficiencia-en-la 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT04008030/a-study-of-nivolumab-nivolumab-plus-ipilimumab-or-investigator-s-choice-chemotherapy-for-the-treatment-of-participants-with-deficient-mismatch-repair-dmmr-microsatellite-instability-high-msi-h 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT04215731/mfolfoxiri-neoadyuvante-mas-bevacizumab-en-pacientes-con-cancer-colorrectal-localmente-avanzado-de-alto-riesgo 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04215731/neoadjuvant-mfolfoxiri-plus-bevacizumab-in-patients-with-high-risk-locally-advanced-rectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06929013/cinetica-de-eliminacion-del-nucleosoma-y-ctcf-en-sangre-en-el-cancer-colorrectal-con-metastasis-peritoneales 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06929013/blood-clearance-kinetics-of-the-nucleosome-and-ctcf-in-peritoneal-metastasis-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07457541/imagenes-moleculares-de-la-expresion-de-la-proteina-de-activacion-de-fibroblastos-mediante-el-uso-de-fapi-marcado-con-tecnecio-99m-hynic 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07457541/molecular-imaging-of-fibroblast-activation-protein-expression-using-labeled-technetium-99m-hynic-fapi 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06605430/cannabis-medicinal-en-pacientes-con-cancer-avanzado-de-pancreas-y-cancer-colorrectal 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06605430/medical-cannabis-in-patients-with-advanced-pancreatic-and-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06337084/eficacia-diagnostica-y-dosimetria-de-mnpr-101-dfo-89zr-en-pacientes-con-tumores-solidos 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06337084/diagnostic-efficacy-and-dosimetry-of-mnpr-101-dfo-89zr-in-patients-with-solid-tumors 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07281716/inmunoterapia-combinada-para-el-tratamiento-del-cancer-colorrectal-metastasico-mss-resistente-a-la-quimioterapia 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07281716/combination-immunotherapy-for-the-treatment-of-chemotherapy-refractory-metastatic-mss-crc 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07283939/estudio-del-algoritmo-pagoda-para-ajustar-las-dosis-de-quimioterapia-y-prevenir-retrasos-no-previstos-en-el-tratamiento 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07283939/studying-the-pagoda-algorithm-for-chemotherapy-dose-changes-to-prevent-unplanned-treatment-delays 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05245786/un-estudio-de-investigacion-anticuerpo-m5a-marcado-con-64cu-en-combinacion-con-quimioterapia-y-radioterapia-estandar-en-el-cancer-colorrectal-localmente-avanzado 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05245786/an-investigational-scan-64cu-labeled-m5a-antibody-in-combination-with-soc-chemotherapy-and-radiotherapy-in-locally-advanced-rectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06402864/evaluacion-del-contacto-con-rayos-x-y-la-braquiterapia-para-la-preservacion-del-recto-en-el-adenocarcinoma-rectal-de-estadio-intermedio 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06402864/evaluation-contact-x-ray-brachytherapy-for-rectal-preservation-in-intermediate-substage-rectal-adenocarcinoma 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07286695/fruquintinib-en-combinacion-con-trifluridina-tipiracil-frente-a-bevacizumab-en-combinacion-con-trifluridina-tipiracil-para-el-cancer-colorrectal-metastasico-avanzado 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07286695/fruquintinib-combined-with-trifluridine-tipiracil-versus-bevacizumab-combined-with-trifluridine-tipiracil-for-advanced-metastatic-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05355363/riesgo-de-hallazgos-metacronicos-tras-la-deteccion-de-lesiones-serradas-y-displasia-de-alto-grado-con-un-intervalo-de-seguimiento 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05355363/risk-of-metachronous-findings-after-detection-of-serrated-lesions-and-high-grade-dysplasia-with-surveillance-delay 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT02843191/quimioterapia-de-consolidacion-para-el-cancer-de-recto-localmente-avanzado-ya-sea-de-localizacion-media-o-baja-tras-la-quimiorradioterapia-neoadyuvante-concurrente 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT02843191/consolidation-chemotherapy-for-locally-advanced-mid-or-low-rectal-cancer-after-neoadjuvant-concurrent-chemoradiotherapy 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT03326791/aspirina-en-metastasis-hepaticas-del-cancer-colorrectal 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT03326791/aspirin-in-colorectal-cancer-liver-metastases 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06949982/eficacia-y-seguridad-de-la-hidroxicloroquina-en-combinacion-con-metotrexato-capecitabina-y-bevacizumab-frente-a-regorafenib-en-participantes-con-cancer-colorrectal-metastasico-refractario-con 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06949982/efficacy-and-safety-of-hydroxychloroquine-combined-with-methotrexate-capecitabine-and-bevacizumab-vs-regorafenib-in-participants-with-refractory-metastatic-colorectal-cancer-with-mutations-in-ras 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07211230/estudio-del-biobanco-de-colagenasa 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07211230/collagenase-biobank-study 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06616870/estudio-del-papel-predictivo-y-pronostico-de-las-variantes-farmacogeneticas-y-radiogenicas-en-la-respuesta-al-tratamiento-neoadyuvante-con-quimiorradiacion-en-pacientes-con-cancer-colorrectal 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06616870/study-of-the-predictive-and-prognostic-role-of-pharmacogenetic-and-radiogenic-variants-on-the-response-to-neoadjuvant-chemoradiation-therapy-in-patients-with-locally-advanced-rectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07290309/supervivientes-unidos-a-traves-de-ejercicios-guiados-a-distancia 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07290309/survivors-uniting-for-remote-guided-exercise 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06614660/imagenologia-metabolica-y-genomica-para-predecir-los-resultados-quirurgicos-del-cancer-colorrectal 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06614660/metabolism-imaging-genomics-for-predicting-the-surgical-outcomes-of-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06563388/radioterapia-ablativa-estereotactica-sabr-para-el-tratamiento-de-pacientes-con-cancer-metastasico-ensayo-id-comet 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06563388/stereotactic-ablative-radiotherapy-sabr-for-the-treatment-of-patients-with-metastatic-cancer-id-comet-trial 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05861505/ensayo-collision-relapse 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05861505/collision-relapse-trial 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06679673/shr-1701-en-combinacion-con-shr2554-y-bp102-para-el-cmmr 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06679673/shr-1701-combined-with-shr2554-and-bp102-for-mcrc 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05107674/un-estudio-de-nx-1607-en-adultos-con-tumores-malignos-avanzados 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05107674/a-study-of-nx-1607-in-adults-with-advanced-malignancies 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07490119/becotatug-vedotina-en-combinacion-con-cetuximab-en-el-tratamiento-en-lineas-posteriores-del-cancer-colorrectal-metastasico-con-ras-tipo-salvaje 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07490119/becotatug-vedotin-combined-with-cetuximab-in-the-later-line-treatment-of-metastatic-ras-wild-type-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05694936/combinacion-de-valproato-sodico-con-el-tratamiento-estandar-con-anticuerpos-monoclonales-dirigidos-al-egfr-receptor-del-factor-de-crecimiento-epidermico-en-pacientes-con-cancer-colorrectal-metastasico 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05694936/combining-sodium-valproate-with-standard-of-care-egfr-epidermal-growth-factor-receptor-monoclonal-antibody-treatment-in-patients-with-metastatic-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07500298/estudio-de-fase-i-de-sar445877-en-combinacion-con-folfox6-y-bevacizumab-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-con-estabilidad-de-microsatelites 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07500298/phase-1-study-of-sar445877-in-combination-with-folfox6-and-bevacizumab-as-first-line-treatment-for-microsatellite-stable-metastatic-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06011772/terapia-antigeno-egf-cimavax-egf-en-combinacion-con-la-terapia-estandar-para-el-cancer-colorrectal-metastasico-con-mutaciones-ras-y-braf-no-detectables 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06011772/egf-depleting-therapy-cimavax-egf-in-combination-with-standard-therapy-for-ras-and-braf-wild-type-metastatic-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06491355/tratamiento-de-primera-linea-con-el-regimen-mfolfox6-y-hlx04-seguido-de-la-combinacion-con-serplulimab-en-cancer-colorrectal-metastasico-inicialmente-irresecable-y-con-estado-mss 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06491355/first-line-treatment-induced-with-mfolfox6-and-hlx04-regimen-following-combined-with-serplulimab-in-mss-initially-unresectable-metastatic-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05167448/un-estudio-de-es104-en-pacientes-con-cancer-colorrectal-metastasico 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05167448/a-study-of-es104-in-patients-with-metastatic-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06283134/un-estudio-clinico-de-biottt001-en-combinacion-con-toripalimab-y-regorafenib-en-pacientes-con-cancer-colorrectal 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06283134/a-clinical-study-of-biottt001-in-combination-with-toripalimab-and-regorafenib-in-patients-with-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06959693/un-estudio-clinico-para-evaluar-la-eficacia-y-la-seguridad-de-envafolimab-en-combinacion-con-cetuximab-y-mfolfox6-en-pacientes-con-cancer-colorrectal-metastasico-mcrc-mss-y-ras-braf-de-tipo-salvaje 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06959693/a-clinical-study-to-evaluate-the-efficacy-and-safety-of-envafolimab-combined-with-cetuxima-and-mfolfox6-in-patients-with-mss-ras-braf-wild-type-metastatic-colorectal-cancer-mcrc 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07222800/symbiotic-gi-03-un-estudio-para-obtener-mas-informacion-sobre-el-farmaco-de-estudio-denominado-pf-08634404-en-combinacion-con-quimioterapia-en-participantes-adultos-con-cancer-colorrectal-metastasico 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07222800/symbiotic-gi-03-a-study-to-learn-about-the-study-medicine-called-pf-08634404-in-combination-with-chemotherapy-in-adult-participants-with-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07506109/un-estudio-de-fase-ii-de-sintilimab-en-combinacion-con-ipilimumab-n01-cetuximab-y-dabrafenib-en-pacientes-con-cancer-colorrectal-metastasico-con-microsatelites-estables-y-mutacion-braf-v600e 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07506109/a-phase-ii-study-of-sintilimab-combined-with-ipilimumab-n01-cetuximab-and-dabrafenib-in-patients-with-microsatellite-stable-braf-v600e-mutated-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06625775/estudio-abierto-con-bbo-10203-en-pacientes-con-tumores-solidos-avanzados 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06625775/open-label-study-of-bbo-10203-in-subjects-with-advanced-solid-tumors 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07504523/terapia-celular-t-personalizada-ineo-vac-t01-en-cancer-colorrectal-avanzado 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07504523/personalized-t-cell-therapy-ineo-vac-t01-in-advanced-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06135571/estudio-sobre-los-patrones-de-metastasis-en-el-ganglio-linfatico-numero-253-en-el-cancer-de-colon-y-recto-izquierdo 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06135571/study-on-the-no-253-lymph-node-metastasis-patterns-in-left-sided-colon-and-rectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05524012/evaluacion-longitudinal-multimodal-de-la-respuesta-durante-el-tratamiento-neoadyuvante-del-cancer-de-recto 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05524012/longitudinal-multimodal-response-assessment-during-neoadjuvant-treatment-of-rectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05970705/regorafenib-en-combinacion-con-tas-102-frente-a-regorafenib-en-monoterapia-en-la-terapia-de-tercera-linea-o-posterior-del-mcrc 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05970705/regorafenib-combined-with-tas-102-versus-regorafenib-monotherapy-in-third-or-later-line-therapy-of-mcrc 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07510932/fruquintinib-en-pacientes-con-cancer-colorrectal-metastasico-refractario-a-las-quimioterapias-estandar-en-corea-del-sur-first-k 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07510932/fruquintinib-in-patients-with-metastatic-colorectal-cancer-refractory-to-standard-chemotherapies-in-south-korea-patients-first-k 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05185245/trasplante-hepatico-para-metastasis-hepaticas-de-cancer-colorrectal-no-susceptibles-de-reseccion 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05185245/liver-transplantation-for-non-resectable-colorectal-liver-metastasis 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06750094/un-estudio-de-amivantamab-y-folfiri-frente-a-cetuximab-bevacizumab-y-folfiri-en-participantes-con-cancer-colorrectal-kras-nras-y-braf-de-tipo-salvaje-que-previamente-han-recibido-quimioterapia 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06750094/a-study-of-amivantamab-and-folfiri-versus-cetuximab-bevacizumab-and-folfiri-in-participants-with-kras-nras-and-braf-wild-type-colorectal-cancer-who-have-previously-received-chemotherapy 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06470178/un-estudio-en-el-mundo-real-sobre-la-terapia-neoadyuvante-de-conversion-para-el-cancer-colorrectal-con-quimioterapia-y-agentes-dirigidos-antiangiogenicos 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06470178/a-real-world-study-of-neoadjuvant-conversion-therapy-for-colorectal-cancer-with-chemotherapy-and-anti-angiogenic-targeted-agents 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07328087/colonyvaq-tm-una-vacuna-neoantigenica-personalizada-guiada-por-metodos-cuanticos-y-clasicos-para-el-cancer-colorrectal-en-estadio-iii-con-mss 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07328087/colonyvaq-tm-a-quantum-classical-guided-personalized-neoantigen-vaccine-for-mss-stage-iii-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06749015/un-estudio-sobre-el-tratamiento-de-pacientes-con-cancer-colorrectal-metastasico-mcrc-con-mutacion-brafv600e 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06749015/a-study-on-treatment-for-patients-with-brafv600e-mutant-metastatic-colorectal-cancer-mcrc 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04689347/5fu-lv-irinotecan-temozolomida-y-bevacizumab-para-el-cancer-colorrectal-metastasico-con-metilacion-del-gen-mgmt-y-estabilidad-de-microsatelites 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04689347/5fu-lv-irinotecan-temozolomide-and-bevacizumab-for-mgmt-silenced-microsatellite-stable-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT03494946/trasplante-hepatico-en-comparacion-con-quimioterapia-en-pacientes-con-cancer-colorrectal 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT03494946/liver-transplantation-compared-to-chemotherapy-in-patients-with-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06395519/un-estudio-del-inhibidor-de-parg-etx-19477-en-pacientes-con-tumores-solidos-avanzados 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06395519/a-study-of-parg-inhibitor-etx-19477-in-patients-with-advanced-solid-malignancies 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07337551/acetato-de-gossipol-folfiri-bevacizumab-en-pacientes-con-cancer-colorrectal-metastasico-mcrc-con-mutacion-en-tp53-y-expresion-positiva-de-lrpprc 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07337551/gossypol-acetate-folfiri-bev-in-mcrc-with-tp53-mutant-and-lrpprc-positive 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06176885/eficacia-y-seguridad-de-la-combinacion-con-inmunoterapia-tras-la-terapia-de-induccion-con-quimioterapia-y-terapia-dirigida-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06176885/efficacy-and-safety-of-combined-with-immunotherapy-after-induction-therapy-with-chemotherapy-and-targeted-therapy-in-the-first-line-treatment-of-microsatellite-stable-mss-initially-unresectable 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06887218/5-fluorouracilo-leucovorina-5fu-lv-en-combinacion-con-regorafenib-en-pacientes-con-cancer-colorrectal-metastasico 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06887218/5-fluorouracil-leucovorin-5fu-lv-in-combination-with-regorafenib-in-patients-with-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06475352/individualizacion-de-la-dosis-de-quimioterapia-en-pacientes-con-canceres-gastrointestinales-que-carecen-de-una-enzima-hepatica-especifica 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06475352/dose-individualization-of-chemotherapy-in-patients-with-gastrointestinal-cancers-lacking-a-specific-liver-enzyme 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT03867799/iscore-secuenciacion-de-la-inmunoterapia-en-el-cancer-de-colon-y-recto 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT03867799/iscore-immunotherapy-sequencing-in-colon-and-rectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06449937/tratamiento-local-hepatico-para-metastasis-de-cancer-colorrectal-multiorganico 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06449937/local-liver-treatment-for-multi-organ-colorectal-cancer-metastases 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT02595931/m6620-e-hidrocloruro-de-irinotecan-en-el-tratamiento-de-pacientes-con-tumores-solidos-metastasicos-o-que-no-pueden-ser-extirpados-mediante-cirugia 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT02595931/m6620-and-irinotecan-hydrochloride-in-treating-patients-with-solid-tumors-that-are-metastatic-or-cannot-be-removed-by-surgery 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT04754672/entrenamiento-de-aptitud-aerobica-o-de-masa-muscular-para-mejorar-el-resultado-en-el-cancer-colorrectal 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04754672/aerobic-fitness-or-muscle-mass-training-to-improve-colorectal-cancer-outcome 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05007132/trifluridina-tipiracil-mas-panitumumab-frente-a-trifluridina-tipiracil-mas-bevacizumab-como-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05007132/trifluridine-tipiracil-plus-panitumumab-versus-trifluridine-tipiracil-plus-bevacizumab-as-first-line-treatment-of-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07536113/evaluacion-de-la-eficacia-y-la-seguridad-de-la-seleccion-basada-en-el-adn-tumoral-circulante-ctdna-para-un-nuevo-tratamiento-con-anti-egfr-en-una-cohorte-de-pacientes-con-cancer-colorrectal 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07536113/assessing-the-efficacy-and-safety-of-ctdna-driven-selection-for-anti-egfr-retreatment-in-a-real-world-metastatic-colorectal-cancer-patients-cohort-the-realchallenge-study 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06549907/un-estudio-exploratorio-de-biomarcadores-sobre-el-bloqueo-dual-de-pd1-pdl1-y-ctla4-y-la-terapia-antiangiogenica 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06549907/a-biomarker-exploratory-study-of-dual-blockade-of-pd1-pdl1-and-ctla4-and-anti-angiogenic-therapy 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04603287/un-estudio-de-si-b001-un-anticuerpo-bispecifico-anti-egfr-her3-en-tumores-epiteliales-localmente-avanzados-o-metastasicos 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT04603287/a-study-of-si-b001-an-egfr-her3-bispecific-antibody-in-locally-advanced-or-metastatic-epithelial-tumors 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT02394834/un-estudio-exploratorio-de-la-sensibilidad-al-tratamiento-y-los-factores-pronosticos-en-un-estudio-de-eficacia-y-seguridad-de-mfolfox6-bevacizumab-frente-a-mfolfox6-panitumumab-en-pacientes-con 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT02394834/an-exploratory-study-of-treatment-sensitivity-and-prognostic-factors-in-a-efficacy-and-safety-study-of-mfolfox6-bevacizumab-versus-mfolfox6-panitumumab-therapy-in-patients-with-chemotherapy-naive 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06440902/exploracion-de-estrategias-terapeuticas-para-el-cancer-colorrectal-metastasico-con-mutacion-nras-de-tipo-salvaje-basada-en-el-adn-tumoral-circulante 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06440902/exploration-of-therapeutic-strategies-for-neoras-wild-type-metastatic-colorectal-cancer-based-on-circulating-tumor-dna 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07021950/ak112-mas-folfiri-frente-a-bevacizumab-mas-folfiri-como-tratamiento-de-segunda-linea-del-cancer-colorrectal-metastasico-mss-pmmr 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07021950/ak112-plus-folfiri-versus-bevacizumab-plus-folfiri-as-second-line-treatment-of-mss-pmmr-metastatic-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07175636/ql1706-radioterapia-y-quimioterapia-a-corto-plazo-para-el-cancer-colorrectal-mss 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07175636/ql1706-with-short-course-radiotherapy-and-chemotherapy-for-mss-rectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06911970/impacto-del-ejercicio-aerobico-en-la-respuesta-inmune-antitumoral-en-pacientes-que-reciben-tratamiento-contra-el-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06911970/impact-of-aerobic-exercise-on-the-anticancer-immune-response-in-patients-receiving-cancer-treatment 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05382442/un-estudio-de-ak112-con-o-sin-ak117-en-el-cancer-colorrectal-metastasico 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05382442/a-study-of-ak112-with-or-without-ak117-in-metastatic-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06849362/estudio-retrospectivo-multicentrico-sobre-la-optimizacion-de-las-estrategias-de-inmunoterapia-combinada-en-el-cancer-colorrectal-avanzado-mss-msi-l-pmmr 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06849362/multicenter-retrospective-study-on-optimizing-combination-immunotherapy-strategies-in-mss-msi-l-pmmr-advanced-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07542262/estudio-clinico-de-fase-ii-abierto-de-un-unico-centro-para-evaluar-la-eficacia-y-la-seguridad-de-la-inmunoterapia-a-dosis-bajas-en-el-tratamiento-de-pacientes-con-cancer-colorrectal-y-cancer-gastrico 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07542262/low-dose-immunotherapy-in-metastatic-and-locally-advanced-colorectal-and-gastric-msi-dmmr-cancers 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07004413/cetuximab-en-administracion-continua-o-intermitente-combinado-con-folfiri-como-tratamiento-de-primera-linea-en-pacientes-con-cancer-colorrectal-metastasico-mcrc-con-ras-braf-tipo-salvaje 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07004413/continuous-or-intermittent-cetuximab-plus-folfiri-as-first-line-treatment-in-ras-braf-wild-type-mcrc-patients 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07194616/ensayo-clinico-sobre-celulas-tumorales-circulantes-en-cancer-de-recto 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07194616/rectal-cancer-ctc-trial 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05447611/papel-de-la-empatia-en-los-resultados-del-tratamiento-curativo-del-cancer-colorrectal-no-metastasico 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05447611/role-of-empathy-in-curative-treatment-outcomes-of-non-metastatic-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07035587/diagnostico-de-multiples-tipos-de-cancer-y-seguimiento-de-tumores-residuales-minimos-tras-el-tratamiento-mediante-el-analisis-de-sangre-y-tecnicas-geneticas-de-alta-sensibilidad 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07035587/diagnosis-of-multiple-cancer-and-monitoring-of-minimal-residual-tumors-after-treatment-using-blood-and-high-sensitivity-genetic-analysis-techniques 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT03449914/el-estudio-gold-g8-en-pacientes-de-edad-avanzada 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT03449914/the-gold-study-g8-in-older-patients 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05725200/estudio-para-investigar-los-resultados-de-un-tratamiento-individualizado-en-pacientes-con-cancer-colorrectal-metastasico 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05725200/study-to-investigate-outcome-of-individualized-treatment-in-patients-with-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05501353/exploracion-de-biomarcadores-asociados-con-el-pronostico-del-cancer-colorrectal-recurrente-y-metastasico-tras-la-cirugia-mediante-metodos-multiomicos 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05501353/explore-biomarkers-associated-with-prognosis-of-recurrent-and-metastatic-crc-after-surgery-by-multi-omics-methods 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07552207/comparacion-de-la-pet-rm-con-68ga-ga-ctr-fapi-y-18f-fdg-para-la-estadificacion-de-los-ganglios-linfaticos-en-el-cancer-de-recto 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07552207/comparison-of-68ga-ga-ctr-fapi-and-18f-fdg-pet-mri-for-lymph-node-staging-in-rectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06411600/terapia-combinada-para-el-crcm-metastasico-con-mutacion-braf-v600e 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06411600/combination-therapy-for-braf-v600e-metastatic-crcm 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06938971/ensayo-clinico-aleatorizado-y-controlado-para-evaluar-los-efectos-del-ejercicio-combinado-de-resistencia-y-aerobico-en-la-calidad-de-vida-relacionada-con-la-salud-en-pacientes-que-reciben 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06938971/randomized-controlled-trial-of-the-effects-of-combined-resistance-and-aerobic-exercise-on-health-related-quality-of-life-in-patients-undergoing-first-line-chemotherapy-for-metastatic-colorectal 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07085169/trifluridina-tipiracil-a-dosis-bajas-con-bevacizumab-en-mcrc 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07085169/low-dose-trifluridine-tipiracil-with-bevacizumab-in-mcrc 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06423937/fruquintinib-mas-camrelizumab-y-haic-en-el-tratamiento-del-cancer-colorrectal-avanzado-no-msi-h 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06423937/fruquintinib-plus-camrelizumab-and-haic-in-the-treatment-of-non-msi-h-advanced-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05253651/un-estudio-de-tucatinib-en-combinacion-con-trastuzumab-y-mfolfox6-frente-al-tratamiento-estandar-en-el-cancer-colorrectal-metastasico-her2-en-primera-linea 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05253651/a-study-of-tucatinib-with-trastuzumab-and-mfolfox6-versus-standard-of-care-treatment-in-first-line-her2-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07365527/sonoporacion-y-respuesta-del-microambiente-tumoral-en-metastasis-hepaticas-de-cancer-colorrectal 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07365527/sonoporation-and-tumor-microenvironment-response-in-colorectal-liver-metastases 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05359393/una-terapia-combinada-que-incluye-inmunoterapia-anti-pd-1-en-cancer-de-recto-mss-con-metastasis-distal-resecable 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05359393/a-combination-therapy-including-anti-pd-1-immunotherapy-in-mss-rectal-cancer-with-resectable-distal-metastasis 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05487248/un-estudio-de-los-cambios-en-el-ctdna-durante-el-tratamiento-en-pacientes-con-cancer-colorrectal-resistente-a-la-quimioterapia 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05487248/a-study-of-on-treatment-ctdna-changes-in-chemo-refractory-colorectal-cancer-patients 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07381764/romance-irinotecan-mas-cetuximab-en-un-nuevo-ciclo-de-tratamiento-versus-trifluridina-tipiracil-mas-bevacizumab-en-cancer-colorrectal-metastasico-molecularmente-seleccionado 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07381764/romance-irinotecan-plus-cetuximab-rechallenge-versus-trifluridine-tipiracil-plus-bevacizumab-in-molecularly-selected-metastatic-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06835179/radioterapia-estereotactica-ablativa-sbrt-combinada-con-capeox-bevacizumab-e-inhibidor-de-pd-1-para-el-tratamiento-del-cancer-colorrectal-metastasico-irresecable-con-mutacion-en-ras-y-de-tipo-mss 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06835179/sbrt-combined-with-capeox-bevacizumab-and-pd-1-inhibitor-for-the-treatment-of-ras-mutant-mss-type-unresectable-metastatic-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06940921/sbrt-ldrt-cadonilimab-para-el-cancer-gastrico-colorrectal-y-ovarico-avanzado-con-metastasis-peritoneales 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06940921/sbrt-ldrt-cadonilimab-for-advanced-gastric-colorectal-and-ovarian-cancers-with-peritoneal-metastases 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05314400/gadoxetato-resonancia-magnetica-abreviada-en-el-cancer-colorrectal-metastasico 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05314400/gadoxetate-abbreviated-mri-in-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07389265/continuacion-del-tratamiento-con-cetuximab-tras-la-progresion-en-primera-linea-en-el-cancer-colorrectal-metastasico 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07389265/continuation-of-cetuximab-beyond-first-line-progression-in-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07391566/lpm6690176-en-combinacion-con-quimioterapia-y-bevacizumab-en-pacientes-con-cancer-colorrectal-metastasico-con-mutacion-en-ras 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07391566/lpm6690176-in-combination-with-chemotherapy-and-bevacizumab-in-metastatic-colorectal-cancer-patients-with-ras-mutation 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT01763125/creacion-de-un-biobanco-de-tumores-a-partir-de-muestras-de-sangre 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT01763125/establishment-of-a-tumor-bank-for-blood-samples 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06244771/un-estudio-que-evalua-el-farmaco-fmc-376-en-participantes-con-tumores-solidos-que-presentan-la-mutacion-kras-g12c 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06244771/a-study-evaluating-fmc-376-in-participants-with-kras-g12c-mutated-solid-tumors 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT02671435/un-estudio-de-durvalumab-medi4736-y-monalizumab-en-tumores-solidos 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT02671435/a-study-of-durvalumab-medi4736-and-monalizumab-in-solid-tumors 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07395063/un-estudio-clinico-sobre-el-tratamiento-del-cancer-colorrectal-metastasico-en-segunda-linea-o-posterior 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07395063/a-clinical-study-on-the-treatment-of-metastatic-colorectal-cancer-at-the-second-line-or-beyond 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05141721/un-estudio-de-una-vacuna-neoantigenica-especifica-para-el-paciente-en-combinacion-con-el-bloqueo-de-los-puntos-de-control-inmunitario-en-pacientes-con-cancer-colorrectal-metastasico 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05141721/a-study-of-a-patient-specific-neoantigen-vaccine-in-combination-with-immune-checkpoint-blockade-for-patients-with-metastatic-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07405736/lubiprostone-en-combinacion-con-terapia-de-mantenimiento-para-la-prevencion-de-la-recurrencia-postoperatoria-en-cancer-colorrectal-con-metastasis-peritoneales 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07405736/lubiprostone-combined-with-maintenance-therapy-for-prevention-of-postoperative-recurrence-in-peritoneal-metastatic-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT03941080/dinamica-del-microbioma-intestinal-en-el-cancer-colorrectal-metastasico-o-irresecable 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT03941080/gut-microbiome-dynamics-in-metastasized-or-irresectable-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05985109/kn-046-regorafenib-mas-otro-tratamiento-en-cancer-colorrectal-metastasico-mss 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05985109/kn-046-plus-regorafenib-in-mss-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06824064/evaluacion-de-rbs2418-en-pacientes-con-cancer-colorrectal-avanzado-metastasico-y-en-progresion 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06824064/evaluation-of-rbs2418-in-patients-with-advanced-metastatic-and-progressive-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07054047/mejorando-el-diagnostico-y-el-tratamiento-de-los-pacientes-con-cancer-de-recto 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07054047/improving-diagnosis-and-treatment-for-patients-with-rectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07076823/seguridad-y-eficacia-de-canagliflozina-en-pacientes-con-cancer-colorrectal-metastasico-con-alta-inestabilidad-de-microsatelites-msi-h 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07076823/safety-and-efficacy-of-canagliflozin-in-patients-with-metastatic-high-microsatellite-instability-msi-h-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06226857/otras-mutaciones-en-oncogenes-que-podrian-influir-en-la-eficacia-de-los-tratamientos-anti-egfr-en-pacientes-con-cancer-colorrectal-metastasico-de-lado-izquierdo-y-con-ras-de-tipo-salvaje 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06226857/other-oncogene-mutations-for-anti-egfr-efficacy-in-patients-with-left-sided-ras-wild-type-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04516681/combinacion-de-acido-ascorbico-intravenoso-y-adebrelimab-en-cancer-colorrectal-metastasico 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04516681/combination-of-iv-ascorbic-acid-and-adebrelimab-in-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06341296/estudio-de-fase-ii-de-liposomas-de-irinotecan-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06341296/phase-ii-study-of-irinotecan-liposomes-in-first-line-treatment-of-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04579380/estudio-basket-con-tucatinib-y-trastuzumab-en-tumores-solidos-con-alteraciones-de-her2 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT04579380/basket-study-of-tucatinib-and-trastuzumab-in-solid-tumors-with-her2-alterations 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT04585750/evaluacion-de-pc14586-en-pacientes-con-tumores-solidos-avanzados-que-presentan-una-mutacion-y220c-en-el-gen-tp53-pynnacle 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04585750/the-evaluation-of-pc14586-in-patients-with-advanced-solid-tumors-harboring-a-tp53-y220c-mutation-pynnacle 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT02888743/durvalumab-y-tremelimumab-con-o-sin-radioterapia-en-dosis-altas-o-bajas-en-el-tratamiento-de-pacientes-con-cancer-colorrectal-metastasico-o-cancer-de-pulmon-no-microcitico 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT02888743/durvalumab-and-tremelimumab-with-or-without-high-or-low-dose-radiation-therapy-in-treating-patients-with-metastatic-colorectal-or-non-small-cell-lung-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07277270/un-estudio-de-gsk5764227-en-combinacion-con-el-tratamiento-estandar-soc-u-otros-agentes-en-participantes-con-tumores-solidos-avanzados 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07277270/a-study-of-gsk5764227-in-combination-with-standard-of-care-soc-or-other-agents-in-participants-with-advanced-solid-tumors 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05322590/bxq-350-en-pacientes-con-carcinoma-colorrectal-metastasico-de-diagnostico-reciente 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05322590/bxq-350-in-newly-diagnosed-metastatic-colorectal-carcinoma 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05319314/gcc19cart-para-pacientes-con-cancer-colorrectal-metastasico 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05319314/gcc19cart-for-patients-with-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT03692429/alloshrink-regimen-estandar-de-quimioterapia-e-inmunoterapia-con-celulas-t-receptor-de-antigeno-quimerico-alogenicas-basadas-en-nkg2d-cyad-101 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT03692429/alloshrink-standard-chemotherapy-regimen-and-immunotherapy-with-allogeneic-nkg2d-based-cyad-101-chimeric-antigen-receptor-t-cells 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04294264/tas-102-y-oxaliplatino-para-el-tratamiento-del-cancer-colorrectal-en-estadio-iv-refractario 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT04294264/tas-102-and-oxaliplatin-for-the-treatment-of-refractory-stage-iv-colon-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07446387/un-estudio-clinico-de-iparomlimab-y-tuvonralimab-en-combinacion-con-bevacizumab-y-un-regimen-de-capox-mcapiri-alternado-cada-tres-semanas-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07446387/a-clinical-study-of-iparomlimab-and-tuvonralimab-combined-with-bevacizumab-and-alternating-triweekly-capox-mcapiri-regimen-as-first-line-treatment-for-unresectable-advanced-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06783569/un-estudio-de-escalada-y-expansion-en-humanos-el-primero-de-su-tipo-en-pacientes-con-tumores-solidos-avanzados 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06783569/a-first-in-human-escalation-and-expansion-study-of-patients-with-advanced-solid-tumors 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07448662/estrategias-de-tratamiento-local-para-las-metastasis-cerebrales-del-cancer-colorrectal 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07448662/local-treatment-strategies-for-brain-metastases-of-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07453875/ldrt-quimioterapia-inmunologica-secuencial-con-nips-para-metastasis-peritoneales-de-cancer-gastrico-y-colorrectal 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07453875/ldrt-sequential-nips-immunochemotherapy-for-peritoneal-metastasis-of-gastric-and-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06763029/irinotecano-en-liposomas-combinado-con-cetuximab-y-vermofenib-en-pacientes-con-cancer-colorrectal-avanzado-que-han-fracasado-en-la-primera-linea-de-tratamiento 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06763029/irinotecan-liposomes-combined-with-cetuximab-vermofenib-in-first-line-failure-of-advanced-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05840263/intervencion-basada-en-la-atencion-plena-para-parejas-en-el-contexto-del-cancer-colorrectal-metastasico 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05840263/couple-based-mindfulness-intervention-for-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04068610/columbia-1-nuevas-terapias-oncologicas-en-combinacion-con-quimioterapia-y-bevacizumab-como-terapia-de-primera-linea-en-el-crc-mss 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT04068610/columbia-1-novel-oncology-therapies-in-combination-with-chemotherapy-and-bevacizumab-as-first-line-therapy-in-mss-crc 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06462963/oligocare-twics-ensayos-dentro-de-cohortes-ensayo-comparativo-de-la-toxicidad-aguda-en-la-radioterapia-estereotactica-ablativa-sbrt-en-una-sola-fraccion-frente-a-multiples-fracciones-para-el 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06462963/oligocare-twics-trials-within-cohorts-trial-comparing-acute-toxicity-in-single-fraction-vs-multiple-fraction-sbrt-for-metastasis-directed-treatment-sprint 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06788171/pulsar-en-combinacion-con-un-anticuerpo-anti-pd-1-y-quimioterapia-mas-bevacizumab-para-el-tratamiento-del-cancer-colorrectal-metastasico-ccrm 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06788171/pulsar-combined-with-pd-1-ab-and-chemotherapy-plus-bev-for-crlm 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05843188/estudio-de-hidroxicloroquina-con-folfiri-y-bevacizumab-en-cancer-colorrectal-metastasico-con-alto-nivel-de-dtp 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05843188/study-of-hydroxychloroquine-with-folfiri-and-bevacizumab-in-dtp-high-metastatic-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06823323/estudio-sobre-la-eficacia-y-la-seguridad-de-lactobacillus-johnsonii-en-combinacion-con-capeox-y-pembrolizumab-para-el-tratamiento-del-cancer-colorrectal-metastasico-mss-pmmr 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06823323/the-study-on-the-efficacy-and-safety-of-lactobacillus-johnsonii-in-combination-with-capeox-and-pembrolizumab-for-the-treatment-of-mss-pmmr-metastatic-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07283575/uso-de-la-metilacion-del-ctdna-para-monitorizar-el-tratamiento-del-cancer-colorrectal-metastasico-promet 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07283575/using-ctdna-methylation-to-monitor-metastatic-colorectal-cancer-treatment-promet 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06873763/nelmastobart-en-combinacion-con-trifluridina-tipiracil-y-bevacizumab-en-el-cancer-colorrectal-metastasico-recurrente 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06873763/nelmastobart-in-combination-with-trifluridine-tipiracil-and-bevacizumab-in-metastatic-recurrent-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06580574/inhibidores-de-los-puntos-de-control-inmunitario-para-la-preservacion-de-organos-en-canceres-gastricos-o-de-colon-no-metastasicos-con-dmmr-msi-h 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06580574/immune-checkpoint-inhibitors-for-organ-preservation-in-non-metastatic-dmmr-msi-h-gastric-or-colon-cancers 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06525428/terapia-sistemica-estandar-combinada-con-radioterapia-en-dosis-altas-bajas-mas-toripalimab-para-el-cancer-colorrectal-metastasico 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06525428/standard-systemic-therapy-combined-with-high-low-dose-radiotherapy-plus-toripalimab-for-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06447727/eficacia-y-seguridad-de-las-microesferas-de-90y-en-combinacion-con-folfiri-y-bevacizumab-en-el-tratamiento-de-segunda-linea-del-cancer-colorrectal-metastasico-ccrm 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06447727/efficacy-and-safety-of-90y-microsphere-combined-with-folfiri-and-bevacizumab-in-second-line-treatment-of-crlm 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05933876/el-impacto-de-la-radioterapia-en-el-cancer-oligometastasico 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05933876/the-impact-of-radiotherapy-on-oligometastatic-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06685276/seguridad-y-eficacia-de-fruquintinib-mas-chidamide-y-sintilimab-en-el-tratamiento-de-tercera-linea-o-posterior-del-cancer-colorrectal-metastasico-mss-pmmr 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06685276/safety-and-efficacy-of-fruquintinib-plus-chidamide-and-sintilimab-in-the-third-and-later-line-treatment-of-mss-pmmr-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06972498/estudio-multicentrico-prospectivo-ivosimab-quimioterapia-como-tratamiento-neoadyuvante-para-metastasis-hepaticas-de-crc-pmmr-mss-resecable 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06972498/a-prospective-multicenter-study-ivosimab-chemotherapy-as-neoadjuvant-for-resectable-pmmr-mss-crc-liver-mets 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06523582/bases-geneticas-de-los-tumores-neuroendocrinos-en-pacientes-mexicanos 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06523582/genetic-bases-of-neuroendocrine-neoplasms-in-mexican-patients 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07491159/fruquintinib-mas-un-inhibidor-de-puntos-de-control-en-combinacion-o-de-forma-secuencial-junto-con-tas-102-en-pacientes-con-cancer-colorrectal-que-han-progresado-tras-recibir-una-terapia-estandar-de 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07491159/fruquintinib-plus-checkpoint-inhibitor-combined-or-sequential-tas-102-in-colorectal-cancer-patients-who-progressed-on-second-line-standard-therapy-a-prospective-multi-cohort-single-centered-phase-ib 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05691491/evaluacion-de-la-combinacion-de-los-farmacos-antineoplasicos-temozolomida-y-m1774-para-determinar-su-seguridad-y-eficacia 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05691491/testing-the-combination-of-the-anti-cancer-drugs-temozolomide-and-m1774-to-evaluate-their-safety-and-effectiveness 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT03869892/estudio-de-fase-iii-sobre-el-tratamiento-de-primera-linea-en-pacientes-con-cancer-colorrectal-metastasico-que-no-son-candidatos-para-recibir-terapia-intensiva 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT03869892/phase-iii-study-in-first-line-treatment-of-patients-with-metastatic-colorectal-cancer-who-are-not-candidate-for-intensive-therapy 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06464692/estudio-para-evaluar-los-eventos-adversos-y-como-el-telisotuzumab-adizutecan-abbv-400-administrado-por-via-intravenosa-iv-se-distribuye-por-el-organismo-de-los-participantes-adultos-con-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06464692/study-to-assess-adverse-events-and-how-intravenously-iv-infused-telisotuzumab-adizutecan-abbv-400-moves-through-the-body-of-adult-participants-with-unresectable-locally-advanced-metastatic-colorectal 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05705492/olanzapina-para-el-manejo-de-la-perdida-de-apetito-asociada-al-cancer-en-pacientes-con-cancer-avanzado-de-esofago-estomago-higado-pancreas-vias-biliares-colon-recto-o-pulmon 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05705492/olanzapine-for-the-management-of-cancer-associated-appetite-loss-in-patients-with-advanced-esophagogastric-hepatopancreaticobiliary-colorectal-or-lung-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06936527/xs-03-en-combinacion-con-folfox-o-folfiri-y-bevacizumab-para-el-tratamiento-de-pacientes-con-cancer-colorrectal-metastasico-con-mutacion-en-el-gen-ras 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06936527/xs-03-in-combination-with-folfox-or-folfiri-and-bevacizumab-for-treatment-of-metastatic-colorectal-cancer-patients-with-ras-mutation 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07007689/un-estudio-multi-omico-del-cancer-colorrectal-con-mutacion-braf-v600e 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07007689/a-multi-omics-study-of-braf-v600e-mutant-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06513221/un-estudio-prospectivo-de-cancer-colorrectal-metastasico-de-tipo-mss-que-recibe-multiples-lineas-de-quimioterapia-estandar-bevacizumab-en-combinacion-con-adebrelimab 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06513221/a-prospective-study-of-mss-type-metastatic-colorectal-cancer-receiving-multiple-lines-of-standard-chemotherapy-bevacizumab-combined-with-adebrelimab 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06821048/estudio-de-la-terapia-car-t-dirigida-contra-el-cea-ptc13-en-el-tratamiento-de-tumores-solidos-malignos-avanzados-cea-positivos 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06821048/study-of-cea-targeting-car-t-ptc13-in-the-treatment-of-cea-positive-advanced-malignant-solid-tumors 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04991948/estudio-del-tratamiento-con-pembrolizumab-tras-la-administracion-de-cyad-101-con-acondicionamiento-previo-con-folfox-en-el-cancer-colorrectal-metastasico 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04991948/study-of-pembrolizumab-treatment-after-cyad-101-with-folfox-preconditioning-in-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05783622/estudio-de-janx008-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05783622/study-of-janx008-in-subjects-with-advanced-or-metastatic-solid-tumor-malignancies 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07007728/iparolimab-tuvonralimab-en-combinacion-con-bevacizumab-y-capeox-como-terapia-de-conversion-para-metastasis-hepaticas-del-cancer-colorrectal 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07007728/iparomlimab-tuvonralimab-combined-with-bevacizumab-and-capeox-as-conversion-therapy-for-colorectal-cancer-liver-metastasis 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT04511039/trifluridina-tipiracil-y-talazoparib-para-el-tratamiento-de-pacientes-con-cancer-colorrectal-o-gastroesofagico-localmente-avanzado-o-metastasico 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04511039/trifluridine-tipiracil-and-talazoparib-for-the-treatment-of-patients-with-locally-advanced-or-metastatic-colorectal-or-gastroesophageal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT03493048/cetuximab-mas-folfoxiri-frente-a-cetuximab-mas-folfox-en-el-tratamiento-del-cancer-colorrectal-metastasico-crclm 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT03493048/cetuximab-plus-folfoxiri-vs-cetuximab-plus-folfox-for-crclm 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT03947385/estudio-de-ide196-en-pacientes-con-tumores-solidos-que-presentan-mutaciones-en-gnaq-11-o-fusiones-en-prkc 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT03947385/study-of-ide196-in-patients-with-solid-tumors-harboring-gnaq-11-mutations-or-prkc-fusions 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06944548/evaluacion-del-efecto-de-la-actividad-fisica-adaptada-sobre-la-modificacion-del-metabolismo-lipidico-durante-la-quimioterapia-para-el-cancer-colorrectal-metastasico 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06944548/evaluation-of-the-effect-of-adapted-physical-activity-on-the-modification-of-lipid-metabolism-during-chemotherapy-for-metastatic-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06952101/un-enfoque-terapeutico-multimodal-personalizado-integrado-y-adaptado-al-estadio-a-nivel-mundial-para-el-adenocarcinoma-rectal-basado-en-la-preservacion-de-organos-y-la-minima-invasion 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06952101/a-global-integrated-personalized-stage-related-multimodal-therapeutic-approach-for-rectal-adenocarcinoma-based-on-organ-sparing-and-mininvasivity 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06540027/el-efecto-de-la-cirugia-minimamente-invasiva-sobre-la-respuesta-inflamatoria-sistemica-en-el-cancer-de-recto 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06540027/the-effect-of-minimally-invasive-surgery-on-systemic-inflammatory-response-in-rectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06202183/ejercicio-fisico-y-microbiota-intestinal-en-pacientes-con-cancer-colorrectal-de-inicio-temprano-que-reciben-quimioterapia-el-ensayo-courage 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06202183/exercise-for-gut-microbiome-in-patients-with-young-onset-colorectal-cancer-undergoing-chemotherapy-the-courage-trial 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07314294/estudio-de-fase-ii-de-emb-01-en-pacientes-con-cancer-colorrectal-recurrente-o-metastasico 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07314294/phase-ii-study-of-emb-01-in-recurrent-metastatic-colorectal-cancer-patients 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06111105/guia-mrd-01-crc-validacion-clinica-y-evaluacion-comparativa-de-los-mejores-diagnosticos-de-ctadn-en-el-cancer-colorrectal 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06111105/guide-mrd-01-crc-clinical-validation-and-benchmarking-of-top-performing-ctdna-diagnostics-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05299840/impacto-del-uso-del-dispositivo-oncogramme-r-en-la-seleccion-del-tratamiento-de-primera-linea-para-pacientes-con-cancer-colorrectal-metastasico 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05299840/impact-of-using-the-oncogramme-r-device-to-select-the-first-line-of-treatment-for-patients-with-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04564898/trifluridina-tipiracil-en-combinacion-con-capecitabina-y-bevacizumab-en-pacientes-con-cancer-colorrectal-metastasico 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT04564898/trifluridine-tipiracil-in-combination-with-capecitabine-and-bevacizumab-in-metastatic-colorectal-cancer-patients 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05854498/irinotecan-liposomal-en-combinacion-con-tas102-y-bevacizumab-para-pacientes-con-cancer-colorrectal-metastasico 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05854498/liposomal-irinotecan-with-tas102-and-bevacizumab-for-patients-with-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06973343/sintilimab-mas-bevacizumab-y-quimioterapia-en-pacientes-con-cancer-colorrectal-mss-pmmr-sin-metastasis-hepaticas 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06973343/sintilimab-plus-bevacizumab-and-chemotherapy-in-mss-pmmr-colorectal-with-no-liver-metastasis 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07318805/un-estudio-para-evaluar-el-medicamento-pf-08032562-en-personas-con-tumores-solidos-avanzados-o-metastasicos 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07318805/a-study-to-learn-about-the-study-medicine-called-pf-08032562-in-people-with-advanced-or-metastatic-solid-tumors 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04008797/un-estudio-de-e7386-en-combinacion-con-otros-farmacos-antineoplasicos-en-participantes-con-tumores-solidos 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT04008797/a-study-of-e7386-in-combination-with-other-anticancer-drug-s-in-participants-with-solid-tumor 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07257653/seguridad-y-eficacia-de-cetuximab-beta-mas-fruquintinib-con-o-sin-inhibidores-de-los-puntos-de-control-inmunitario-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-irresecable 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07257653/the-safety-and-efficacy-of-cetuximab-beta-plus-fruquintinib-with-or-without-immune-checkpoint-inhibitorrs-in-first-line-treatment-of-ras-braf-wild-type-unresectable-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04584008/evaluacion-de-agentes-dirigidos-en-canceres-digestivos-en-china-basada-en-las-caracteristicas-moleculares 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT04584008/targeted-agent-evaluation-in-digestive-cancers-in-china-based-on-molecular-characteristics 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06895031/estudio-de-jyp0015-en-pacientes-con-tumores-solidos-avanzados-que-presentan-mutaciones-especificas-en-ras 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06895031/study-of-jyp0015-in-patients-with-advanced-solid-tumors-harboring-specific-mutations-in-ras 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06184698/irinotecan-liposomal-y-leucovorina-5-fluorouracilo-mas-bevacizumab-en-el-cancer-colorrectal-metastasico 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06184698/liposomal-irinotecan-and-leucovorin-5-fluorouracil-plus-bevacizumab-in-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06662786/un-estudio-de-amivantamab-y-mfolfox6-o-folfiri-frente-a-cetuximab-y-mfolfox6-o-folfiri-como-tratamiento-de-primera-linea-en-participantes-con-cancer-colorrectal-irresecable-o-metastasico-del-lado 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06662786/a-study-of-amivantamab-and-mfolfox6-or-folfiri-versus-cetuximab-and-mfolfox6-or-folfiri-as-first-line-treatment-in-participants-with-kras-nras-and-braf-wild-type-unresectable-or-metastatic-left-sided 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06340646/centro-de-participacion-de-pacientes-y-secuenciacion-genomica-del-cancer-de-la-universidad-de-washington-wu-pe-cgs 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06340646/washington-university-participant-engagement-and-cancer-genomic-sequencing-center-wu-pe-cgs 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06427005/fruquintinib-mas-s-1-y-raltitrexed-rsf-para-el-cmmr 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06427005/fruquintinib-plus-s-1-and-raltitrexed-rsf-for-mcrc 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05786924/ensayo-de-fase-i-ii-de-s241656-en-malignidades-seleccionadas-con-mutaciones-ras-mapk 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05786924/phase-1-2-trial-of-s241656-in-selected-ras-mapk-mutation-positive-malignancies 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT02293954/el-uso-del-anticuerpo-monoclonal-marcado-con-cobre-64-cu-64-anti-cea-m5a-en-la-tomografia-por-emision-de-positrones-pet-para-el-diagnostico-de-pacientes-con-cancer-cea-positivo 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT02293954/copper-cu-64-anti-cea-monoclonal-antibody-m5a-pet-in-diagnosing-patients-with-cea-positive-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07169734/un-estudio-para-investigar-ale-p03-como-terapia-unica-en-pacientes-adultos-con-tumores-solidos-avanzados-o-metastasicos-cldn1-seleccionados 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07169734/a-study-to-investigate-ale-p03-as-monotherapy-in-adult-patients-with-selected-advanced-or-metastatic-cldn1-solid-tumors 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06646341/emvi-como-factor-determinante-de-la-metastasis-en-el-cancer-colorrectal 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06646341/emvi-as-a-determinant-of-metastasis-in-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06934018/efecto-del-ancho-del-margen-quirurgico-en-la-recurrencia-y-la-supervivencia-en-pacientes-con-oligometastasis-hepatica-de-cancer-colorrectal 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06934018/effect-of-surgical-margin-width-on-recurrence-and-survival-in-patients-with-hepatic-oligometastasis-of-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06543836/tratamiento-guiado-por-ctdna-con-tki-mas-inhibidor-de-pd-1-en-el-cancer-colorrectal-avanzado-pmmr-mss 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06543836/ctdna-guided-treatment-of-tki-plus-pd-1-inhibitor-for-advanced-pmmr-mss-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07071844/between-bevacizumab-y-trifluridina-tipiracil-administrados-cada-dos-semanas-para-reducir-la-neutropenia-de-grado-3-4-en-pacientes-con-mcrc 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07071844/between-biweekly-bevacizumab-trifluridine-tipiracil-to-reduce-grade-3-4-neutropenia-in-mcrc-patients 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT02804815/add-aspirin-un-ensayo-clinico-que-evalua-los-efectos-de-la-aspirina-sobre-la-recurrencia-de-la-enfermedad-y-la-supervivencia-tras-la-terapia-primaria-en-tumores-solidos-no-metastasicos-comunes 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT02804815/add-aspirin-a-trial-assessing-the-effects-of-aspirin-on-disease-recurrence-and-survival-after-primary-therapy-in-common-non-metastatic-solid-tumours 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT04854213/prelude-1-evaluacion-prospectiva-de-los-efectos-biologicos-inducidos-por-la-radioterapia-en-pacientes-con-enfermedad-oligo-metastasica-de-cancer-colorrectal-y-enfermedad-limitada-a-los-pulmones 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04854213/prelude-1-prospective-evaluation-of-radiotherapy-induced-biologic-effects-in-colorectal-cancer-oligometastatic-patients-with-lung-limited-disease-evolution-of-cancer-genetics-and-regulatory-immune 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04083599/ensayo-de-seguridad-gen1042-y-actividad-antitumoral-en-participantes-con-tumores-solidos-malignos 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT04083599/gen1042-safety-trial-and-anti-tumor-activity-in-participants-with-malignant-solid-tumors 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06200831/reseccion-simultanea-frente-a-reseccion-escalonada-del-cancer-colorrectal-con-metastasis-hepaticas-sincronicas 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06200831/simultaneous-vs-staged-resection-of-colorectal-cancer-with-synchronous-liver-metastases 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06723236/un-estudio-de-mgc028-en-participantes-con-tumores-solidos-avanzados 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06723236/a-study-of-mgc028-in-participants-with-advanced-solid-tumors 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06342401/deteccion-temprana-del-cancer-colorrectal-en-pacientes-jovenes 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06342401/early-onset-colorectal-cancer-detection 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04230187/bevacizumab-mas-mfolfoxiri-como-tratamiento-de-primera-linea-para-pacientes-con-cancer-colorrectal-metastasico-irresecable 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04230187/bevacizumab-plus-mfolfoxiri-as-first-line-treatment-for-patients-with-unresectable-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04222413/metarrestin-ml-246-en-pacientes-con-tumores-solidos-metastasicos 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04222413/metarrestin-ml-246-in-subjects-with-metastatic-solid-tumors 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07349043/ensayo-clinico-prospectivo-de-seguridad-y-eficacia-sobre-la-terapia-con-aerosol-intraperitoneal-presurizado-para-la-metastasis-peritoneal-del-cancer-colorrectal 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07349043/a-prospective-safety-and-efficacy-clinical-trial-of-pressurized-intraperitoneal-aerosol-therapy-for-peritoneal-metastasis-of-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04562727/ablacion-por-microondas-combinada-con-quimioterapia-para-metastasis-hepaticas-de-cancer-colorrectal-un-estudio-de-cohortes-multicentrico 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT04562727/microwave-ablation-combined-with-chemotherapy-for-colorectal-liver-metastases-a-multicenter-cohort-study 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07043387/optimizando-la-radioembolizacion-para-el-cancer-colorrectal-intrahepatico-y-el-cancer-hepatico-metastasico 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07043387/streamlining-radioembolization-for-ccc-and-metastatic-liver-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06879886/vigilancia-guiada-por-la-enfermedad-residual-minima-en-el-cancer-colorrectal-metastasico-en-estadio-iv-susceptible-de-reseccion-surveillance-ii 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06879886/mrd-guided-surveillance-in-resectable-stage-iv-metastatic-colorectal-cancer-surveillance-ii 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05129787/ablacion-frente-a-reseccion-de-metastasis-hepaticas-del-cancer-colorrectal 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05129787/ablation-vs-resection-of-colorectal-cancer-liver-metastases 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05629442/ctdna-y-preservacion-de-organos-respuesta-completa-patologica-en-el-cancer-de-recto 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05629442/ctdna-and-organ-preservation-pathologic-cr-in-rectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05787587/un-estudio-del-inhibidor-de-parg-ide161-en-participantes-con-tumores-solidos-avanzados 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05787587/a-study-of-parg-inhibitor-ide161-in-participants-with-advanced-solid-tumors 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05775146/radioterapia-estereotactica-ablativa-sbrt-de-metastasis-tras-el-tratamiento-neoadyuvante-para-el-cancer-colorrectal-con-metastasis-hepaticas-sincronicas 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05775146/sbrt-of-metastases-following-neo-adjuvant-treatment-for-colorectal-cancer-with-synchronous-liver-metastases 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06018714/eficacia-del-fruquintinib-modificado-en-metastasis-hepaticas-del-cancer-colorrectal-un-estudio-de-fase-ii 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06018714/efficacy-of-modified-fruquintinib-in-colorectal-cancer-liver-metastases-a-phase-ii-study 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05747716/terapia-de-radiacion-estereotactica-sbrt-combinada-con-fruquintinib-mas-un-anticuerpo-anti-pd-1-ctla-4-como-tratamiento-de-tercera-linea-en-pacientes-con-mcrc 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05747716/sbrt-combined-with-fruquintinib-plus-pd-1-ctla-4-antibody-for-third-line-treatment-in-mcrc 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05310643/nivolumab-e-ipilimumab-en-pacientes-con-mcrc-dmmr-msi-refractarios-a-anti-pd1 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05310643/nivolumab-and-ipilimumab-in-anti-pd1-resistant-dmmr-msi-mcrc 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07549412/un-estudio-de-precemtabart-tocentecan-con-o-sin-bevacizumab-en-comparacion-con-trifluridina-tipiracil-mas-bevacizumab-en-participantes-con-cancer-colorrectal-metastasico-previamente-tratado-proceade 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07549412/a-study-of-precemtabart-tocentecan-with-or-without-bevacizumab-compared-to-trifluridine-tipiracil-plus-bevacizumab-in-participants-with-previously-treated-metastatic-colorectal-cancer-proceade-crc-03 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04940546/seguridad-del-tratamiento-neoadyuvante-con-sintilimab-xelox-bevacizumab-en-pacientes-con-metastasis-colorrectales-mcrlm-con-pmmr-mss 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT04940546/neoadjuvant-safety-of-sintilimab-xelox-bevacizumab-in-pmmr-mss-crlm-patients 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07550088/bal-bot-agent-797-en-crc-con-pmmr-y-metastasis-hepaticas 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07550088/bal-bot-agent-797-in-pmmr-crc-with-liver-metastases 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06399757/un-estudio-para-investigar-apl-5125-en-adultos-con-tumores-solidos-avanzados 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06399757/a-study-to-investigate-apl-5125-in-adults-with-advanced-solid-tumors 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07359456/evaluacion-de-ivonescimab-en-combinacion-con-quimioterapia-en-pacientes-con-cancer-colorrectal-metastasico-sin-metastasis-hepaticas 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07359456/testing-ivonescimab-in-combination-with-chemotherapy-in-patients-with-metastatic-colorectal-cancers-without-liver-metastases 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07551596/evaluacion-de-la-combinacion-de-farmacos-antineoplasicos-botensilimab-agen1181-y-balstilimab-agen2034-tras-el-tratamiento-estandar-para-el-cancer-colorrectal-ensayo-combat 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07551596/testing-the-combination-of-anti-cancer-drugs-botensilimab-agen1181-and-balstilimab-agen2034-after-standard-treatment-for-colorectal-cancer-combat-trial 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06185556/ensayo-coldfire-iii-eficacia-de-la-electroforesis-irreversible-y-la-radioterapia-estereotactica-corporal-en-metastasis-hepaticas-de-cancer-colorrectal-perivasculares-y-peribiliares 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06185556/coldfire-iii-trial-efficacy-of-irreversible-electroporation-and-stereotactic-body-radiotherapy-for-perivascular-and-peribiliary-colorectal-liver-metastases 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07553572/aplicacion-digital-para-la-monitorizacion-remota-y-el-manejo-de-los-sintomas 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07553572/remote-monitoring-and-symptom-management-digital-application 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04221893/radioterapia-para-el-tratamiento-de-canceres-gastrointestinales-metastasicos 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04221893/radiation-therapy-for-the-treatment-of-metastatic-gastrointestinal-cancers 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06922383/un-estudio-clinico-de-arfolitixorina-en-pacientes-con-mcrc 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06922383/a-clinical-study-of-arfolitixorin-in-patients-with-mcrc 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06134388/sulfasalazina-en-pacientes-con-cancer-colorrectal-metastasico 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06134388/sulfasalazine-in-patients-with-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05688280/inyeccion-intratumoral-de-ip-001-tras-ablacion-termica-en-pacientes-con-crc-nsclc-y-sts 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05688280/intratumoral-injection-of-ip-001-following-thermal-ablation-in-patients-with-crc-nsclc-and-sts 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05985954/estudio-de-fase-1b-abierto-con-ulixertinib-y-cetuximab-o-ulixertinib-en-combinacion-con-cetuximab-y-encorafenib-en-pacientes-con-cancer-colorrectal-irresecable-o-metastasico-que-previamente-han 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05985954/open-label-phase-1b-study-of-ulixertinib-and-cetuximab-or-ulixertinib-in-combination-with-cetuximab-and-encorafenib-in-patients-with-unresectable-or-metastatic-colorectal-cancer-who-have-previously 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07061210/un-estudio-exploratorio-de-hrs-2189-en-combinacion-con-adebrelimab-y-bp102-para-el-cancer-colorrectal-metastasico 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07061210/an-explorative-study-of-hrs-2189-combined-with-adebrelimab-and-bp102-for-metastatic-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT04693377/crioablacion-combinada-con-radioterapia-estereotactica-de-cuerpo-completo-para-el-tratamiento-de-metastasis-oseas-dolorosas-el-ensayo-crome 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04693377/cryoablation-combined-with-stereotactic-body-radiation-therapy-for-the-treatment-of-painful-bone-metastases-the-crome-trial 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06192680/irinotecano-liposomal-y-capecitabina-mas-bevacizumab-como-terapia-de-segunda-linea-en-el-cancer-colorrectal-metastasico 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06192680/liposomal-irinotecan-and-capecitabine-plus-bevacizumab-as-second-line-therapy-in-metastatic-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06356584/fruquintinib-en-combinacion-con-sintilimab-radioterapia-para-el-tratamiento-en-tercera-linea-del-cancer-colorrectal-con-metastasis-hepaticas 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06356584/fruquintinib-combined-with-sintilimab-radiotherapy-for-third-line-treatment-of-colorectal-cancer-with-liver-metastases 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05639413/una-cohorte-prospectiva-clinico-biologica-de-pacientes-con-cancer-colorrectal-metastasico-con-mutacion-brafv600e 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05639413/a-clinical-biological-prospective-cohort-of-patients-with-brafv600e-mutated-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05991102/tratamiento-con-campos-electromagneticos-de-radiofrecuencia-de-modulacion-de-amplitud-combinado-con-tas-102-lonsurf-y-bevacizumab-en-el-cancer-colorrectal-metastasico-refractario 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05991102/amplitude-modulated-radiofrequency-electromagnetic-field-treatment-combined-with-tas-102-lonsurf-and-bevacizumab-in-refractory-metastatic-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT03919461/ensayo-internacional-sobre-la-prevencion-de-metastasis-del-cancer-colorrectal-2 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT03919461/colorectal-metastasis-prevention-international-trial-2 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06717295/el-estudio-ccaned-cipher-deteccion-temprana-del-cancer-y-monitorizacion-de-la-respuesta-al-tratamiento-mediante-el-analisis-transcriptomico-basado-en-inteligencia-artificial-de-las-plaquetas-y-las 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06717295/the-ccaned-cipher-study-early-cancer-detection-and-treatment-response-monitoring-using-ai-based-platelet-and-immune-cell-transcriptomic-profiling 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT03845166/un-estudio-de-xl092-como-terapia-en-monoterapia-y-en-combinacion-en-sujetos-con-tumores-solidos 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT03845166/a-study-of-xl092-as-single-agent-and-combination-therapy-in-subjects-with-solid-tumors 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07262619/eik1005-002-un-estudio-de-investigacion-clinica-que-evalua-eik1005-un-inhibidor-de-la-helicasa-de-werner-como-monoterapia-y-en-combinacion-con-pembrolizumab-en-participantes-con-tumores-solidos 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07262619/eik1005-002-a-clinical-research-study-evaluating-eik1005-a-werner-helicase-inhibitor-as-monotherapy-and-in-combination-with-pembrolizumab-in-participants-with-advanced-solid-tumors-including 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05217446/un-estudio-de-encorafenib-mas-cetuximab-administrados-en-combinacion-con-pembrolizumab-en-comparacion-con-pembrolizumab-solo-en-pacientes-con-cancer-colorrectal-metastasico-no-tratado-previamente 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05217446/a-study-of-encorafenib-plus-cetuximab-taken-together-with-pembrolizumab-compared-to-pembrolizumab-alone-in-people-with-previously-untreated-metastatic-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06199232/tratamiento-dirigido-mas-tislelizumab-y-haic-para-el-cancer-colorrectal-metastasico-crclm-en-estadio-avanzado-que-no-ha-respondido-al-tratamiento-sistemico-estandar 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06199232/targeted-treatment-plus-tislelizumab-and-haic-for-advanced-crclm-failed-from-standard-systemic-treatment 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05797077/terapia-de-mantenimiento-postoperatoria-para-metastasis-hepaticas-resecables-del-cancer-colorrectal-guiada-por-ctdna 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05797077/postoperation-maintenance-therapy-for-resectable-liver-metastases-of-colorectal-cancer-guided-by-ctdna 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06105021/estudio-de-fase-i-de-celulas-t-receptor-de-celulas-t-autologas-cd8-y-cd4-modificadas-geneticamente-en-sujetos-con-tumores-solidos-avanzados-o-metastasicos 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06105021/phase-i-study-of-autologous-cd8-and-cd4-engineered-t-cell-receptor-t-cells-in-subjects-with-advanced-or-metastatic-solid-tumor 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06456515/regorafenib-y-sintilimab-en-combinacion-con-electroacupuntura-en-crc-mss 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06456515/regorafenib-and-sintilimab-in-combination-with-electroacupuncture-in-mss-crc 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT01792934/quimioterapia-y-reseccion-quirurgica-maxima-de-las-metastasis-de-cancer-colorrectal-multiorganico 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT01792934/chemotherapy-and-maximal-tumor-debulking-of-multi-organ-colorectal-cancer-metastases 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07167446/potencial-neuroprotector-del-cannabidiol-cbd-en-la-prevencion-de-la-neuropatia-inducida-por-oxaliplatino-ox 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07167446/neuroprotective-potential-of-cannabidiol-cbd-in-preventing-oxaliplatin-ox-induced-neuropathy 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06208397/resonancia-magnetica-para-la-evaluacion-de-los-patrones-de-crecimiento-histopatologicos-en-metastasis-hepaticas-de-cancer-colorrectal 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06208397/mre-for-assessment-of-histopathological-growth-patterns-in-colorectal-liver-metastases 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07399236/prediccion-basada-en-inteligencia-artificial-de-la-metastasis-hepatica-en-el-cancer-colorrectal-un-estudio-retrospectivo 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07399236/ai-based-prediction-of-liver-metastasis-in-colorectal-cancer-a-retrospective-study 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05081024/establecimiento-de-un-biomarcador-de-ctdna-para-mejorar-las-estrategias-de-preservacion-de-organos-en-pacientes-con-cancer-de-recto 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05081024/establishing-a-ctdna-biomarker-to-improve-organ-preserving-strategies-in-patients-with-rectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07044921/estudio-clinico-de-un-tratamiento-combinado-basado-en-irinotecan-liposomal-ii-para-el-cancer-colorrectal-resistente-al-irinotecan 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07044921/clinical-study-of-irinotecan-liposome-ii-based-combination-treatment-for-irinotecan-resistant-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07079462/comparacion-de-la-radioterapia-abdominal-guiada-por-pet-con-68ga-fapi-combinada-con-la-terapia-estandar-de-segunda-linea-y-cadonilimab-frente-a-la-terapia-estandar-de-segunda-linea-en-el-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07079462/comparing-68ga-fapi-pet-guided-abdominal-radiotherapy-combined-with-second-line-standard-therapy-and-cadonilimab-versus-second-line-standard-therapy-in-colorectal-cancer-with-peritoneal-metastasis 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04547166/un-estudio-clinico-para-evaluar-la-eficacia-y-la-seguridad-de-serplulimab-hlx10-en-combinacion-con-bevacizumab-hlx04-y-quimioterapia-xelox-en-pacientes-con-cancer-colorrectal-metastasico-mcrc 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04547166/a-clinical-study-to-evaluate-efficacy-and-safety-of-serplulimab-hlx10-combined-with-bevacizumab-hlx04-and-chemotherapy-xelox-in-patients-with-metastatic-colorectal-cancer-mcrc 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07585279/un-estudio-clinico-de-irinotecan-liposomal-para-la-terapia-de-segunda-linea-en-el-cancer-colorrectal-metastasico 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07585279/a-clinical-study-of-liposomal-irinotecan-for-second-line-therapy-in-metastatic-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT03350126/relevancia-de-la-evaluacion-irecist-para-la-tasa-de-respuesta-global-dcr-en-pacientes-con-cancer-colorrectal-metastasico-mmr-msi-tratados-con-nivolumab-e-ipilimumab 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT03350126/irecist-evaluation-s-relevance-for-dcr-in-mmr-msi-metastatic-colorectal-cancer-patients-on-nivolumab-and-ipilimumab 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT04457284/temozolomida-cisplatino-y-nivolumab-en-pacientes-con-cancer-colorrectal 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT04457284/temozolomide-cisplatin-and-nivolumab-in-people-with-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT03587480/reseccion-mesorrectal-total-rmt-con-diseccion-de-los-ganglios-linfaticos-laterales-frente-a-rmt-tras-quimiorradioterapia-neoadyuvante 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT03587480/total-mesorectal-excision-tme-with-lateral-lymph-node-dissection-versus-tme-after-neoadjuvant-chemo-radiotherapy 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05354674/firma-de-aprendizaje-profundo-multimodal-para-la-evaluacion-de-la-respuesta-al-bevacizumab-en-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05354674/multimodal-deep-learning-signature-for-evaluation-of-response-to-bevacizumab-in-patient-with-colorectal-cancer-liver-metastasis 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06047015/electroforesis-irreversible-nanoknife-r-e-inmunoterapia-para-el-tratamiento-del-cancer-colorrectal-en-estadio-iv 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06047015/irreversible-electroporation-nanoknife-r-and-immunotherapy-for-the-treatment-of-stage-iv-colorectal-cancer 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT03978078/una-base-de-datos-clinicobiologica-en-canceres-digestivos-metastasicos 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT03978078/a-clinicobiological-database-in-metastatic-digestive-cancers 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06547203/cetuximab-irinotecan-y-toripalimab-en-un-estudio-de-cancer-colorrectal-derecho-ultra-seleccionado-con-mutaciones-ras-braf-de-tipo-salvaje 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06547203/cetuximab-irinotecan-toripalimab-in-ras-braf-wild-type-ultraselected-right-sided-colorectal-cancer-study 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT02906943/evaluacion-de-acidos-nucleicos-dirigida-a-tumores-en-toda-la-provincia-de-ontario 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT02906943/ontario-wide-cancer-targeted-nucleic-acid-evaluation 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04491929/terapia-de-radiacion-interna-selectiva-con-microesferas-de-resina-de-90y-para-metastasis-hepaticas-de-cancer-colorrectal-refractario 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04491929/selective-internal-radiation-therapy-with-90y-resin-micropheres-for-refractory-colorectal-cancer-liver-metastases 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06997458/biopsia-liquida-cancer-de-pulmon-y-cancer-de-colon-en-andalucia 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT06997458/liquid-biopsy-lung-and-colon-cancer-in-andalucia 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07430527/revision-del-protocolo-para-el-tratamiento-del-cancer-colorrectal-en-atencion-secundaria 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07430527/secondary-care-colorectal-cancer-pathway-review 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07172282/infinitive-inmunoterapia-para-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07172282/infinitive-immunotherapy-for-patients-with-colorectal-liver-metastases 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05965817/reseccion-guiada-por-fluorescencia-de-metastasis-hepaticas-de-cancer-colorrectal-utilizando-sgm-101-e-indocianina-verde 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05965817/fluorescence-guided-resection-of-colorectal-liver-metastases-using-sgm-101-and-indocyanine-green 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06349590/manipulacion-de-la-microbiota-intestinal-mediante-una-dieta-preoperatoria-estandarizada-para-prevenir-la-recurrencia-y-la-metastasis-del-cancer-colorrectal-tras-la-cirugia 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06349590/manipulation-of-the-gut-microbiome-by-a-standardized-preoperative-diet-to-prevent-colorectal-cancer-recurrence-and-metastasis-following-surgery 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06562543/un-ensayo-para-evaluar-la-seguridad-y-la-actividad-del-fruquintinib-en-poblaciones-minoritarias-con-cancer-colorrectal-avanzado-previamente-tratado 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT06562543/a-trial-to-evaluate-the-safety-and-activity-of-fruquintinib-in-minority-populations-with-advanced-previously-treated-colorectal-cancer 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05768503/comparacion-de-chidamide-sintilimab-bevacizumab-con-el-regimen-estandar-de-segunda-linea-folfiri-bevacizumab-en-pacientes-con-mcrc-avanzado-mss-pmmr 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT05768503/comparing-chidamide-sintilimab-bev-with-standard-second-line-folfiri-bev-in-advanced-mss-pmmr-mcrc 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04929223/un-estudio-que-evalua-la-seguridad-y-la-eficacia-de-las-terapias-dirigidas-en-subpoblaciones-de-pacientes-con-cancer-colorrectal-metastasico-intrinsic 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT04929223/a-study-evaluating-the-safety-and-efficacy-of-targeted-therapies-in-subpopulations-of-patients-with-metastatic-colorectal-cancer-intrinsic 2026-05-20 weekly 0.7 https://crcwarriors.org/ensayo/NCT07435584/everolimus-en-cancer-colorrectal-metastasico-con-deficiencia-de-cdk12-ever-recode 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT07435584/everolimus-in-cdk12-deficient-metastatic-colorectal-cancer-ever-recode 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05838768/estudio-de-hro761-en-monoterapia-o-en-combinacion-en-pacientes-con-cancer-que-presenten-alteraciones-especificas-en-el-adn-denominadas-inestabilidad-de-microsatelites-o-deficiencia-en-la-reparacion 2026-05-20 weekly 0.6 https://crcwarriors.org/ensayo/NCT05838768/study-of-hro761-alone-or-in-combination-in-cancer-patients-with-specific-dna-alterations-called-microsatellite-instability-or-mismatch-repair-deficiency 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/oxaliplatin 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/oxaliplatin/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/uracil 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/uracil/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/fluorouracil 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/fluorouracil/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/5-fluorouracil 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/5-fluorouracil/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/leucovorin 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/leucovorin/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/bevacizumab 2026-05-14 weekly 0.7 https://crcwarriors.org/medicamento/bevacizumab/ensayos 2026-05-14 weekly 0.6 https://crcwarriors.org/medicamento/capecitabine 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/capecitabine/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/irinotecan 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/irinotecan/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/cetuximab 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/cetuximab/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/pembrolizumab 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/pembrolizumab/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/met 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/met/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/panitumumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/panitumumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/regorafenib 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/regorafenib/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/rego 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/rego/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/nivolumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/nivolumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/tislelizumab 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/tislelizumab/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/fruquintinib 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/fruquintinib/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/trifluridine 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/trifluridine/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/paclitaxel 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/paclitaxel/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/atezolizumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/atezolizumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/cyclophosphamid 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cyclophosphamid/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/cyclophosphamide 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cyclophosphamide/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/durvalumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/durvalumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/ipilimumab 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/ipilimumab/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/celecoxib 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/celecoxib/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/cele 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/cele/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/cisplatin 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cisplatin/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/sintilimab 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/sintilimab/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/gemcitabine 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/gemcitabine/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/aldesleukin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aldesleukin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/aspirin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aspirin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/carboplatin 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/carboplatin/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/s-1 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/s-1/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pemetrexed 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/pemetrexed/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/encorafenib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/encorafenib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/aflibercept 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aflibercept/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fludarabine 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/fludarabine/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/cadonilimab 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/cadonilimab/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/binimetinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/binimetinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/balstilimab 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/balstilimab/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/botensilimab 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/botensilimab/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/docetaxel 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/docetaxel/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/erlotinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/erlotinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/trametinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/trametinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/everolimus 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/everolimus/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nab-paclitaxel 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/nab-paclitaxel/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/serplulimab 2026-04-23 weekly 0.7 https://crcwarriors.org/medicamento/serplulimab/ensayos 2026-04-23 weekly 0.6 https://crcwarriors.org/medicamento/tori 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/tori/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/avelumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/avelumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/toripalimab 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/toripalimab/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/metformin 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/metformin/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/sargramostim 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sargramostim/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vemurafenib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/vemurafenib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/dexamethasone 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/dexamethasone/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/temozolomide 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/temozolomide/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tremelimumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tremelimumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/adagrasib 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/adagrasib/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/peg 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/peg/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/cemiplimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cemiplimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dostarlimab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/dostarlimab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/cabozantinib 2026-04-14 weekly 0.7 https://crcwarriors.org/medicamento/cabozantinib/ensayos 2026-04-14 weekly 0.6 https://crcwarriors.org/medicamento/lidocaine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lidocaine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/camrelizumab 2026-04-16 weekly 0.7 https://crcwarriors.org/medicamento/camrelizumab/ensayos 2026-04-16 weekly 0.6 https://crcwarriors.org/medicamento/ivonescimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ivonescimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/metronidazole 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/metronidazole/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/mitomycin 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/mitomycin/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/raltitrexed 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/raltitrexed/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/apatinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/apatinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/adebrelimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/adebrelimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tucatinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tucatinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ramucirumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ramucirumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sorafenib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/sorafenib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/sirolimus 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sirolimus/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/envafolimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/envafolimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/palbociclib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/palbociclib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/selumetinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selumetinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pertuzumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/pertuzumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/sunitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/sunitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/amg 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/amg/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/tipiracil 2026-04-18 weekly 0.7 https://crcwarriors.org/medicamento/tipiracil/ensayos 2026-04-18 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab+deruxteca 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab+deruxteca/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hydroxychloroquine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hydroxychloroquine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gefitinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gefitinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bortezomib 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/bortezomib/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab+deruxtecan 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab+deruxtecan/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/filgrastim 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/filgrastim/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/ql1706 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ql1706/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tas 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tas/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/abemaciclib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/abemaciclib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/infliximab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/infliximab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/vandetanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vandetanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cediranib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cediranib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/chidamide 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/chidamide/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sulindac 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sulindac/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dasatinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dasatinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/melphala 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/melphala/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vorinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/vorinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/dabrafenib 2026-04-02 weekly 0.7 https://crcwarriors.org/medicamento/dabrafenib/ensayos 2026-04-02 weekly 0.6 https://crcwarriors.org/medicamento/lapatinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lapatinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/axitinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/axitinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vorinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vorinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/melphalan 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/melphalan/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ak112 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ak112/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/lenvatinib 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/lenvatinib/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/iparomlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/iparomlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tuvonralimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tuvonralimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cobimetinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cobimetinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/indocyanine+green 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/indocyanine+green/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/olaparib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/olaparib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/tegafu 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tegafu/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sasanlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sasanlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/temsirolimus 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/temsirolimus/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/veliparib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/veliparib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/azacitidine 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/azacitidine/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/tegafur 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tegafur/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/chemo 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/chemo/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/other 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/other/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/amivantamab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/amivantamab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/g17dt 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/g17dt/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eflornithine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eflornithine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/doxorubicin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/doxorubicin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bkm120 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/bkm120/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/moviprep 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/moviprep/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/g17d 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/g17d/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/retifanlimab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/retifanlimab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/sol 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/sol/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/zanidatamab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/zanidatamab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pdr001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pdr001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/enzalutamide 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/enzalutamide/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/naliri 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/naliri/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/anlotinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/anlotinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/nktr 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/nktr/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/omeprazole 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/omeprazole/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dexmedetomidine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dexmedetomidine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tocilizumab 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/tocilizumab/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/fianlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/fianlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etrumadenant 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etrumadenant/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/decitabine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/decitabine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ts-1 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ts-1/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/shr-8068 2026-04-02 weekly 0.7 https://crcwarriors.org/medicamento/shr-8068/ensayos 2026-04-02 weekly 0.6 https://crcwarriors.org/medicamento/nintedanib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/nintedanib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/lenalidomide 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lenalidomide/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/methotrexate 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/methotrexate/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/osimertinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/osimertinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/fulvestrant 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/fulvestrant/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/sym004 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sym004/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/penpulimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/penpulimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/propofol 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/propofol/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ruxolitinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/ruxolitinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/lorigerlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lorigerlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sotorasib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sotorasib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/spartalizumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/spartalizumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/entinostat 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/entinostat/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/riluzole 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/riluzole/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tiragolumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tiragolumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pegfilgrastim 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pegfilgrastim/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/adc 2026-03-29 weekly 0.7 https://crcwarriors.org/medicamento/adc/ensayos 2026-03-29 weekly 0.6 https://crcwarriors.org/medicamento/nktr- 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/nktr-/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/sevoflurane 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sevoflurane/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ribociclib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/ribociclib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/epacadostat 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/epacadostat/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/tivozanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tivozanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sgm-101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sgm-101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bbi608 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bbi608/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tno155 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/tno155/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/bp102 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bp102/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hlx10 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hlx10/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pazopanib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/pazopanib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/midazolam 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/midazolam/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/imiquimod 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/imiquimod/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/t3011 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/t3011/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hmn14 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hmn14/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/allostim 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/allostim/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/afatinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/afatinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/bibf 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bibf/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/radiotherapy 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/radiotherapy/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/inavolisib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/inavolisib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ganitumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ganitumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/e7386 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7386/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/semaxanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/semaxanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rmc-6236 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rmc-6236/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/crizotinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/crizotinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/osi-906 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/osi-906/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/etbx-011 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-011/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bupivacain 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bupivacain/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/thymalfasin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/thymalfasin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tucidinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tucidinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/indomethacin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/indomethacin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ropivacaine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ropivacaine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tucidinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tucidinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/doxycycline 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/doxycycline/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/enadenotucirev 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/enadenotucirev/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/romidepsi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/romidepsi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/amg-655 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/amg-655/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mk-2206 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mk-2206/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eniluracil 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eniluracil/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vedolizumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/vedolizumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/indomethaci 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/indomethaci/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/nalirifox 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/nalirifox/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/plenvu 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/plenvu/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pucotenlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pucotenlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/romidepsin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/romidepsin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/jab-21822 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jab-21822/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gvax 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gvax/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/panobinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/panobinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mangafodipir 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mangafodipir/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/relatlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/relatlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/trifluridine-tipiracil 2026-04-15 weekly 0.7 https://crcwarriors.org/medicamento/trifluridine-tipiracil/ensayos 2026-04-15 weekly 0.6 https://crcwarriors.org/medicamento/flucytosine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/flucytosine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/thymalfasi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/thymalfasi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/etrolizumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/etrolizumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/nimotuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nimotuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cs-1008 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cs-1008/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dalotuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dalotuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/selinexo 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selinexo/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vismodegib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vismodegib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/zimberelimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/zimberelimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/egfr 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/egfr/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/saline 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/saline/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/selinexor 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selinexor/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/amg-479 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/amg-479/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/daraxonrasib 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/daraxonrasib/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/niraparib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/niraparib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/incb001158 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/incb001158/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/imatinib 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/imatinib/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/bibf-1120 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/bibf-1120/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/e7820 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7820/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abx-egf 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/abx-egf/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gsk5764227 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gsk5764227/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/onvansertib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/onvansertib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pd-0325901 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pd-0325901/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/chemoradiotherapy 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/chemoradiotherapy/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/brivanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/brivanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cyclosporine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cyclosporine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ner1006 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ner1006/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/panobinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/panobinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mangafodipi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mangafodipi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/neomyci 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/neomyci/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/maraviroc 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/maraviroc/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eribulin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eribulin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/magrolimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/magrolimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ci-1040 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ci-1040/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abbv-400 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/abbv-400/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nis793 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/nis793/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/cv301 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cv301/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/imc-a12 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/imc-a12/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tinzaparin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tinzaparin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/napabucasi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/napabucasi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/rimiducid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rimiducid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/calmangafodipir 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/calmangafodipir/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gdc-1971 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gdc-1971/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/reolysi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/reolysi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/conatumumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/conatumumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/masitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/masitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/rec-4881 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/rec-4881/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/budigalimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/budigalimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bms-986340 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bms-986340/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/inc280 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/inc280/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/kd018 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/kd018/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/arfolitixorin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/arfolitixorin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ca102n 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ca102n/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/udenafil 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/udenafil/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/volrustomig 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/volrustomig/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/foxy-5 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/foxy-5/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cmab009 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cmab009/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ibi363 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ibi363/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/amt2003 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/amt2003/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/rmc-9805 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rmc-9805/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/alt-803 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/alt-803/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pro95780 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/pro95780/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/e7070 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7070/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bevacizumab-irdye800cw 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bevacizumab-irdye800cw/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pirfenidone 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/pirfenidone/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/enzastaurin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/enzastaurin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/nv1020 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nv1020/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hdm201 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hdm201/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bibw-2992 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bibw-2992/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/dovitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/dovitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/enoxaparin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/enoxaparin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hs-20093 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hs-20093/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/denosumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/denosumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vatalanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vatalanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/floxuridine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/floxuridine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rivaroxaba 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/rivaroxaba/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/xilonix 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/xilonix/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/artesunate 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/artesunate/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bms-986016 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bms-986016/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bli850 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bli850/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hlx208 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hlx208/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/copanlisib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/copanlisib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/regn7075 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/regn7075/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/defactinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/defactinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/calderasib 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/calderasib/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/larotrectinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/larotrectinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bi-765049 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bi-765049/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/dulanermin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dulanermin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cannabidiol 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/cannabidiol/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ridaforolimus 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ridaforolimus/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/naproxen 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/naproxen/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/prednisone 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/prednisone/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/lubiprostone 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/lubiprostone/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/fleet 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/fleet/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/neomycin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/neomycin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bupivacaine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bupivacaine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ufox 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ufox/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/nilotinib 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/nilotinib/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/dsp107 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dsp107/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gi-4000 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gi-4000/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rosuvastati 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/rosuvastati/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/oleclumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/oleclumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/trk-950 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/trk-950/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hua33 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hua33/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bisacodyl 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bisacodyl/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/jab-3312 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jab-3312/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cb-839 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cb-839/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gastrografin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gastrografin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/plerixafo 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/plerixafo/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sgi-110 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sgi-110/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mm-151 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-151/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/carmustine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/carmustine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ompenaclid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ompenaclid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mm-398 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-398/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rivaroxaban 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rivaroxaban/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/js207 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/js207/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/thalidomide 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/thalidomide/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/il2 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/il2/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/silymarin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/silymarin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/desflurane 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/desflurane/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/rapamyci 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/rapamyci/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/loperamide 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/loperamide/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/m9140 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/m9140/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mcla-129 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mcla-129/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/si-b003 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/si-b003/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etbx-051 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-051/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/can04 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/can04/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etbx-061 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-061/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gi-6301 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gi-6301/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/grt-c901 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/grt-c901/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/grt-r902 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/grt-r902/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/talazoparib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/talazoparib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nc410 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nc410/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rifaximi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/rifaximi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ly3214996 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ly3214996/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/rapamycin 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/rapamycin/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/famitinib 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/famitinib/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bmx-001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bmx-001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/shr-1701 2026-04-02 weekly 0.7 https://crcwarriors.org/medicamento/shr-1701/ensayos 2026-04-02 weekly 0.6 https://crcwarriors.org/medicamento/prexasertib 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/prexasertib/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tovorafenib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tovorafenib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/flox 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/flox/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/plerixafor 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/plerixafor/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/simvastatin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/simvastatin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ulixertinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ulixertinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/resveratrol 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/resveratrol/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/cm-24 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cm-24/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cp-675 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/cp-675/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/g-csf 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/g-csf/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ono-4578 2026-04-18 weekly 0.7 https://crcwarriors.org/medicamento/ono-4578/ensayos 2026-04-18 weekly 0.6 https://crcwarriors.org/medicamento/piritramid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/piritramid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mm-121 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-121/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/curcumin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/curcumin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/dtx 2026-03-29 weekly 0.7 https://crcwarriors.org/medicamento/dtx/ensayos 2026-03-29 weekly 0.6 https://crcwarriors.org/medicamento/pds0101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pds0101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/acetaminophen 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/acetaminophen/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/m7824 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/m7824/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/silymari 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/silymari/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/simvastati 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/simvastati/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/golytely 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/golytely/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bl-b01d1 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bl-b01d1/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/byl719 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/byl719/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/aipalolitovorelizumab 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/aipalolitovorelizumab/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mgd007 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mgd007/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vactosertib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/vactosertib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/sym021 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sym021/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/xl092 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/xl092/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/adalimumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/adalimumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/incb106385 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/incb106385/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/interferon 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/interferon/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ly3023414 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/ly3023414/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/tegavivint 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/tegavivint/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/levoleucovori 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/levoleucovori/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mesalamine 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/mesalamine/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/tg6002 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tg6002/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ropidoxuridine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ropidoxuridine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cyad-101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cyad-101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/glutamine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/glutamine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ezabenlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ezabenlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ngm438 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ngm438/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/isis 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/isis/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/gv20-0251 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gv20-0251/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/epinephrine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/epinephrine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/propranolol 2026-05-01 weekly 0.7 https://crcwarriors.org/medicamento/propranolol/ensayos 2026-05-01 weekly 0.6 https://crcwarriors.org/medicamento/naproxe 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/naproxe/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/nsaid 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/nsaid/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sc-201 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/sc-201/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/shr-a1811 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/shr-a1811/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/n-803 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/n-803/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tegavivi 2026-03-29 weekly 0.7 https://crcwarriors.org/medicamento/tegavivi/ensayos 2026-03-29 weekly 0.6 https://crcwarriors.org/medicamento/ethynyluracil 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ethynyluracil/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/avx701 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/avx701/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tinzapari 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tinzapari/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/surufatinib 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/surufatinib/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/ixabepilone 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ixabepilone/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/selenium 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/selenium/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hlx07 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/hlx07/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/jdq443 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jdq443/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pds01adc 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pds01adc/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/krn330 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/krn330/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/levoleucovorin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/levoleucovorin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bi-1701963 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bi-1701963/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rifaximin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rifaximin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sg001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sg001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/jx-594 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jx-594/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/reolysin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/reolysin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tas-102 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tas-102/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ferumoxytol 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ferumoxytol/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rosuvastatin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rosuvastatin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/jmt101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jmt101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/b1962 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/b1962/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cibisatamab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cibisatamab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/elironrasib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/elironrasib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/obinutuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/obinutuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/alectinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/alectinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/ibrutinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ibrutinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ngr-htnf 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ngr-htnf/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/venetoclax 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/venetoclax/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/si-b001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/si-b001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gm-ct-01 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/gm-ct-01/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/napabucasin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/napabucasin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/isunakinra 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/isunakinra/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tu2218 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tu2218/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/trisulfate 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/trisulfate/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/liverpearls-irinotecan 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/liverpearls-irinotecan/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dkn-01 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dkn-01/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/icrucumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/icrucumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/treatme 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/treatme/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/cnto-328 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/cnto-328/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/es104 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/es104/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tc-510 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tc-510/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cu-tz-sara 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/cu-tz-sara/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mw4911 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mw4911/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/pf-07220060 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pf-07220060/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bevacizumab-awwb 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bevacizumab-awwb/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/xl888 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/xl888/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pep503 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/pep503/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ga-102 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/ga-102/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/kzr-261 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/kzr-261/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bms-986490 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bms-986490/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/metarresti 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/metarresti/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/eo2040 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/eo2040/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tak-186 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tak-186/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/inulin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/inulin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mgd009 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mgd009/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/qs21 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/qs21/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/amg-706 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/amg-706/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/gen1042 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gen1042/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bempegaldesleukin 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/bempegaldesleukin/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/pf-05212384 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/pf-05212384/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/catumaxomab 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/catumaxomab/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bnt314 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/bnt314/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/pb101 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/pb101/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/cp-751 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cp-751/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nktr-262 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/nktr-262/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/nktr-102 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nktr-102/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/golimumab 2026-04-23 weekly 0.7 https://crcwarriors.org/medicamento/golimumab/ensayos 2026-04-23 weekly 0.6 https://crcwarriors.org/medicamento/prasterone 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/prasterone/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bnt327 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/bnt327/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/gi-102 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/gi-102/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/tinodasertib 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/tinodasertib/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/danvatirsen 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/danvatirsen/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/gen-011 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/gen-011/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/menthol 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/menthol/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/eco-4601 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/eco-4601/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/jmt108 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/jmt108/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/esg401 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/esg401/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/glucagon 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/glucagon/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab-deruxtecan 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab-deruxtecan/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/tas102 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/tas102/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/devimistat 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/devimistat/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/ak117 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/ak117/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/wnt974 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/wnt974/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/pf-06946860 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/pf-06946860/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/kqb368 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/kqb368/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/lt-002 2026-04-23 weekly 0.7 https://crcwarriors.org/medicamento/lt-002/ensayos 2026-04-23 weekly 0.6 https://crcwarriors.org/medicamento/gdc-0994 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/gdc-0994/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/disp-10 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/disp-10/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/clsp-1025 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/clsp-1025/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/bbo-10203 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/bbo-10203/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/paricalcitol 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/paricalcitol/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/alt803 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/alt803/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/dexpantenol 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dexpantenol/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/midostauri 2026-03-29 weekly 0.7 https://crcwarriors.org/medicamento/midostauri/ensayos 2026-03-29 weekly 0.6 https://crcwarriors.org/medicamento/ramosetron 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ramosetron/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rph-030 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/rph-030/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/prednisolone 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/prednisolone/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/falimarev 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/falimarev/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/pixatimod 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pixatimod/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tecemotide 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/tecemotide/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/xnw27011 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/xnw27011/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/regimen/folfox 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/capox 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfoxiri 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfox-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-cetuximab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-panitumumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfoxiri-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/capecitabine-mono 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/pembrolizumab-mono 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/encorafenib-cetuximab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/trastuzumab-pertuzumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/trifluridine-tipiracil 2026-02-13 monthly 0.8 https://crcwarriors.org/articulo/2174/estudio-sobre-el-efecto-de-los-antibioticos-en-la-eficacia-de-los-inhibidores-de-pd-1-y-su-mecanismo-regulador-a-traves-de-la-comunidad-bacteriana-intestinal 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2174/study-on-the-effect-of-antibiotics-on-the-efficacy-of-pd-1-inhibitors-and-its-regulatory-mechanism-via-the-intestinal-bacterial-community 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2163/el-regorafenib-potencia-la-eficacia-terapeutica-anti-pdcd1-pd-1-en-el-cancer-colorrectal-al-promover-la-degradacion-de-cd274-pd-l1-mediada-por-sqstm1-p62 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2163/regorafenib-enhances-anti-pdcd1-pd-1-therapeutic-efficacy-in-colorectal-cancer-by-promoting-sqstm1-p62-mediated-cd274-pd-l1-degradation 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2150/el-papel-del-adn-tumoral-circulante-en-la-terapia-adyuvante-de-precision-para-el-cancer-colorrectal-una-revision-exploratoria 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2150/the-role-of-circulating-tumor-dna-in-precision-adjuvant-therapy-for-colorectal-cancer-a-scoping-review 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2143/la-privacion-del-sueno-inhibe-la-funcion-de-los-linfocitos-t-cd8-al-aumentar-la-expresion-de-galectina-9-en-las-celulas-de-cancer-colorrectal 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2143/sleep-deprivation-inhibits-cd8-t-cell-function-by-elevating-galectin-9-expression-in-colorectal-cancer-cells 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2118/ensayo-fruquitas-diseno-del-estudio-de-un-ensayo-aleatorizado-de-fase-iii-del-grupo-de-colaboracion-engic-que-evalua-la-combinacion-de-trifluridina-tipiracil-con-o-sin-fruquintinib-en-pacientes-con 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2118/fruquitas-trial-study-design-of-an-engic-intergroup-randomized-phase-iii-of-trifluridine-tipiracil-fruquintinib-in-pre-treated-metastatic-gastro-oesophageal-adenocarcinoma 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2103/creacion-de-una-plataforma-solida-para-estudios-iniciados-por-investigadores-la-experiencia-de-i-care 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2103/building-a-robust-investigator-initiated-platform-the-i-care-experience 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2074/ingenieria-de-nanocapsulas-para-la-silenciamiento-eficiente-de-nsun2-y-una-terapia-inmunomoduladora-en-el-cancer-colorrectal-metastasico 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2074/nanocarriers-engineering-for-efficient-nsun2-silencing-and-immune-responsive-therapy-in-metastatic-colorectal-cancer 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2069/oncogenicidad-e-implicaciones-terapeuticas-de-los-biomarcadores-moleculares-en-el-carcinoma-colorrectal 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2069/oncogenicity-and-therapeutic-implications-of-molecular-biomarkers-in-colorectal-carcinoma 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2027/inmunoterapia-en-el-cancer-colorrectal-localizado-practica-actual-y-perspectivas-futuras 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2027/immunotherapy-in-localized-colorectal-cancer-current-practice-and-future-directions 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2020/nivolumab-mas-ipilimumab-y-cobimetinib-en-pacientes-con-cancer-colorrectal-metastasico-con-microsatelites-estables-reparacion-deficiente-del-emparejamiento-del-adn-previamente-tratados-el-ensayo-de 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2020/nivolumab-plus-ipilimumab-and-cobimetinib-in-previously-treated-microsatellite-stable-dna-mismatch-repair-proficient-metastatic-colorectal-cancer-the-phase-ii-checkmate-142-trial 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/1999/el-inhibidor-selectivo-de-kras-g12d-mrtx1133-suprime-la-proliferacion-y-modula-diferencialmente-la-quimiosensibilidad-en-el-carcinoma-mucinoso-de-ovario 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/1999/kras-g12d-selective-inhibitor-mrtx1133-suppresses-proliferation-and-differentially-modulates-chemosensitivity-in-ovarian-mucinous-carcinoma 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/1980/datos-sobre-las-firmas-transcriptomicas-de-microarn-los-genes-diana-predichos-y-el-analisis-de-vias-de-senalizacion-en-respuesta-a-cetuximab-o-panitumumab-en-celulas-de-cancer-colorrectal 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/1980/data-on-microrna-transcriptomic-signatures-predicted-gene-targets-and-pathway-analysis-in-response-to-cetuximab-or-panitumumab-in-colorectal-cancer-cells 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/1978/nuevos-y-consolidados-objetivos-terapeuticos-en-el-cancer-colorrectal-traslacion-de-la-biologia-a-la-terapia 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/1978/emerging-and-established-targets-in-colorectal-cancer-translating-biology-into-therapeutics 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/1977/la-validacion-integrada-a-traves-de-la-transcriptomica-y-la-proteomica-identifica-a-slc35d3-como-un-antigeno-de-superficie-selectivo-para-tumores-en-los-carcinomas-colorrectales-y-neuroendocrinos 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/1977/integrated-transcriptomic-and-proteomic-validation-identifies-slc35d3-as-a-tumor-selective-surface-antigen-for-colorectal-and-neuroendocrine-carcinomas 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/1976/identificacion-preclinica-y-validacion-clinica-de-biomarcadores-dinamicos-para-trifluridina-tipiracil-con-o-sin-bevacizumab-en-el-cancer-colorrectal-metastasico 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/1976/preclinical-identification-and-clinical-validation-of-dynamic-biomarkers-for-trifluridine-tipiracil-with-or-without-bevacizumab-in-metastatic-colorectal-cancer 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/1955/relevancia-pronostica-y-para-el-seguimiento-del-oxido-nitrico-sistemico-en-pacientes-con-cancer-de-colon 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/1955/prognostic-and-monitoring-relevance-of-systemic-nitric-oxide-in-patients-with-colon-cancer 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/1950/una-nanoparticula-hibrida-con-membrana-que-mimetiza-y-modula-la-respuesta-inmune-mediante-fototermia-inhibe-el-crecimiento-y-la-metastasis-del-cancer-colorrectal 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/1950/hybrid-membrane-camouflaged-photothermal-immunomodulatory-nanoparticle-inhibits-colorectal-cancer-growth-and-metastasis 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/1888/camino-a-seguir-crioablacion-para-metastasis-hepaticas-de-cancer-colorrectal 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/1888/path-forward-cryoablation-for-colorectal-liver-metastases 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/1876/prediccion-de-dmmr-a-partir-de-histopatologia-de-cancer-colorrectal-aprovechamiento-de-regiones-no-tumorales-y-de-bajo-aumento 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/1876/dmmr-prediction-from-colorectal-cancer-histopathology-leveraging-non-tumor-and-low-magnification-regions 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/1856/los-estudios-sobre-los-caf-hipoxicos-revelan-que-el-eje-pthrp-vitamina-d-ras-es-fundamental-en-los-caf 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/1856/hypoxic-caf-studies-unveil-pthrp-vitamin-d-ras-axis-as-pivotal-in-the-caf 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/1814/el-analisis-integrado-de-la-transcriptomica-unicelular-y-espacial-revela-el-microambiente-del-cancer-colorrectal 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/1814/integrated-single-cell-and-spatial-transcriptomics-reveal-the-colorectal-cancer-microenvironment 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/1738/tnmplot-una-plataforma-mejorada-para-la-identificacion-de-dianas-farmacologicas-mediante-el-analisis-de-la-expresion-genica-en-diferentes-estadios-y-en-diversos-tipos-de-cancer 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/1738/tnmplot-an-enhanced-platform-for-pharmacological-target-identification-through-cross-stage-and-pan-cancer-gene-expression-analysis 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/1644/el-doble-papel-del-receptor-de-peptidos-formilados-1-fpr1-en-la-inflamacion-y-la-carcinogenesis-gastrointestinal-mecanismos-e-implicaciones-terapeuticas 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/1644/the-dual-role-of-formyl-peptide-receptor-1-fpr1-in-gastrointestinal-inflammation-and-carcinogenesis-mechanisms-and-therapeutic-implications 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/1511/cambios-en-la-6a-edicion-de-la-clasificacion-de-la-organizacion-mundial-de-la-salud-de-los-tumores-del-sistema-digestivo 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/1511/changes-in-the-6th-edition-of-the-world-health-organization-classification-of-tumours-of-the-digestive-system 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2176/establecimiento-de-una-radioinmunodiagnosis-predirigida-basada-en-68-ga-dota 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2176/establishment-of-68-ga-dota-based-pretargeted-radioimmunodiagnosis 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2175/descifrando-el-paradigma-multifuncional-y-traslacional-de-los-sistemas-nanoparticulados-contra-el-cancer-colorrectal 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2175/unraveling-the-multifunctional-and-translational-paradigm-of-nanoparticulate-systems-against-colorectal-cancer 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2173/un-ensayo-clinico-nacional-multicentrico-aleatorizado-controlado-de-grupos-paralelos-de-fase-iii-que-compara-el-tratamiento-neoadyuvante-con-folfoxiri-y-quimiorradioterapia-frente-al-tratamiento 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2173/a-national-multicentre-randomised-controlled-parallel-arms-phase-iii-clinical-trial-of-neoadjuvant-folfoxiri-and-chemoradiotherapy-versus-neoadjuvant-capox-folfox-and-chemoradiotherapy-in-patients 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2171/adn-tumoral-circulante-y-biomarcadores-de-precision-en-el-cancer-colorrectal-implicaciones-para-el-diagnostico-seguimiento-y-manejo-de-la-enfermedad-avanzada 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2171/circulating-tumor-dna-and-precision-biomarkers-in-colorectal-cancer-implications-for-diagnosis-monitoring-and-management-of-advanced-disease 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2170/la-via-de-senalizacion-mapk-erk-en-el-cancer-colorrectal-avances-recientes-y-nuevos-conocimientos 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2170/the-mapk-erk-signaling-pathway-in-colorectal-cancer-recent-advances-and-emerging-insights 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2165/evaluacion-del-adn-tumoral-circulante-metilado-de-bcat1-e-ikzf1-como-biomarcador-pronostico-en-los-adenocarcinomas-esofagogastricos 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2165/assessment-of-methylated-bcat1-and-ikzf1-circulating-tumor-dna-as-a-prognostic-biomarker-in-esophagogastric-adenocarcinomas 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2164/analisis-de-las-similitudes-y-diferencias-en-las-guias-de-practica-clinica-globales-para-el-cancer-gastrico-una-revision-de-las-ultimas-guias-de-taiwan-en-comparacion-con-las-guias-de-asia-pacifico 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2164/tackling-similarities-and-differences-in-global-practice-guidelines-for-gastric-cancer-a-review-on-the-latest-taiwan-guidelines-with-asia-pacific-european-and-us-guidelines 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2162/mutaciones-oncogenicas-frecuentes-en-el-cancer-colorrectal-factores-clave-en-la-carcinogenesis-y-posibles-dianas-terapeuticas 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2162/common-oncogenic-mutations-in-colorectal-cancer-drivers-of-carcinogenesis-and-potential-therapeutic-targets 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2160/oncologia-de-precision-facilitada-por-la-cirugia-en-un-sarcoma-de-la-arteria-pulmonar-msi-h-con-sindrome-de-lynch-un-caso-clinico 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2160/surgery-enabled-precision-oncology-in-an-msi-high-pulmonary-artery-sarcoma-with-lynch-syndrome-a-case-report 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2159/analisis-molecular-comparativo-del-cancer-colorrectal-en-arabia-saudi-alteraciones-geneticas-y-caracteristicas-clinicas-distintas 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2159/comparative-molecular-analysis-of-colorectal-cancer-in-saudi-arabia-distinct-genetic-alterations-and-clinical-features 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2158/evaluacion-del-ct-adn-y-el-estado-mutacional-en-la-biopsia-liquida-de-pacientes-con-cancer-colorrectal-metastasico 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2158/evaluation-of-ct-dna-and-mutational-status-in-liquid-biopsy-of-patients-with-metastatic-colorectal-cancer 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2156/caracterizacion-preclinica-y-resultados-de-la-fase-1-de-tqb2102-un-conjugado-anticuerpo-farmaco-biparatopico-her2-de-primera-generacion-en-pacientes-con-tumores-solidos-avanzados 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2156/preclinical-characterization-and-phase-1-results-of-tqb2102-a-first-in-class-her2-biparatopic-antibody-drug-conjugate-in-patients-with-advanced-solid-tumors 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2155/eficacia-de-la-dieta-mediterranea-para-la-prevencion-primaria-de-enfermedades-oncologicas-una-revision-sistematica-y-metaanalisis-que-se-incluye-en-las-guias-nacionales-italianas-la-dieta-mediterranea 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2155/efficacy-of-mediterranean-diet-for-the-primary-prevention-of-oncological-diseases-a-systematic-review-and-meta-analysis-featured-in-the-italian-national-guidelines-la-dieta-mediterranea 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2154/prx5-como-un-factor-clave-en-la-regulacion-de-la-capacidad-de-auto-renovacion-y-la-tumorigenicidad-de-las-celulas-madre-del-cancer-colorrectal 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2154/prx5-as-a-critical-driver-of-colorectal-cancer-stemness-and-tumorigenicity 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2153/caracteristicas-y-resultados-de-pacientes-con-neoplasias-previas-al-cancer-colorrectal-un-analisis-de-concordancia-por-puntuacion-de-propension 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2153/characteristics-and-outcomes-of-patients-with-malignancies-prior-to-colorectal-cancer-a-propensity-score-matched-analysis 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2152/endometriosis-y-cancer-de-ovario-evidencia-epidemiologica-conocimientos-moleculares-y-toma-de-decisiones-clinicas 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2152/endometriosis-and-ovarian-cancer-epidemiological-evidence-molecular-insights-and-clinical-decision-making 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2149/ensayo-de-adn-tumoral-circulante-libre-de-tejido-y-resultados-en-pacientes-en-un-ensayo-de-fase-iii-de-quimioterapia-adyuvante-basada-en-folfox-alliance-n0147 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2149/tissue-free-circulating-tumor-dna-assay-and-patient-outcome-in-a-phase-iii-trial-of-folfox-based-adjuvant-chemotherapy-alliance-n0147 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2148/un-modelo-basado-en-organoides-ortotopicos-para-estudiar-la-disfuncion-temprana-de-celulas-t-cd8-y-la-respuesta-a-la-inmunoterapia-en-el-cancer-colorrectal 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2148/an-orthotopic-organoid-based-model-to-study-early-cd8-t-cell-dysfunction-and-immunotherapy-response-in-colorectal-cancer 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2144/terapia-con-celulas-v1t-car-alogenicas-dirigidas-contra-b7-h3-en-tumores-solidos-avanzados-un-estudio-de-fase-i 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2144/allogeneic-b7-h3-targeted-car-v1t-cell-therapy-in-advanced-solid-tumors-a-phase-i-study 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2142/mfolfoxiri-neoadyuvante-con-o-sin-cadonilimab-frente-a-mfolfox6-en-cancer-colorrectal-localmente-avanzado-un-ensayo-aleatorizado-de-fase-2-optical-2 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2142/neoadjuvant-mfolfoxiri-with-or-without-cadonilimab-versus-mfolfox6-in-locally-advanced-colorectal-cancer-a-randomized-phase-2-trial-optical-2 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2141/superacion-de-la-inmunosupresion-mediada-por-sting-mediante-un-agonista-bifuncional-de-sting-inhibidor-de-pd-l1-para-mejorar-la-inmunidad-antitumoral 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2141/overcoming-sting-driven-immunosuppression-with-a-bifunctional-sting-agonist-pd-l1-inhibitor-for-enhanced-antitumor-immunity 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2138/dinamica-del-adn-tumoral-circulante-y-resultados-clinicos-en-pacientes-con-cancer-colorrectal-avanzado-tratados-con-un-regimen-de-induccion-y-mantenimiento-basado-en-cetuximab 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2138/circulating-tumor-dna-dynamics-and-clinical-outcomes-in-patients-with-advanced-colorectal-cancer-treated-with-cetuximab-based-induction-and-maintenance-treatment 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2134/la-dinamica-temprana-del-ctdna-predice-la-respuesta-a-mosperafenib-en-el-cancer-colorrectal-metastasico-con-mutacion-braf-v600 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2134/early-ctdna-dynamics-predict-response-to-mosperafenib-in-braf-v600-mutant-metastatic-colorectal-cancer 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2133/troxerutina-como-flavonoide-bioactivo-perspectivas-sobre-sus-mecanismos-anticancerigenos-y-aplicaciones-terapeuticas 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2133/troxerutin-as-a-bioactive-flavonoid-insights-into-its-anticancer-mechanisms-and-therapeutic-applications 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2132/optimizacion-estructural-de-los-inhibidores-de-la-tirosil-adn-fosfodiesterasa-1-basados-en-benzofenantridinona-y-benzofenantridina-y-su-actividad-de-potenciacion-de-la-radioterapia 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2132/structural-optimization-of-benzophenanthridinone-and-benzophenanthridine-tyrosyl-dna-phosphodiesterase-1-inhibitors-and-their-radiosensitizing-activity 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2130/evaluaciones-endoscopicas-y-radiologicas-de-la-inmunoterapia-neoadyuvante-en-pacientes-con-cancer-colorrectal-localmente-avanzado-con-dmmr-msi-h-o-mutacion-en-los-genes-pole-pold1 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2130/endoscopic-and-imaging-evaluations-of-neoadjuvant-immunotherapy-in-patients-with-locally-advanced-colorectal-cancer-with-dmmr-msi-h-or-pole-pold1-mutation 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2128/inmunoterapia-y-microbiota-intestinal-una-revision-de-los-adyuvantes-terapeuticos-microbianos-para-la-inmunoterapia-en-tumores-solidos 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2128/immunotherapy-with-guts-a-review-of-microbial-therapeutic-adjuncts-for-immunotherapy-in-solid-tumors 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2127/seguridad-y-eficacia-de-folfiri-3-irinotecan-en-dosis-divididas-para-el-cancer-colorrectal-irresecable-un-analisis-estratificado-basado-en-los-polimorfismos-del-gen-ugt1a1 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2127/safety-and-efficacy-of-folfiri-3-split-dose-irinotecan-for-unresectable-colorectal-cancer-a-stratified-analysis-based-on-ugt1a1-gene-polymorphisms 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2126/evaluaciones-pragmaticas-de-tecnologias-sanitarias-de-biosimilares-un-estudio-piloto-sobre-el-uso-de-bevacizumab-en-el-cancer-colorrectal-para-nice 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2126/pragmatic-health-technology-appraisals-of-biosimilars-a-pilot-case-study-of-bevacizumab-in-colorectal-cancer-for-nice 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2125/quimioterapia-supramolecular-visualizada-basada-en-oxpt-ttvp-cb-8-activacion-del-dano-oxidativo-para-inducir-la-muerte-celular-programada-inmunogenica-y-potenciar-la-eliminacion-de-las-celulas 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2125/supramolecular-visualized-chemotherapy-based-on-oxpt-ttvp-cb-8-activating-oxidative-damage-to-induce-icd-for-enhancing-the-killing-of-tumor-cells 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2122/informe-de-caso-adenocarcinomas-colorrectales-sincronicos-con-estado-de-reparacion-del-desajuste-discordante-un-caso-de-sindrome-similar-a-lynch-y-asociacion-con-la-via-serrada 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2122/case-report-synchronous-colorectal-adenocarcinomas-with-discordant-mismatch-repair-status-a-case-of-lynch-like-syndrome-and-serrated-pathway-association 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2120/el-acido-urico-soluble-induce-el-agotamiento-de-los-linfocitos-t-cd8-al-provocar-una-hiperactivacion-mediada-por-ksr1-de-la-via-mapk 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2120/soluble-uric-acid-drives-cd8-t-cell-exhaustion-by-inducing-ksr1-mediated-mapk-hyperactivation 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2116/la-inflamacion-sistemica-y-la-fibrosis-hepatica-como-factores-predictivos-de-los-resultados-quirurgicos-en-metastasis-hepaticas-del-cancer-colorrectal-un-estudio-de-supervivencia-basado-en 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2116/systemic-inflammation-and-liver-fibrosis-as-predictors-of-surgical-outcomes-in-colorectal-cancer-liver-metastasis-a-biomarker-based-survival-study 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2115/arn-no-codificantes-largos-en-las-neoplasias-femeninas-revision-exhaustiva-de-los-mecanismos-moleculares-las-lagunas-clinicas-y-las-perspectivas-terapeuticas 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2115/long-noncoding-rnas-in-female-malignancies-critical-review-of-molecular-mechanisms-clinical-gaps-and-therapeutic-perspectives 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2114/ensayos-de-microscopia-de-inmunofluorescencia-multiple-para-la-evaluacion-farmacodinamica-de-la-activacion-de-la-tirosina-quinasa-met-en-la-membrana-plasmatica-y-el-nucleo 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2114/multiplex-immunofluorescence-microscopy-assays-for-pharmacodynamic-assessment-of-met-tyrosine-kinase-activation-in-the-plasma-membrane-and-nucleus 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2113/panorama-genomico-completo-de-erbb2-en-tumores-gastrointestinales-chinos-panoramas-centrados-en-mutaciones-y-oportunidades-de-tratamiento-de-precision 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2113/comprehensive-genomic-landscape-of-erbb2-in-chinese-gi-tumors-mutation-centered-landscapes-and-precision-treatment-opportunities 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2112/el-ensayo-sherpa-un-estudio-de-fase-i-que-combina-el-inhibidor-de-shp2-rmc-4630-y-el-inhibidor-de-erk-ly3214996-en-pacientes-con-cancer-de-pancreas-cancer-de-pulmon-no-microcitico-y-cancer 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2112/the-sherpa-trial-a-phase-i-study-combining-shp2-inhibitor-rmc-4630-and-erk-inhibitor-ly3214996-in-patients-with-kras-mutant-pancreatic-non-small-cell-lung-and-colorectal-cancer 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2111/optimizacion-de-la-terapia-con-pembrolizumab-para-el-cancer-colorrectal-metastasico-de-novo-msi-h-dmmr-mediante-el-uso-de-ecuaciones-integro-diferenciales-basadas-en-datos 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2111/optimisation-of-pembrolizumab-therapy-for-de-novo-metastatic-msi-h-dmmr-colorectal-cancer-using-data-driven-delay-integro-differential-equations 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2110/las-mutaciones-que-son-el-objetivo-de-la-inmunoterapia-nous-209-aparecen-en-las-primeras-etapas-de-las-lesiones-precancerosas-de-los-portadores-del-sindrome-de-lynch-que-presentan-inestabilidad-de 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2110/mutations-targeted-by-nous-209-immunotherapy-occur-early-in-lynch-syndrome-carriers-precancer-lesions-with-microsatellite-instability 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2106/un-estudio-clinico-exploratorio-preliminar-de-xiao-chai-hu-tang-administrado-en-combinacion-con-quimioterapia-basada-en-irinotecan-en-cancer-colorrectal-avanzado 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2106/a-preliminary-exploratory-clinical-study-of-xiao-chai-hu-tang-co-administered-with-irinotecan-based-chemotherapy-in-advanced-colorectal-cancer 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2105/la-decoccion-de-dabupi-atenua-la-mucositis-intestinal-inducida-por-fluorouracilo-mediante-la-activacion-del-receptor-x-farnesoide-y-la-regulacion-al-alza-de-la-dihidropirimidina-deshidrogenasa 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2105/dabupi-decoction-mitigates-fluorouracil-induced-intestinal-mucositis-via-farnesoid-x-receptor-activation-and-dihydropyrimidine-dehydrogenase-upregulation 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2102/la-transcripcion-y-el-empalme-no-canonicos-modelan-el-inmunopeptidoma-del-cancer-colorrectal-en-tumores-msi-y-mss 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2102/non-canonical-transcription-and-splicing-shape-the-colorectal-cancer-immunopeptidome-in-msi-and-mss-tumors 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2099/alteracion-de-la-interaccion-entre-el-lipopolisacarido-bacteriano-y-las-celulas-inmunitarias-en-el-cancer-colorrectal-en-comparacion-con-el-tejido-intestinal-adyacente 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2099/altered-crosstalk-of-bacterial-lipopolysaccharide-with-immune-cells-in-colorectal-cancer-compared-to-paired-adjacent-intestinal-tissue 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2098/firma-pronostica-y-caracterizacion-del-microambiente-inmunitario-en-el-cancer-colorrectal-basada-en-genes-relacionados-con-las-interleucinas 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2098/prognostic-signature-and-immune-microenvironment-characterization-in-colorectal-cancer-based-on-interleukin-related-genes 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2097/el-analisis-de-redes-farmacologicas-multiomicas-y-la-validacion-computacional-revelan-que-la-amodiaquina-y-la-desetiloamodiaquina-son-candidatos-multitarget-que-regulan-la-apoptosis-en-el 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2097/multi-omics-network-pharmacology-and-computational-validation-reveal-amodiaquine-and-desethylamodiaquine-as-apoptosis-regulating-multi-target-candidates-in-colon-adenocarcinoma 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2096/descifrando-la-heterogeneidad-de-las-celulas-del-cancer-colorrectal-identificacion-de-biomarcadores-y-subpoblaciones-celulares-impulsoras-de-la-enfermedad-mediante-scissor-y-cibersortx-en-el-analisis 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2096/unveiling-colorectal-cancer-cell-heterogeneity-identification-of-biomarkers-and-disease-driving-cell-subpopulations-through-scissor-and-cibersortx-on-integrated-transcriptomic-profiling 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2095/el-aprendizaje-profundo-consciente-de-firmas-revela-distintos-programas-de-genes-conductores-y-procesos-mutacionales-en-glioblastoma-y-adenocarcinoma-de-colon 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2095/signature-aware-deep-learning-reveals-distinct-driver-gene-programs-and-mutational-processes-in-glioblastoma-and-colon-adenocarcinoma 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2094/puntuacion-revisada-de-la-carga-tumoral-para-la-estratificacion-pronostica-en-pacientes-con-cancer-colorrectal-metastasico-que-reciben-inmunoterapia-un-estudio-retrospectivo 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2094/revised-tumor-burden-score-for-prognostic-stratification-in-metastatic-colorectal-cancer-patients-receiving-immunotherapy-a-retrospective-study 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2093/toward-targeting-the-untargetable-un-conjugado-egfr-peptido-farmaco-no-canonico-logra-una-potente-actividad-antitumoral-en-el-ccr-con-mutacion-de-kras 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2093/toward-targeting-the-untargetable-a-non-canonical-egfr-peptide-drug-conjugate-achieves-potent-antitumor-activity-in-kras-mutant-crc 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2087/resistencia-adquirida-a-los-inhibidores-de-los-puntos-de-control-inmunitario-en-diversos-tipos-de-tumores-un-analisis-reconstruido-de-datos-individuales-de-pacientes 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2087/acquired-resistance-to-immune-checkpoint-inhibitors-across-tumor-types-a-reconstructed-individual-patient-data-analysis 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2086/aprendizaje-profundo-basado-en-laminas-histologicas-de-cd3-para-la-prediccion-del-pronostico-del-cancer-de-colon-analisis-de-tres-cohortes-internacionales-de-cancer-de-colon-en-estadio-iii 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2086/deep-learning-based-on-cd3-histological-slides-for-prediction-of-colon-cancer-outcome-analysis-of-three-international-stage-iii-colon-cancer-cohorts 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2081/mutaciones-geneticas-que-rigen-la-sensibilidad-y-la-resistencia-a-la-ferroptosis-un-enfoque-de-precision-para-la-terapia-del-cancer 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2081/genetic-mutations-governing-ferroptosis-sensitivity-and-resistance-a-precision-approach-to-cancer-therapy 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2080/un-estado-celular-con-alta-activacion-de-la-via-mapk-y-baja-activacion-de-la-via-wnt-favorece-la-diseminacion-metastasica-en-el-cancer-colorrectal 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2080/a-high-mapk-low-wnt-cell-state-drives-metastatic-dissemination-in-colorectal-cancer 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2076/correlacion-entre-el-reconocimiento-de-organoides-tumorales-autologos-por-los-linfocitos-infiltrantes-tumorales-procedentes-de-canceres-epiteliales-metastasicos-y-la-respuesta-clinica 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2076/correlation-between-recognition-of-autologous-tumor-organoids-by-tumor-infiltrating-lymphocytes-from-metastatic-epithelial-cancers-and-clinical-response 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2075/terapia-combinada-predirigida-con-177-lu-225-ac-para-el-cancer-colorrectal 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2075/pretargeted-177-lu-225-ac-combination-therapy-of-colorectal-cancer 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2072/la-nanomedicina-autoamplificable-reprograma-el-metabolismo-redox-para-desencadenar-la-ferroptosis-inmunogenica-en-el-cancer-de-colon-el-analisis-multiomico-identifica-a-ampd3-como-un-nuevo-regulador 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2072/self-amplifying-nanomedicine-reprograms-redox-metabolism-to-trigger-immunogenic-ferroptosis-in-colon-cancer-multiomics-identifies-ampd3-as-a-novel-regulator 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2067/usp21-promueve-la-evasion-inmune-en-el-cancer-colorrectal-mediante-la-desubiquitinacion-y-la-estabilizacion-de-la-catenina 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2067/usp21-drives-immune-evasion-in-colorectal-cancer-via-deubiquitination-and-stabilization-of-catenin 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2065/los-organoides-tumorales-inactivados-fisicamente-permiten-la-rapida-y-personalizada-expansion-de-celulas-t-citotoxicas-para-la-inmunoterapia-de-tumores-solidos 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2065/physically-inactivated-tumor-organoids-enable-rapid-and-personalized-enrichment-of-cytotoxic-t-cells-for-solid-tumor-immunotherapy 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2063/inmunoterapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-susceptible-de-reseccion 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2063/neoadjuvant-immunotherapy-for-resectable-locally-advanced-colorectal-cancer 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2062/respuesta-completa-duradera-a-pembrolizumab-tras-la-inhibicion-de-braf-mek-en-un-caso-de-cancer-colorrectal-recurrente-con-msi-h-dmmr-y-mutacion-braf-v600e-informe-de-un-caso 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2062/durable-complete-response-to-pembrolizumab-after-braf-mek-inhibition-in-recurrent-msi-h-dmmr-braf-v600e-mutant-colon-cancer-a-case-report 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2056/microbiota-intestinal-y-dieta-en-el-cancer-colorrectal-factores-determinantes-convergentes-de-la-carcinogenesis 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2056/gut-microbiota-and-diet-in-colorectal-cancer-converging-determinants-of-carcinogenesis 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2055/el-panorama-de-las-variables-genomicas-y-socioeconomicas-en-pacientes-con-cancer-colorrectal-segun-su-origen-genetico 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2055/the-landscape-of-genomic-and-socioeconomic-variables-in-colorectal-cancer-patients-based-on-genetic-ancestry 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2054/pembrolizumab-en-un-unico-ciclo-como-tratamiento-neoadyuvante-para-el-cancer-de-colon-en-estadio-i-iii-con-deficiencia-de-mmr-el-ensayo-reset-c 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2054/neoadjuvant-single-cycle-pembrolizumab-for-stage-i-iii-mmr-deficient-colon-cancer-the-reset-c-trial 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2051/las-estatinas-lipofilicas-reducen-los-niveles-de-gpx4-para-promover-la-ferroptosis-y-sensibilizar-las-celulas-cancerosas-al-bloqueo-de-los-puntos-de-control-inmunitario 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2051/lipophilic-statins-deplete-gpx4-to-promote-ferroptosis-and-sensitize-cancer-cells-to-immune-checkpoint-blockade 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2050/el-hidrogel-de-doble-farmaco-que-contiene-meloxicam-1-d-mt-actua-como-inmunomodulador-para-revertir-la-recurrencia-postoperatoria-del-tumor-y-la-metastasis 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2050/meloxicam-1-d-mt-dual-drug-hydrogel-serves-as-an-immunomodulator-to-reverse-tumor-postoperative-recurrence-and-metastasis 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2048/quimioterapia-neoadyuvante-total-combinada-con-bloqueo-de-pd-1-e-il-2-en-cancer-colorrectal-localmente-avanzado-mss-pmmr-resultados-a-corto-plazo-de-un-estudio-prospectivo-de-un-solo-brazo-de-fase-ii 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2048/total-neoadjuvant-chemotherapy-combined-with-pd-1-blockade-and-il-2-in-mss-pmmr-locally-advanced-rectal-cancer-short-term-results-of-a-prospective-single-arm-phase-ii-study 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2046/de-los-grupos-de-pacientes-a-la-practica-clinica-una-firma-de-8-genes-combinada-con-la-presencia-de-un-componente-mucinoso-permite-estratificar-el-beneficio-de-la-adicion-de-un-anti-ctla-4-al 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2046/from-clusters-to-clinic-an-8-gene-signature-combined-with-mucinous-component-stratifies-benefit-of-anti-ctla-4-addition-to-anti-pd-1-in-dmmr-msi-h-metastatic-colorectal-cancer 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2044/panorama-genomico-terapias-dirigidas-y-mecanismos-de-resistencia-en-pacientes-con-cancer-colorrectal-metastasico-seleccionados-mediante-analisis-molecular 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2044/genomic-landscape-targeted-therapies-and-mechanisms-of-resistance-in-molecularly-selected-metastatic-colorectal-cancer-patients 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2039/es-necesaria-la-cirugia-en-pacientes-con-cancer-colorrectal-con-deficiencia-en-la-reparacion-del-desajuste-y-alta-inestabilidad-de-microsatelites-que-presentan-una-respuesta-clinica-completa-tras-la 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2039/is-surgery-necessary-for-mismatch-repair-deficient-microsatellite-instability-high-colorectal-cancer-patients-with-a-clinical-complete-response-after-neoadjuvant-immunotherapy-a-retrospective-cohort 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2038/sotorasib-mas-panitumumab-y-5-fluorouracilo-en-el-tratamiento-de-primera-linea-de-pacientes-con-cancer-colorrectal-irresecable-con-mutacion-kras-g12c-que-no-son-aptos-para-quimioterapia-combinada 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2038/sotorasib-plus-panitumumab-and-5-fluorouracil-in-first-line-treatment-of-patients-with-unresectable-kras-g12c-mutated-colorectal-cancer-unfit-for-a-doublet-triplet-chemotherapy-engic-01-prodige-107 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2035/las-meloaxilinas-a-e-cinco-alcaloides-indolicos-monoterpenoides-ineditos-obtenidos-de-melodinus-axillaris-suprimen-el-cancer-colorrectal-al-dirigirse-a-la-via-del-metabolismo-del-hierro 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2035/meloaxilines-a-e-five-unprecedented-monoterpenoid-indole-alkaloids-from-melodinus-axillaris-suppress-colorectal-cancer-by-targeting-the-iron-metabolism-pathway 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2034/proteina-quinasa-2-que-interactua-con-el-receptor-ripk2-aspectos-estructurales-funciones-fisiopatologicas-y-avances-en-la-quimica-medicinal-para-el-diseno-de-inhibidores 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2034/receptor-interacting-protein-kinase-2-ripk2-structural-insights-pathophysiological-roles-and-medicinal-chemistry-advances-in-inhibitor-design 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2030/la-respuesta-previa-a-los-agentes-anti-vegf-predice-la-eficacia-de-trifluridina-tipiracil-mas-bevacizumab-en-pacientes-con-cancer-colorrectal-metastasico 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2030/prior-response-to-anti-vegf-agents-predicts-the-efficacy-of-trifluridine-tipiracil-plus-bevacizumab-in-patients-with-metastatic-colorectal-cancer 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2029/ensayo-de-fase-ib-ii-con-analisis-correlativos-de-doxorrubicina-mas-la-combinacion-de-durvalumab-en-pacientes-con-sarcoma-de-tejidos-blandos-avanzado 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2029/phase-ib-ii-trial-with-correlative-analyses-of-doxorubicin-plus-durvalumab-combination-in-patients-with-advanced-soft-tissue-sarcoma 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2028/estudio-de-fase-i-de-telisotuzumab-adizutecan-temab-a-abbv-400-un-nuevo-conjugado-anticuerpo-farmaco-dirigido-a-c-met-en-pacientes-con-cancer-colorrectal-en-lineas-de-tratamiento-avanzadas-y-tumores 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2028/phase-i-study-of-telisotuzumab-adizutecan-temab-a-abbv-400-a-novel-c-met-antibody-drug-conjugate-in-patients-with-late-line-colorectal-cancer-and-advanced-solid-tumors 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2017/heterogeneidad-molecular-de-los-canceres-con-erbb2-alterado-una-panoramica-del-cancer-en-cohortes-estadounidenses-y-japonesas 2026-05-20 monthly 0.5 https://crcwarriors.org/articulo/2017/molecular-heterogeneity-of-erbb2-altered-cancers-a-pan-cancer-landscape-across-us-and-japanese-cohorts 2026-05-20 monthly 0.5 https://crcwarriors.org/news-detail.php?id=nuevas-funcionalidades-en-el-buscador-de-ensayos-clinicos-mapa-interactivo-filtros-avanzados-y-mas 2026-05-20 monthly 0.5 https://crcwarriors.org/news-detail.php?id=nueva-experiencia-de-noticias-cientificas-ia-personalizada-traduccion-en-tiempo-real-y-mucho-mas 2026-05-20 monthly 0.5 https://crcwarriors.org/news-detail.php?id=lanzamos-la-beta-de-crc-warriors-buscamos-testers 2026-05-19 monthly 0.5 https://crcwarriors.org/news-detail.php?id=glosario-de-farmacos-2-0-mas-inteligente-mas-completo-mas-potente 2026-05-20 monthly 0.5 https://crcwarriors.org/combinaciones/63 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/62 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/33 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/34 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/36 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/52 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/11 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/45 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/42 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/1 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/12 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/48 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/13 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/30 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/53 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/3 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/5 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/50 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/15 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/39 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/59 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/2 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/49 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/56 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/64 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/38 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/4 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/16 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/19 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/54 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/51 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/40 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/55 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/18 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/61 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/41 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/20 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/21 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/22 2025-12-07 monthly 0.5 https://crcwarriors.org/help/getting-started.php 2026-05-01 monthly 0.4 https://crcwarriors.org/help/clinical-trials-guide.php 2026-05-01 monthly 0.4 https://crcwarriors.org/help/understanding-mutations.php 2026-05-01 monthly 0.4 https://crcwarriors.org/help/medication-database.php 2026-05-01 monthly 0.4 https://crcwarriors.org/help/privacy-security.php 2026-05-01 monthly 0.4 https://crcwarriors.org/help/faq.php 2026-05-01 monthly 0.4